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Chapter 1 
GENERAL INTRODUCTION 
1.1 Haemostasis 
The haemostatic balance is the equilibrium between the two opposing systems 
coagulation and fibrinolysis. An activated coagulation system leads to thrombin 
formation, and active thrombin will start the eventual formation of fibrin, the 
insoluble protein matrix of a blood clot. Fibrin has only a temporary function. 
After it has fulfilled its role, e.g. in tissue repair, it will be converted to soluble 
degradation products, and this causes lysis of the blood clot. 
The degradation of fibrin is catalysed by plasmin. Plasmin, the product of an 
activated fibrinolytic system, is a proteolytic enzyme (not specific for fibrin) 
which circulates in the blood stream as an inactive precursor: plasminogen. It is 
activated by plasminogen activators such as tissue-type plasminogen activator (t-
PA), which are highly specific proteases. 
Thus, in its most elementary form, the haemostatic balance can be described 
as the equilibrium between fibrin formation and dissolution, i.e. under normal 
physiological conditions the fibrin concentration should be in a steady state. 
In the following paragraphs a short description will be given of the structure of 
fibrin(ogen) and the multistep processes involved in fibrin formation and 
dissolution. 
1.1.1 Fibrinogen and fibrin 
Mammalian fibrinogens consist of a double set of three polypeptide chains: 
Ao, Bß, and γ. Since all three chain types are homologous, they probably 
evolved from a common ancestor (Doolittle 1980, Menschen 1980). The 
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Figure 1 Primary structure of the Aa-, BB- and γ-chain of human 
fibrinogen C-C connections represent disulfide bonds, 
fibrinopeptides are m italics, glycosylation sites are underlined, 4 
Indicates cleavage site of thrombin 
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individual fibrinogen chains are synthesized by the parenchymal cells of the liver 
and assembled within the rough endoplasmatic reticulum. 
Several reviews on the structure of fibrin(ogen) have been published (Doolittle 
1981, Menschen 1981). The primary structures of the individual chains of 
fibrinogen has been established in several laboratories by direct sequencing of 
the polypeptide chains, and has also been derived from mRNA/DNA sequences. 
The amino acid sequences shown in figure 1 are the consensus sequences as 
can be found in the NBRF Protein Database (George ei al. 1986): Αα-chain, code 
FGHUA, accession-number A03116; Bß-chain, code FGHUB, accession-number 
A03121; Y(B)-chain, code FGHUGB, accession-number A03126. 
Structure of fibrinogen 
The two Aa-chains, two Bß-chains and two γ-chains of fibrinogen are kept 
together by disulfide-bridges as depicted in figure 1, according to Menschen et 
al. (1983). A number of models has been proposed with a view to integrate the 
available information on the amino acid sequences, results of chemical and 
enzymatic fragmentation, size and shape of the molecule as derived from 
physicochemical measurements, and electron microscopical images. The 
schematic model of the fibrinogen molecule on the basis of such information is 
shown in figure 2, which is adapted from Doolittle (1984). In a slightly modified 
model, suggested by Hoeprich and Doolittle (1983) on the basis of NMR results, 
the two amino-terminal stretches of the two γ-chains are aligned in an antiparallel 
fashion. 
The central domain (nodule) contains the amino termini of the six polypeptide 
chains. The fibrinopeptides A and В are located at the amino-terminal ends of 
the Ασ- and Bß-chain, respectively. The two distal domains are connected to the 
central domain by coiled coils (i.e. the three protein chains twisted into an cr-
helix, also designated a supercoil), 112 residues in length (160 Â). The two 
halves of the symmetrical fibrinogen molecule are connected by a single disulfide 
bridge between the two Ασ-chains and two disulfide bonds between the two γ-
chains. Disulfide rings {i.e. three disulfide bridges which are not to far apart and 
keep the three protein chains together; for an example see figure 10) are present 
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on both ends of the coiled coil connector, holding all three chains in place 
There are four oligosaccharide substitutions, two located on the γ-chains close 
to the central domain and two on the Bß-chams, one within each distal domain 
Crosslinking sites are situated near the carboxyl termini of the γ-chains, 
extending from the globular distal domains On each Αα-chain (towards the 
carboxyl terminal end), there are two crosslinking acceptor sites (Gin) and five 
potential donor sites (Lys) Also in the middle of the Αα-chains crosslinking sites 
occur 
Figure 2 Schematic model of the fibrinogen molecule according to 
Doolittle (1984) For explanation see text, the arrows originating 
from "thrombin" designate the cleavage sites of this enzyme 
The blood coagulation system 
A complex cascade of reactions following an injury or trauma, eventually leads 
to the formation (activation) of thrombin from its zymogen prothrombin 
Thrombin is a proteolytic enzyme capable of hydrolyzmg specifically a few 
peptide bonds in fibrinogen, / e an arginyl-glycyl bond (between positions 16 and 
17 of the Aa chain and between positions 14 and 15 of the Bß-cham, see figure 
1), thus liberating fibnnopeptides A and В Only these arginyl-glycyl bonds are 
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hydrolysed although fibrinogen contains eleven more arginyl-glycyl bonds. 
Removal of the two fibrinopeptides A and В exposes new amino termini which 
have binding sites on the distal domains. This binding leads to polymerization. 
The polymerization of the fibrin monomers to form a fibrin-gel occurs by a 
half-staggered overlap mechanism as evidenced by electron micrographs (Ferry 
ef al. 1954). The next step in the polymerization process is the crosslinking of 
the subunits in the fibrin gel by the formation of isopeptide bonds between 
adjacent monomers, by an enzyme called factor XIII. Factor XIII is activated by 
thrombin from a Factor XIII precursor (a zymogen) occurring in plasma and in 
platelets. The active enzyme links neighbouring monomers by formation of 
peptide bonds between the side chains of special lysine residues and glutamine 
residues. In this way two γ-chains of neighbouring monomers are linked 
covalently and in the anti-parallel sense by two amide bonds between the side-
chains of Y-Lys40" and y-GIn398. The subsequent crosslinking of similar sites on 
the Aa-chains further completes the crosslinking of fibrin. 
1.1.2 Fibrinolysis 
Figure 3 shows the t-PA pathway of fibrinolysis. Fibrin is fragmented by the 
serine protease plasmin, which is activated from its zymogen plasminogen. The 
activation of plasmin is at least partly exerted by tissue-type plasminogen 
activator (t-PA), which is also a serine protease. Only a few other proteolytic 
actions of t-PA are known, which illustrate the high specificity of t-PA for 
plasminogen. 
The specific and strong stimulation of the plasminogen activation by t-PA in 
the presence of fibrin (see figure 3 and paragraph 1.1.4) confines the generation 
of plasmin (and thus the fibrinolytic activity) to the fibrin surface. 
t-PA is synthesized by vascular endothelial cells which secrete the activator 
into the blood stream. The amino acid sequence of t-PA has been determined 
partly by amino acid sequencing (Pohl ef al. 1984) and from the cDNA sequence 
(Pennica ef al. 1983). t-PA consists of 527 amino acids, which corresponds with 
a molecular weight of about 65,000. 
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Figure 3 Schematic pathway of the t-PA route of fibrinolysis, see text for 
description. (-) Is inhibition, (+) Is enhancement/Interaction. 
Abbreviations: arAP, Oj-antiplasmin; FbDP's, fibrin degradation 
products, PAI, plasminogen activator inhibitor; t-PA, tissue-type 
plasminogen activator. Adapted from Kluft (1988). 
The mature protein has a single polypeptide chain (that can be cleaved by 
plasmin to give two-chain t-PA during fibrinolysis [Rijken ef al. 1982]). t-PA 
comprises two kringle domains. Apart from those kringles there are various 
domains in the polypeptide structure, offering multiple possibilities for regulation 
of availability and activity (Kluft 1988). The primary function of t-PA is to 
hydrolyse one specific Arg-Val peptide bond in the plasminogen molecule, which 
yields the active plasmin. The biological half-life of t-PA activity in the circulation 
is very short (3 to 6 minutes in humans) because of the rapid clearance by the 
liver and the inhibition by PAI-1. 
Reviews on structure/function relationships and regulation of the activity of t-PA 
have been presented by Kluft 1988 and by Rijken 1988. 
The plasminogen structure is known and has been reviewed by Castellino 
(1984). Mature plasminogen (also designated Glu-plasminogen, after its amino 
terminal amino acid) contains 790 amino acids in a single polypeptide chain. 
Lys-plasminogen is formed by plasmin cleavage of the amino terminal 76 amino 
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acids from Glu-plasminogen. Hydrolysis of the Arg580 - Val5*1 peptide bond yields 
active plasmin, which is composed of a heavy chain and a light chain, connected 
by disulfide bridges. The heavy chain contains five homologous kringle domains. 
Plasminogen has been shown to have binding sites for lysine-analogues 
(Christensen 1984) such as 6-amino hexanoic acid (AHA, also known as e-
aminocaproic acid) and 6-amino hexane (AH). There are two classes of AHA 
binding sites, one strong and five weaker sites. The binding of fibrin to 
plasminogen is decreased by AHA and AHA analogues, indicating the importance 
of lysine residues on the fibrin molecule for binding of plasminogen. 
Binding of t-PA and plasminogen to fibrin 
t-PA binds to fibrin with a dissociation constant of about 150 nM (Rijken et al. 
1982). Nieuwenhuizen ef al. (1983) suggest that a binding site for t-PA and/or 
plasminogen is located in the segment Aa 148-197 which is accessible in fibrin, 
but not in fibrinogen. In a later study (Yonekawa et al. 1989, 1990) it has been 
suggested that still another binding site for t-PA, also not accessible in 
fibrinogen, might be operative in fibrin; this site is located in fragment FCB-5 (i.e. 
γ-(311-336) disulfide linked to γ-(337-379), see paragraph 1.1.3). These binding 
sites become exposed upon conversion of fibrinogen to fibrin, in the course of 
fibrinogen degradation by plasmin (see 1.1.3), or during cleavage of fibrinogen 
with cyanogen bromide (see 1.1.3). 
Though it is clear that plasmin must bind to fibrin for hydrolysis to occur, 
there is no direct evidence for the binding of plasmin to fibrin, since any free 
plasmin generated in w'vo is quickly inactivated by a2-antiplasmin (figure 3). 
Fibrin-bound plasmin appears to be less susceptible to inhibition by a2-
antiplasmin than free plasmin and this limits, to some extent, the plasmin activity 
to the fibrin surface. 
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1.1.3 The degradation of fibrinogen 
Degradation of fibrinogen by plasmin 
Plasmin cleaves fibrinogen, as well as fibrin, at several lysyl- and arginyl-
bonds. In the former case soluble fibrinogen degradation products (FgDP's) and 
in the latter case soluble fibrin degradation products (FbDP's, figure 3) are 
formed. The digestion proceeds through a number of overlapping steps: 
The initial products are a family of fibrinogen derivatives (fragments X) in which 
the Aa chains have been degraded to various extents at their carboxyl terminal 
ends (molecular weights vary from 240,000 to 320,000). 
Further digestion with plasmin results in an asymmetric cleavage of fragment 
X which yields one fragment Y (molecular weight 170.000) and one fragment D 
(molecular weights ranging from 80,000 to 93,000) per fibrinogen molecule. 
Fragment Y is finally split into another fragment D and one fragment E (molecular 
weight approximately 50,000). Fragment E comprises major parts of the central 
domain (figure 2) of fibrinogen, including fibrinopeptides A. One fragment D 
includes one distal domain (figure 2). 
Depending on the conditions during digestion, different fragments D are 
formed. Digestion in the presence of calcium-ions leads to fragments D 
(designated as DMle) with the intact carboxyl terminal part of the γ-chain. 
Digestion in the presence of EDTA or EGTA gives rise to fragments D (known as 
DEQTA). i n which residues 304 till 427 of the γ-chain are missing (Van Ruijven-
Vermeer ef a/. 1979). 
Degradation of fibrinogen by cyanogen bromide 
Treatment with cyanogen bromide in an acidic medium is a reliable method to 
cleave proteins specifically at methionyl residues (Gross 1967, Needleman 1970). 
During the procedure the methionyl residues are transformed into carboxyl 
terminally located homoserine lactones (Hse). Apart from many small peptides 
(there are 66 methionyl residues in one molecule of fibrinogen), five larger 
fragments remain upon cyanogen bromide cleavage (Menschen ef al. 1984): FCB-
1, molecular weight approximately 60,000, similar to fragment E (obtained by 
plasmin digestion; central domain of fibrinogen); FCB-2, molecular weight 
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approximately 43,000; FCB-3, molecular weight approximately 27,000; FCB-4, 
molecular weight approximately 5000, and a fragment FCB-5 with a molecular 
weight of approximately 7000. 
Table 1 shows the chain remnant composition of the individual fragments 
(adapted and extended from Nieuwenhuizen 1988), and also those of fibrinogen 
and of fibrin monomer. 
1.1.4 Inhibitors and stimulators of fibrinolysis 
Inhibition of fibrinolysis 
Some of the inhibitors of fibrinolysis are depicted in figure 3. For a more 
complete review see Kluft (1988). 
Inhibition at the t-PA level can be performed by PAM (endothelial type of 
plasminogen activator inhibitor) or by PAI-2 (placental-type of PAI). PAM binds 
rapidly to t-PA and forms an inactive complex. The inhibition rate of t-PA by PAI-
1 is strongly reduced by binding of t-PA to structures such as fibrin. The extent 
of protection is not documented. 
Inhibition at the level of plasmin is mainly performed by a2-antiplasmin. 
Plasmin (not protected by fibrin, see above) is rapidly inhibited by a2-antiplasmin. 
Normally, only very low levels of plasmin-a2-antiplasmin complexes are present in 
the circulation. These levels, however, can increase considerably during disease. 
This means that the plasminogen-to-plasmin conversion normally takes place at a 
relatively slow rate, but can increase strongly under special pathological 
conditions. Regulation of the plasmin activity or action occurs also at the level 
of fibrin, since a2-antiplasmin can be crosslinked to fibrin which is then degraded 
more slowly than fibrin with no crosslinked a2-antiplasmin. 
Stimulation of fibrinolysis 
All molecular models for the mechanism of fibrinolysis emphasize the 
stimulating and regulating role of fibrin and the binding of the fibrinolytic 
components to fibrin. Thus, fibrin plays a role as the substrate of fibrinolysis and 
as an effector in its own degradation. Activation of plasminogen by plasminogen 
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TABLE 1 
Cham (remnant) compositions of fibrin, fibrinogen, 
Fragment 
Fibrinogen 
Fibrin monomer 
Fragment X 
Fragment Y 
Fragment D^,, 
Fragment 0 , ^ 
Fragment E 
FCB-1 
FCB-2 
FCB-3 
FCB-4 
FCB-5 
Aa chain 
('Ala - ""Prob 
("Gly - ""Proij 
('Ala - "Lys), 
'Ala - ""Lys 
+ 'Ala-"Lys 
"Val - ,e7Arg 
"Val - "'Arg 
('Ala - "Lys), 
('Ala - 51Hse)2 
'«Lys - «"HM 
M
'Glu-47eHse 
... 
BB chain 
('rrGlu - "'Glnjj 
("Gly - "«'Gin), 
('nGlu - «'Glnb 
'rrGlu - «'Gin 
+ "Lys-^Lys 
"•Asp - «'Glu 
''•Asp - «'Glu 
("Lys-'»Lys), 
('ябіи - "'Hse)2 
""Glu - ^Hse 
+ ^ y r - ^ H s e 
+ ^ A s n - ^ H s e 
— 
'"Phe-^Hse 
and fragments 
y-chain 
('Tyr.-'Leu), 
('Tyr-^Leu), 
('Tyr-^Leub 
Tyr - ""Leu 
+ 'Туг-"Lys 
"Ser - ""Leu 
"Ser-"Lys 
('Тут-»Lys), 
('Туг - '»Hse), 
•»Lys-^Hse 
— 
— 
3
"Gln - '"Hse 
+ ^'Asn - 37eHse 
activators (particularly t-PA) is accelerated specifically by fibrin and virtually not 
by fibrinogen It is conceivable that the conversion of fibrinogen to fibrin leads 
to the formation or exposure of sites not operational or hidden in fibrinogen 
which are capable of stimulating the plasminogen activation by t-PA A simple 
assay has been developed (Drapier et al. 1970, Verheijen ef al. 1982) to 
determine the rate-enhancing capacity of fibrin and fibrin(ogen) fragments 
(designated as stimulators). The assay is outlined in figure 4. The concentration 
of p-nitroanilme formed per time squared is proportional to the rate of plasmm 
formation (activation rate). The ratio of the activation rate m the presence of the 
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stimulator over that m absence of a stimulator is designated as the stimulation 
factor (SF). 
H D Val Leu Lys ρ N i t r o a n i l i d ^ 
t PA 
P l a s m i n o g e n — ^ — - P l a s m i η 1 
S t i m u l a t o r 
p - N i t r o a n i l ne 
+ 
H D Val L P J Lyb OH 
Figure 4 Outline of an assay to measure the rate-
enhancing effect of a stimulator on the 
plasminogen to plasmin conversion by t-PA 
Table 2 summarizes stimulation factors obtained for several stimulators and 
their concentrations which give half of the maximum stimulation factor ( с ^ ) 
The accelerating effect on t-PA mediated plasminogen activation is not limited to 
fibrin and its fragments alone Also other proteins and polymers have been 
shown to exert similar effects (e g thrombospondm, polylysme, and denatured 
immunoglobulins, for an overview see Nieuwenhuizen 1988) 
In early publications the rate-enhancing properties in plasminogen activation 
have been ascribed mainly to carboxyl-termmal lysines These seem to satisfy 
the requirements for binding to the lysine binding sites of plasminogen, ι e the 
presence of an e-ammo- and an a-carboxyl group, separated by a hydrophobic 
carbon chain (e g AHA, see paragraph 112) It has been described (Voskuilen 
et al 1987) that also a constituent lysyl residue of the chain, / e the lysyl residue 
at position 157 in the Αα-chain may contribute to the observed rate enhancement 
by fibrin This lysyl residue (Aa-1s7Lys) may interact with the postulated 
ammohexyl sites m plasminogen (Christensen 1984) or with t-PA One could 
speculate about a spatial conformation in Ασ-(148-161) in which the carboxyhc 
side chain of an aspartyl- or glutamyl-residue in combination with the e-ammo 
group of the non-terminal lysyl-residue mimics a carboxyl terminal lysine 
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TABLE 2 
Stimulation factors (SF) of some fibrin(ogen) derivatives 
and the concentrations required for half-maximal stimulation (с^р) 
Stimulator 
Fibrin monomer 
CNBr dig. fibrinogen 
FCB-2 
FCB-5 
Ασ-(148-207) 
Ασ-(148-160) 
Αα-(149-160) 
SF 
34 
36 
39 
25 
20 
11.3 ± 3.2 
9.1 ± 3.6 
CHSF ί η μ Μ 
0.02 
0.08 
0.12 
0.80 
0.50 
12 
15 
Ref. 
Nieuwenhuizen et al. 1983* 
Nieuwenhuizen et al. 198Я' 
Nieuwenhuizen et al. 1983* 
Yonekawa ef al. 1989, 1990 
Nieuwenhuizen ef al. 1983 
Voskuilen et al. 1987 
Voskuilen ef al. 1987 
1.2 An introduction to Peptide Chemistry 
Peptide chemistry is the part of organic chemistry that deals with the 
chemistry of protein fragments; one aspect is to provide tools for preparing 
amino acid derivatives that can be linked into peptides. 
When two amino acids are to be condensed to form a dipeptide all the functions 
in the amino component and the carboxyl component that are not allowed to 
react, must be reversibly blocked by protective groups. The carboxyl function 
has to be activated since the hydroxy! moiety of the carboxyl group is not a 
leaving group. Apart from this, the integrity of the chiral centers on the two 
amino acids must be preserved during the coupling reaction. 
The process of condensation thus consists of three stages: 
(1) Protection as indicated above 
(2) Activation of the carboxyl component 
(3) Acylation of the amino component 
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Figure 5 Formation of an amide bond (peptide bond), L leaving group, Pr,, 
Pr2, and Ргз are protective groups; R, and R2 are the side chain of 
an amino acid. 
ad 1. The applied protective groups provide for the temporary protection of the 
α-amino function, and the semipermanent protection of the side chain functions. 
For the protection of the α-amino groups a number of alkoxycarbonyl functions 
have been developed (for a review see Bodanszky 1984). Their applicability 
depends on the properties of the parent alcohols: to render their removal 
selective, these properties have to match. This principle has been treated by 
Barany and Merrifield (1977), who coined the term orthogonality for it. 
This quality describes the nature of the protective groups with respect to each 
other: if Pr,, for example, is a base-labile amino-protective group, Pr2 and Рт3 
should preferably be acid-labile protective groups, i.e. removal of Pr, may not 
affect Pr2 or Pr,. The dipeptide derivative obtained can be extended at its amino 
terminus by acylation with another activated amino acid with side-chain Вз(Рг2) to 
form a tripeptide derivative, and so on. 
ad 2. The a-carboxyl function of N-protected amino acid derivatives should be 
activated, to allow aminolysis by the amino component (cf. figure 5). Activation 
of an a-carboxyl group in an amino acid derivative includes the risk on 
racemization: if an intramolecular enolization can take place, cf. figure 6, 
racemization will always occur to a certain extent (Kemp 1979, Benoiton and 
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Chen 1981). If the a-carboxyl group forms part of a peptide, racemization can 
generally not be prevented, since the pertinent carboxyl group forms part of an 
acylamino acid. 
It has been found that amino acid derivatives, belonging to the class of f-
butyloxycarbonyl amino acids, racemize slowly or not at all (Benoiton and Chen 
1981), provided an excess of nucleophilic base is absent in the reaction mixture. 
The azide coupling, introduced long ago by Curtius (1902), is a well known 
exception: an azide usually does not cyclize to give oxazolones. This reaction is 
an important tool in the condensation of peptide units to longer chains (see 
below). 
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Figure 6 Unwanted formation of an oxazolone-ring and concomitant loss of 
chlrality If Pr, is an acyl-type amino protective group. 
The acylation competes with racemization: Kisfaludy (1970) found 
alkoxycarbonylamino acid pentafluorphenyl esters to react so rapidly with the 
amino components, that, even a molar excess of triethylamine was found to be 
harmless. 
Strategy and tactics 
ad 3. The consequence of these considerations is to follow the strategy of 
stepwise acylation using alkyloxycarbonylamino acids and to begin the synthesis 
of a peptide (in contrast to the in vivo synthesis of proteins) at the carboxyl 
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terminal amino acid, as advocated by Bodanszky and Du Vigneaud (1959*'ь). 
The strategy evolved to the use of benzyloxycarbonyl groups for the 
temporary protection of α-amino groups (removal: catalytic hydrogenolysis) in 
combination with protective functions derived from ferf-butyl alcohol for 
semipermanent protection of side-chain functions (removal: mild acidolysis, 
Schwyzer and Sieber 1963). Following the introduction of functions built to 
undergo ß-elimination (Kader and Stirling 1964, Carpino and Han 1970, 1972) the 
fundamental strategies of today were defined. At present, one can choose from 
a wide variety of protecting groups, which respect these considerations; making 
a choice from them, and finding the optimal combinations, resorts under the 
tactics of a particular synthesis. 
For an overview of almost all available protecting groups (some examples in 
figure 7), leaving groups and/or coupling reagents (some examples in figure 8) 
see Bodanszky 1984 and references therein. 
Sometimes, in the synthesis of longer peptides, a suitable strategy might 
include one or more fragment condensations: smaller peptide derivatives are 
easier to purify and the synthesis of fragments allows simultaneous operations. 
In condensation reactions the danger of racemization (cf. figure 6) is immanent. 
As indicated, the risk of racemization may be minimized when acid azides are 
used, but the azide coupling has its own number of aberrations, one of them 
being the Curtius-rearrangement to isocyanides, leading to the loss of the 
activated C-terminal amino acid. 
A very practical modification of the azide method eliminating most of these 
difficulties has been given by Honzl and Rudinger (1961). In their procedure the 
carboxyl terminus of a peptide is protected by an alkyl ester (Pr3 in figure 5), e.g. 
a methyl ester, which is hydrazinolysed (the alkyl ester acts as a leaving group in 
this reaction) as usual. Upon treatment of the hydrazide with an alkyl nitrite, e.g. 
ferf.-butylnitrite, the azide is formed. The peptide-azide is not isolated because 
of its instability (isocyanates may be formed) but it is brought directly into 
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Figure 7 Protective groups used in this dissertation; Mpc, Verhart an Tesser 1988; Fmoc, 
Carpino and Han 1970, 1972, Z, Bergmann and Zervas 1932, Boc, Ben-lshai and 
Berger 1952; OBu', Roeske 1959; Bu', Schröder 1964; Trt, Stelakatos ef al. 1966; 
Pmc, Ramage and Green 1987; Msc, Tesser and Balvert-Geers 1975. 
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reaction with the free amino-terminus of another peptide, usually without 
racemization. For a review see Meienhof er (1979). 
König and Geiger (1970) have introduced the principle of racemization-
inhibition during the unification of two partially protected peptides. Racemization 
appears to be suppressed if during the activation of the carboxyl component a 
modest excess of a non-acylating weak acid is added. The most versatile 
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Figure β Frequently used leaving groups and coupling reagents 
additive turned out to be 1-hydroxybenzotriazole (König and Geiger 1970), since 
it: 1. donates protons (pKa=4.1), reducing the chance of racemization; 2. 
potentiates the action of the condensing agent (i.e. DCC) by formation of active 
esters, and 3. prevents formation of N-acylurea's by reduction of the lifetime of 
the (presumed) O-acylurea intermediate. 
Thus, an alternative for the azide-method, a route for the condensation of two 
peptide fragments is the in situ activation with DCC (Sheehan and Hess 1955) or 
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TBTU (Knorr ef al. 1989) in an excess of HOBt. This route almost always leads 
to by-products (racemization). The only two C-terminal amino acid residues that 
are completely inert as far as racemization is concerned, in either method for 
fragment condensation, are the glycyl or prolyl residue. 
Solid Phase Peptide Synthesis (SPPSÌ 
The most important application of the stepwise strategy for synthesis of 
peptides is the solid-phase method of Merrifield (1963). In SPPS the protecting 
group РГэ in figure 5 is not an ordinary protecting group, like -OMe or -OBu1, but 
a linker attached to a solid support. If the rules of orthogonality are obeyed, 
then the protecting group Pr, can be removed while Pr2 and Pr, remain intact. 
The soluble reaction products simply can be washed away and a second amino 
acid derivative can be introduced as depicted in figure 5, either via an active 
ester or via an in situ coupling. After a predefined number of cycles the fully 
protected target peptide can be cleaved from the resin in a medium which 
attacks Prj. This approach is the ideal course of a peptide synthesis on a solid 
support. 
According to the protective group tactics, SPPS can be divided into two major 
classes. One class (designated the "Boc-chemistry" in SPPS) uses an acid labile 
α-amino protection (Pr,, i.e. Boc) and a more acid stable side chain protection 
(Pr2, benzyl-type ethers and esters, substituted with groups that have a negative 
inductive effect, such as CI or N02), while the linker (Prj) is much more acid 
stabile than Pr, and Pr2. Resin-bound peptides prepared via the "Boc-chemistry" 
must be cleaved from the resin using extremely strong acids like liquid hydrogen 
fluoride (HF) or trifluoromethanesulfonic acid (TFMSA). For a comprehensive 
overview of techniques, protecting groups, linkers, and solid supports used in the 
SPPS "Boc-chemistry", see Stewart and Young (1984) and references therein. 
Another class (called the "Fmoc-chemistry" in SPPS) uses the base labile Na-
Fmoc protecting group and f erf.-butyl type protecting groups (acid labile, i.e. -
Bu', -OBu' and Boc; see figure 7) for side chain protection. The solid phase 
linker (РГэ) is also acid labile. Most frequently used in the "Fmoc-chemistry" is 4-
alkoxybenzyl alcohol, (the "Wang"-linker [Wang 1973] endowed with a stability 
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comparable to that of the ferf -butyl functions) The 2-methoxy-4-alkoxybenzyl 
alcohol linker, "SASRIN"-linker (Mergler ef al Ιθββ·"), sensitive to dilute (0 5 -
1 0%) trifluoroacetic acid, is ideally suited for the preparation of fully protected 
peptides An overview of techniques, protecting groups, linkers, and solid 
supports in the SPPS ' Fmoc-chemistry" is given in Fields and Noble (1990) and 
references therein 
The concept of SPPS lends itself for automation Two types of automated 
processors are being developed, a continuous-flow processor and a batch 
processor The latter can be operated m a semi-automatic way and leaves the 
opportunity to monitor the progress of the coupling reaction via, for instance, a 
ninhydrm-test for free ammo-groups, this so-called Kaiser Test (Kaiser ef al 
1970), is the most frequently used technique for monitoring completeness of 
acylation in SPPS 
1 3 Conjugation of a peptide to a carrier protein 
Peptide-carrier conjugates have to be used to raise antipeptide antibodies, 
since generally, non-conjugated peptides consisting of 10-25 ammo acid residues 
do not elicit antibodies following injection in animals To induce immunogenicity, 
peptides are coupled to macromolecular carriers, usually proteins (such as 
bovine serum albumin (BSA) or keyhole limpet haemocyanm (KLH)), to synthetic 
carriers (/ e multi-chain poly(DL-Ala)-(L-Lys), [Audibert ef al 1982]), or they are 
incorporated in liposomes, micelles or immuno-stimulatmg complexes known as 
iscoms (Morem ef al. 1984) Since peptides and proteins contain several 
functional groups, conjugation using carbodiimide (Goodfriend et al 1964, Davis 
ef al 1984) or homobifunctional reagents (e g glutardialdehyde, [Avrameas 1969, 
Pfaff ef al. 1982]) generate a great number of different products (and is therefore 
known as the "chaos" coupling, Peeters ef al 1989) In order to obtain the best 
defined product, heterobifunctional cross-linkers should be used m such a way 
that the peptide couples specifically, and m a predictable fashion to the carrier 
Some aspects of chemical cross-linkers and the modification of proteins have 
been reviewed by Han ef al (1984) and Feeney (1987) 
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In a useful method for preparing peptide-carrier conjugates advantage is taken 
of the fast nucleophilic addition of a thiol group to the double bond of a 
maleimide (Marrian 1949). The amino groups of a carrier can be acylated to a 
predefined extent by the addition of an active ester bearing a maleimide moiety 
such as succinimidyl m-maleimidobenzoate, MBS (Kitagawa and Aikawa 1976); 
succinimidyl e-i/V-maleimidoJ-n-hexanoate, MHS (Keller and Rudinger 1975); 
succinimidyl 4-(N-maleimidomethyl)-cyc/o-hexane-1-carboxylate, SMCC 
(Yoshitake et al. 1979). A peptide that does not contain a sulfydryl group can be 
functionalized during its synthesis at the amino terminus by acylation with S-
acetylthioacetic acid (Ata-OH) or the succinimidyl ester of Ata-OH (Sata) (Duncan 
et al. 1983). An alternative is the insertion of a protected cysteinyl residue as 
carboxyl-terminal residue (the synthesis of the peptide starts with a carboxy-
terminal cysteine) or at any other position in the chain. Treating an Ata-peptide 
with base, even hydroxylamine, results in the liberation of the sulfydryl group. 
Subsequently the maleylated carrier is allowed to react with the HS-peptide, see 
figure 9 route A. 
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Figure 9 Synthesis of protein-peptlde conjugates (Peelers er β/. 19Θ9) 
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Since both the peptide and the protein are covalently connected through 
acylation of an amino group in both of them, it is evident but nonetheless 
important to note that also the protein can be thiolated and the peptide 
maleylated. 
In another method of controlled conjugation S-S links are formed between the 
peptide and a carrier protein by the thiolysis of activated disulfides introduced by 
the acylation of a protein or a peptide with succinimidyl 3-(2-pyridyldithio)pro-
pionate (SPDP) (Carlsson ef al. 1978), see figure 9 route B. 
When carrier protein - peptide conjugates are used as immunogens, the 
potential immunogenicity of the linker groups has to be considered. Peeters ef 
al. (1989) described a comparison of four bifunctional reagents for coupling 
peptides to proteins and the effect of the three moieties (protein, linker, peptide) 
on the immunogenicity of the conjugates. The results from this study clearly 
show a very high antibody-level against the rigid linkers produced by SMCC and 
MBS, and very low levels against the flexible linker produced by MHS. The 
lowest level was obtained by the aliphatic disulfide originating from SPDP. 
However, a major drawback of SPDP coupling is the resulting disulfide linkage, 
which confers a susceptibility to reductive cleavage by ubiquitously occurring 
thiol compounds. In contrast, the thio-ether linkage resulting from MHS is very 
stable. Therefore, Peeters ef al. (1989), conclude that MHS is the bifunctional 
reagent of choice for coupling peptides to proteins. 
1.4 Aim of the investigations 
As pointed out in paragraph 1.1.4 the sequence Aa-(148-160) is the shortest 
sequence known at present to enhance the rate of plasminogen to plasmin 
activation by t-PA. The location and position relative to the Bß- and γ-chain of 
this site in the fibrin(ogen) molecule is outlined in figure 10. The fact that 
fibrinogen (in contrast to fibrin) does not act as a stimulator led to the hypothesis 
that the sequence Ασ-(148-160) in fibrinogen is not accessible to plasminogen 
and/or t-PA, and that, upon conversion of fibrinogen to fibrin, this site apparently 
would become exposed. This theory was proven by making monoclonal 
antibodies against synthetic Ασ-(148-160). These monoclonal antibodies react 
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with fibrin and nol with fibrinogen. Chapter 2 is an account of the synthesis, 
conjugation to bovine serum albumin, of Aa-(148-160), and production and 
characterization of monoclonal antibodies against Ασ-(148-160). 
Figure 10 Schematic model of the fibrinogen molecule (Doolittle 1984), with 
(Inset) an enlarged detail, which is a schematic representation of 
the distal disulfide ring and a small part of the coiled-coil, 
showing the exact position of the sequence Aa-(148-160) in the 
coiled-coil relative to short stretches of the 6- and γ-chaln 
Homology searches show that a charge distribution similar to that found in 
Ασ-(148-160) (see below) is also present in the γ-chain, more specifically in the 
sequence γ-(316-322). This sequence is a part of FCB-5, which has been shown 
to have stimulating capacity (Yonekawa ef al. 1989, 1990). During the fibrinogen-
to-fibnn conversion, Ασ-(148-160) appears to become accessible to monoclonal 
antibodies elicited against synthetic Aa-(148-160) (see Chapter 2). Since a 
similar situation may exist for (at least parts of) FCB-5, we have prepared 
monoclonal antibodies against a part (i.e. γ-(312-324)) of FCB-5, and found that 
these are fibrin-specific and do not bind fibrinogen. 
Chapter 3 is an account of the synthesis, conjugation to bovine serum albumin of 
fibrinogen-Y-(312-324)-tridecapeptide, and production and characterization of the 
obtained monoclonal antibodies. 
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Chapter 4 describes the synthesis and the stimulation factors of successive 
linear hexapeptides and of a tetrapeptide within the sequence Aa-(148-160), in 
order to further locate the stimulating site within Aa-(148-160). 
The results described by Voskuilen ef al. (1987) suggest that not only 
carboxyl-terminally located lysine-residues, but also Aa-Lys157, contribute 
considerably to the rate-enhancing effect of fibrin. 
Chapter 5 describes the synthesis and the stimulating capacity of several 
peptide-analogues of Αα-(14θ-160) in which Aa-Lys157 has been replaced by some 
lysine-analogues and several other amino acid residues, on the conversion of 
plasminogen to plasmin. 
The sequence of Aa-(148-160) shows an interesting charge distribution, 
Lys-Arg-Leu-Glu-Val-Asp-Ile-Asp-Ile-Lys-Ile-Arg-Ser 
+ + 0 - 0 - 0 - 0 + 0 + 0 
/. . negative and neutral amino acid residues alternate, and are embraced by two 
sets of positively charged residues. This sequence appears to be highly 
conserved in fibrinogen of several species. 
Chapter 6 deals with the synthesis and the stimulating capacities of synthetic 
peptide analogues, derived from Aa-(148-160), in which the typical charge 
distribution is interrupted by exchanging Aa-Val152 by charged (and some 
uncharged) amino acid residues. 
Ten Kortenaar ef a/. (1985) describe that an azide-coupling involving an 
amino-terminal aspartyl residue with an unprotected carboxylic side-chain, 
proceeds with high yield and purity. 
If this phenomenon would be generally applicable such a coupling procedure 
could be a new tool in the methodology of peptide-fragment condensation (see 
paragraph 1.2). 
Chapter 7 describes the synthesis of protected peptide azides with similar 
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substitutions of Val as those in chapter 6. To check the reaction described by 
ten Kortenaar et al. (1985), the protected peptide azides were allowed to react 
with the amino-terminal (ß-unprotected) Asp153 of the fully protected Aa-(153-160) 
fragment. 
In chapter 8, the use in solid phase peptide chemistry of a new ami no-
protective group, the Mpc-group (which is devoid of the disadvantages of the 
Fmoc-group), is described. Also, an improved synthesis of Mpc-ONSu and of 
some Mpc-amino acids will be described in detail in chapter 8. 
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Chapter 2 
THE SEQUENCE Aa-(148-160) IN FIBRIN, BUT NOT IN FIBRINOGEN, 
IS ACCESSIBLE TO MONOCLONAL ANTIBODIES 
Wim J.G. Schielen*, Marijke Voskuilen, Godefridus I. Tesser*, 
Willem Nieuwenhuízen 
Gaubius Institute TNO, Leiden 
*Lab. Organic Chemistry, University of Nijmegen 
Proc. Natl. Acad. Sci. USA, 86(1989)8951-8954 
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ABSTRACT 
Fibrin, but not fibrinogen, accelerates the t-PA catalyzed activation of 
plasminogen. We have shown before (J. Biol. Chem., 1987; 262: 5944-5946) that 
essential information for this accelerating capacity of fibrin resides in the 
sequence Αα-(14β-160). Our working hypothesis, based on those findings, is that 
Aa-(148-160) is buried in fibrinogen and becomes accessible to proteins such as 
plasminogen and/or t-PA, when fibrinogen is converted to fibrin. 
To test this hypothesis we have raised a monoclonal antibody (MoAb) against 
synthetic Aa-(148-160) and found that this MoAb reacts with fibrin and OQÎ with 
fibrinogen. This finding shows that Ασ-(148-160) becomes accessible when 
fibrinogen is converted to fibrin, and that Aa-(148-160) is a fibrin-specific 
neoantlgenic determinant. 
INTRODUCTION 
When the coagulation system is activated, thrombin is generated. Thrombin 
will convert circulating fibrinogen to fibrin monomer by the cleavage of flbrino-
peptides, A and B, from the amino-terminal ends of the two fibrinogen Aa and Bß 
chains, respectively. 
The fibrin monomers will aggregate through the resulting new amino-termini of 
the α and ß chains which constitute sites, that bind to complementary sites in the 
carboxyl-terminal domains (Doolittle 1981, Laudano and Doolittle 1981) of other 
fibrin(ogen) molecules. 
The carboxyl-terminal sites already exist in fibrinogen, and at low concen-
trations fibrin will be kept in solution by complexation with fibrinogen. Beyond a 
critical (local) concentration fibrin will aggregate to form a fibrin gel i.e. a 
thrombus will be formed. 
With the advent of the MoAb technology it has become possible to raise 
antibodies against molecular features, which are specific for fibrin and do not 
occur in fibrinogen (neoantigenic determinants). Examples are MoAb's which 
have been raised against the new amino-termini of the fibrin α-chains (Scheefers-
Borchel ef a/. 1985, Liau ef a/. 1987) and ß-chains (Hui ef al. 1983). Those 
antibodies were elicited using conjugates of a carrier protein and synthetic 
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peptides with an amino acid sequence, identical to that occurring in the amino-
terminal stretches of the fibrin α and 8 chains, respectively. 
The activation of plasminogen by tissue-type plasminogen activator (t-PA) is 
greatly accelerated by fibrin, but not by fibrinogen. We have shown before 
(Nieuwenhuizen eí al. 1983b) that the sequence Aa-(148-197) and in particular Ασ-
(148-160) (Voskuilen et al. 1987) and lysine Ασ 157 (Voskuilen et al. 1987) play an 
essential role in this acceleration. Our working hypothesis based on those 
findings is, that this part of the Αα chain is buried in fibrinogen and becomes 
accessible to proteins such as plasminogen and t-PA during the fibrinogen-to-
fibrin conversion. If this hypothesis is correct, Aa-(148-160) would also become 
accessible to antibodies upon fibrin formation, and antibodies against Aa-(148-
160) would be expected to react with fibrin and not with fibrinogen. 
In this paper we describe the production of MoAb's against this part of the 
Αα chain using a conjugate of bovine serum albumin and a synthetic peptide with 
the sequence of Aa-(148-160). The resulting antibodies react exclusively with 
fibrin, and not with fibrinogen. This demonstrates that Aa-(148-160) is a fibrin-
specific neoantigenic determinant, and supports our hypothesis that the 
sequence Aa-(148-160) is inaccessible in fibrinogen and becomes accessible in 
fibrin. 
MATERIALS AND METHODS 
Synthesis of [Ata-D.L-Nle147 ]-Fibrinogen-Aa-(147-160)-tetradecapeptide 
Fibrinogen-Aa-(148-160)-tridecapeptide (Lys-Arg-Leu-Glu-Val-Asp-Ile-Asp-Ile-Lys-
ІІ -Arg-Ser) was extended with acetylthioacetyl-D,L-norleucine at the amino-
terminus. Thus, methionine present in fibrinogen at Αα 147 is replaced by D,L-
Nle. This procedure allows the coupling to a carrier protein, and (via the Nle-
content) the subsequent determination of the number of coupled peptides per 
carrier protein molecule. The [Ata-D,L-Nle,47]-Fibrinogen-Aa-(147-160)-
tetradecapeptide (Ata-PH) was synthesized by Solid Phase Peptide Synthesis 
(SPPS) using the p-alkoxybenzyl alcohol resin (Wang 1973) and №-(9-fluore-
nyl)methyloxycarbonyl amino acids (Fmoc amino acids) (ten Kortenaar ef al. 
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1986). During SPPS the amino acid side chains were protected with acid-labile 
protecting groups: the e-amino group of Lys with Boc, the δ-guanidino group of 
Arg with Pms, the γ-carboxyl group of Glu and the ß-carboxyl group of Asp with 
OBu' and the ß-hydroxyl group of Ser with Bu'. Fmoc-Ser (Bu'J-OH (2 eq.) was 
coupled to the resin (1.07 mMoles/g), by in situ activation with dicyclohexyl-
carbodiimide (DCC, 2 eq.) and 4-(dimethylamino)pyridine (DMAP, 2 eq.). To 
suppress racemization, 1-hydroxy-1-benzotriazole (HOBt, 4 eq.) was added (van 
Nispen et al. 1985). All reactants were dissolved in DMF. After 16 hrs at 5°C the 
remaining alcohol groups of the resin were capped with benzoylchloride and 
Pyridin in DMF for 1 hour. The subsequent cleavage of the Fmoc groups was 
carried out in 20% piperidine/DMF. Coupling of Fmoc-Arg(Pms)-OH (3 eq.) was 
performed by in situ activation with DCC (3.3 eq.)/HOBt (3.6 eq.) in DMF. The 
Fmoc group was cleaved off with 20% piperidine/DMF. Finally, norleucine was 
introduced as Fmoc-D,L-Nle-OH and the Ata group as described above. 
The fully protected Ata-P,« was cleaved from the resin during a two hour reaction 
with 55% trifluoroacetic acid in dichloromethane; all side chain protecting groups 
(except the Pms group) are cleaved in this mixture simultaneously. After 
evaporation in vacuo the residue was treated with a mixture of 
TFA/methanesulfonic acid/thioanisole (10/1/1) for 2 hrs at ambient temperature 
to remove the Pms group. 
The crude Ata-P,4 was purified via countercurrent distribution using the 
extraction system n-butanol/acetic acid/water (5/1 /4) over 200 transfers. A 
chromatographically pure fraction was obtained. Except for serine, this fraction 
had the expected amino acid composition (moles/mole; Nie defined as 1; 
theoretical composition in parentheses) i.e. Arg 2.15 (2.00), Asp 2.14 (2.00), Glu 
1.03 (1.00), He 3.04 (3.00), Leu 0.98 (1.00), Lys 2.14 (2.00), Nie 1.00 (1.00), Ser 
0.56(1.00), Val 1.01 (1.00). 
The low amount of Ser is due to deterioration in the very strongly acidic 
conditions during hydrolysis before amino acid analysis. 
Coupling of the tetradecapeptide to BSA 
To 50 mg BSA (Carl Roth, Karlsruhe, FRG; 99% pure) dissolved in 1 ml buffer 
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(phosphate, pH = 8.0), 4.5 mg 6-(1-maleimido)hexanoic acid 1-succinimide ester 
was added (Peeters eí al. 1989). After 5 minutes the reaction mixture was 
subjected to gel filtration on a Sephadex G-25 column (Pharmacia, Uppsala, 
Sweden), run in phosphate buffer pH = 6.0. 
The peptide derivative was activated by cleaving the acetyl group from the Ata-
moiety by dissolution in a mixture of 4 M NaOH/methanol/dioxane (1/5/14) for 
exactly 15 seconds and subsequent neutralization with acetic acid. The solution 
containing the neutralized thioacetyl-tetradecapeptide (Tha-P,«) was added to the 
functionalized BSA and allowed to react for two hours at ambient temperature 
(Keller and Rudinger 1975). The reaction mixture was dialyzed against distilled 
water for 24 hours and lyophilized. The amount of incorporated Nie, as 
determined by amino acid analysis, showed that on average 4 to 5 Tha-P,4 
molecules were linked per BSA molecule. 
Antigens 
Human fibrinogen was purified as described before (van Ruijven-Vermeer and 
Nieuwenhuizen 1978). 
Fibrin monomers were prepared according to Haverkate and Timan (1976) and 
stored as a 13.4 mg/ml solution in 20 mM acetic acid at -20oC. Prior to use they 
were diluted to 0.45 mg/ml with 20 mM acetic acid (fibrin monomer solution, see 
below). 
Fibrinogen Aa chain was obtained by reduction and carboxymethylation of 
fibrinogen and purified according to Doolittle and coworkers (1977). 
Cyanogen bromide digestion of fibrinogen was performed according to Blombäck 
ef al. (1968). CNBr fragment FCB-2 (comprising the sequence Aa-(148-207)) was 
isolated from the digest as described by us before (Nieuwenhuizen ef al. 1983") 
by a method adapted partly from the procedure of Olexa ef al. (1979). 
Soluble fibrin was generated in plasma by addition of thrombin (Leo, Ballerup, 
Denmark; 10 μ\, 2 NIH/ml) to 0.1 ml portions of normal pooled citrated plasma. 
At timed intervals (between 0-75 seconds) 40 μΙ aliquots were taken in which the 
thrombin reaction was quenched by 20-fold dilution in PBS containing 0.05% 
Tween 20 and hirudin (0.2 U/ml). 
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In some experiments Arvin (= Agkistrodon rhodostoma venom protease) 
(Defibrase, Pentapharm, Basel, Switzerland) was used instead of thrombin, under 
the same conditions. In these experiments, however, the reaction was quenched 
by the addition of diisopropylfluorophosphate (DFP) to a final concentration of 1 
mM. 
Immunization scheme 
Female BALB/c mice were injected intraperitoneally with 125 μg immunogen (co­
rresponding with approximately 10 pg of BSA-linked peptide) in Freund complete 
adjuvant (Difco, Amsterdam, The Netherlands) and then twice at 2 weeks 
intervals with 125 μg immunogen in Freund incomplete adjuvant. An 
intraperitoneal injection of 250 цд immunogen in 0.15 M NaCI was given three 
days before fusion. 
Fusion 
The immunized mice were killed in ether vapor and spleen cells were harvested. 
Spleen cells (7.8*107) were fused with 1.4*107 non-producing myeloma cells 
(Sp2/0 AG14) in the presence of 40% polyethyleneglycol 4000 (Baker, Deventer, 
The Netherlands), essentially as described by Köhler and Milstein (1975). The 
cell suspension was diluted and divided over 96 wells microtitration plates 
(Costar, Cambridge, Mass.). Media of growing cells were screened for antibody 
production as described below. Cell lines producing reactive antibodies were 
subcloned twice by limiting dilution (0.5 cells/well) as described by Oi and 
Herzenberg (1980). 
Hybridoma selection procedure 
Hybridoma's were selected using an enzyme-linked immunosorbent assay 
(ELISA). The ELISA was performed essentially as described before (Koppert et 
al. 1985 and 1986) with purified Aa chains or FCB-2 as immobilized antigens. 
Immunoreactive mouse immunoglobulin was visualized with horse-radish 
peroxidase (HRP) labelled rabbit antimouse immunoglobulin (from Nordic, 
Tilburg, The Netherlands) using 3,3',5,5'-tetramethyl benzidine (TMB, from Aldrich 
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Chemical Co, Milwaukee), and Н
г
О
г
 as the substrate mixture (Bos et al 1981) 
Subclass assessment and purification of the MoAb's 
Subclass assessment was carried out by Immunoelectrophoresis (IEF) as des­
cribed by Radi (1981) Antisera against mouse α-, μ-, δ-, e-, γ-, κ-, and λ-chain 
were gifts from Dr Radi (Institute for Experimental Gerontology TNO, Rijswijk, 
The Netherlands) 
Since the MoAb appeared to precipitate at low ionic strength, purification was 
carried out by simply dialysmg of the ascites fluids against 0 005 M sodium 
phosphate pH 6 0 
RESULTS 
Preparation of the monoclonal antibodies 
Two weeks after fusion and selection, cell growth was observed in 260 of the 
380 seeded wells The media of 4 wells reacted with Aa chain in the ELISA 
system The cells from two of the positive wells were cloned and recloned After 
cloning and reclonmg 4 clones were chosen for further study One is described 
in this paper This line has been m culture for 2 months and has been injected 
into the peritoneal cavity of BALB/c mice for m vivo production of ascites fluid 
Also in vivo the clone appeared to be stable / e more than 2 months (3 
passages) 
We will refer to the MoAb produced by this clone as anti-Fb-1/2 Subclass 
assessment showed that anti-Fb-1/2 is of the ІдМ/к subclass Therefore it could 
not be purified by protein A-Sepharose chromatography It precipitates, however, 
during dialysis against a low ionic strength buffer (0 005 M sodium phosphate, 
pH 6), and can easily be redissolved by addition of a high ionic strength buffer 
(1 7 M NaCI, 0 05 M sodium phosphate, pH 6) and remains in solution upon 
dilution to physiological ionic strengths 
Specificity of the monoclonal antibodies 
In purified systems anti-Fb-1/2 showed the following characteristics in the 
ELISA system (see above) It did not react with BSA which was used as a carrier 
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protein, nor with fragment E, and only weakly with pure fibrinogen. It reacted, 
however, strongly with fibrinogen Aa chain and FCB-2. Apparently, Αα-(14β-160) 
in FCB-2 and in Aa-chain, but not in fibrinogen, can interact with the MoAb. 
Figure 1 Dose-response curves of 20-fold diluted plasma with a fibrinogen concentration 
of 2.4 mg/ml (0) and of the same 20-fold diluted normal plasma but with fibrin 
monomer added to a final concentration of 15 pg/ml (4) 
Anti-Fb-1/2 is able to interact with fibrin (in the μg/ml range) in a plasma mi­
lieu i.e. in excess fibrinogen, as shown in figures 1 and 2. (The fibrinogen con­
centration of the plasma was 2.4 mg/ml). In figure 1, results of an experiment 
are depicted in which microtitration plates coated with anti-Fb-1/2 were used. 
The coated wells were incubated with serial dilutions of a pooled normal plasma 
which was spiked with fibrin monomer solution. Captured antigen was tagged 
with rabbit polyclonal anti-FDM conjugated with HRP (Koppert et al. 1985 and 
1986), and visualized by incubation with TMB/H202 substrate. Fibrin concen­
trations down to 1 pg/ml are readily detectable. 
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Virtually identical dose-response curves were obtained when the fibrin 
monomer concentration was varied and the plasma dilution kept constant (not 
shown). In figure 2 a similar experiment is shown Now the soluble fibrin was 
generated m plasma by treating the plasma for different periods of time with 
thrombin A progressive increase in response with time of thrombin treatment is 
seen Treatment with Arvm, which releases only fibrmopeptide A, yields 
comparable results Normal plasma gives virtually no response 
Figure 2 Dose-response curves of normal plasma with a fibrinogen concentration of 2 4 
mg/ml (0) and of the same normal plasma treated with thrombin for 25 sec (Π), 
50 sec (•), or 75 sec (•) 
DISCUSSION 
Other investigators have shown that the new ammo-terminal ends, which 
result from cleavage of the fibrmopeptides A and В from the ammo-terminal ends 
of the fibrinogen Acr- and Bß-chams, respectively, constitute fibrin-specific 
epitopes (Scheefers-Borchel ef al 1985, Liau et al. 1987 and Hui ef al. 1983) 
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Several fibrin-specific antibodies of this type are currently available (for review 
see Nieuwenhuizen 1987"). 
Over the last years we have studied in detail the accelerating effect exerted by 
fibrin on the t-PA catalyzed plasminogen activation. 
We found that not only fibrin, but also non-physiological fragments of fibrinogen 
(but DQÎ intact fibrinogen) such as the plasmin fragment DEQTA (Verheijen ef al. 
1982') and the CNBr fragment FCB-2 (Nieuwenhuizen ef al. 1983") accelerate the 
plasminogen activation by t-PA (Verheijen ef al. 1982" and Menschen 1981). The 
activity of FCB-2 and DeeTA resides in their Aa-chain remnants. Since the Ασ-
chain remnants of DEQTA and FCB-2 are composed of the stretches Aa-(111-197) 
and Aa-(148-207), respectively, we concluded that essential information must 
reside within Ασ-(148-197) (Nieuwenhuizen ef al. 1983ь). In a more recent study 
(Voskuilen ef al. 1987), we could delineate the essential structure even further i.e. 
to Aa-(148-160), and we could show that lysine Aa 157 plays a crucial role. 
On these results we based the working hypothesis, that the stretch Aa-(148-
160) is buried in fibrinogen, and is exposed upon transformation of fibrinogen to 
fibrin, and by digestion of fibrinogen with plasmin or with CNBr. 
This concept is supported by our present findings i.e. that MoAb's directed 
against Aa-(148-160) react with fibrin and not with fibrinogen. The weak 
reaction, which is observed with purified fibrinogen and with 20-fold diluted 
plasma (Figures 1 and 2) is probably caused by trace contaminations of soluble 
fibrin. It has been reported that normal plasma levels of soluble fibrin are 
between 0.5 and 13.5 μg/mì (Nieuwenhuizen ef al. 1987"). It is very unlikely, 
therefore, that fibrinogen preparations can be obtained with lower fibrin 
concentrations. 
Our results show for the first time, that Aa-(148-160) is a fibrin-specific 
epitope. At present the applicability of anti-Fb-1/2 as capture antibody in a 
sandwich-type EIA for soluble fibrin in plasma, is investigated. 
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ABSTRACT 
Fibrin, but not fibrinogen, accelerates the activation of plasminogen catalyzed 
by t-PA. Detailed studies showed that (part of) this rate-enhacing effect of fibrin 
is brought about by two sites in the fibrin molecule: one in Aa-(148-160) and one 
in FCB-5. During the fibrinogen-to-fibrin conversion, Aa-(148-160) appears to 
become accessible, since monoclonal antibodies against synthetic Aa-(148-160) 
react with fibrin, but not with fibrinogen. Since a similar situation may exist for 
(at least parts of) FCB-5, we have prepared monoclonal antibodies against a part 
(i.e. γ-(312-324)) of FCB-5, and found that these are fibrin-specific and do not 
bind fibrinogen. 
We conclude that γ-(312-324) is hidden in fibrinogen and is exposed by the 
formation of fibrin. 
INTRODUCTION 
Thrombin, formed from its precursor prothrombin by an activated coagulation 
system, converts the soluble blood protein fibrinogen to insoluble fibrin. Fibrin is 
known to play an important role as the protein matrix of a blood clot. Fibrin has 
only a temporary function; after it has fulfilled its role, e.g. in tissue repair, it will 
be converted to soluble degradation products, with concomitant lysis of the 
blood clot. The crucial step in this fibrinolytic process is the activation of 
plasminogen to plasmin by plasminogen activators such as t-PA (Rijken ef al. 
1979, Collen 1980). The formed plasmin converts fibrin to soluble degradation 
products. 
The activation of plasminogen by t-PA is greatly accelerated by fibrin, but 
virtually not by fibrinogen (Wallen 1977, Allan and Pepper 1981, Hoylaerts ef al. 
1982). Not only fibrin, but also plasmin-generated fragments of fibrin (D-dimer) 
and of fibrinogen (DEQTA) accelerate the t-PA catalysed plasminogen activation 
(Verheijen ef al. 1982"). Also, cyanogen bromide digests of fibrin(ogen) 
accelerate the plasminogen activation and the effect is partly recovered in FCB-2 
(Nieuwenhuizen ef al. '\983ь). Further studies (Voskuilen ef al. 1987) showed that 
part of the rate-enhancing effect of fibrin is brought about by Aa-(148-160) which 
is a constituent of FCB-2. On the basis of these findings and the fact that 
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monoclonal antibodies (MoAbs) against synthetic Αα-(148-160) are fibrin-specific, 
we concluded that the stretch Aa-(148-160) Is burled in fibrinogen but becomes 
exposed upon the flbrinogen-to-fibrin conversion (Schielen ef al. 1989). 
Recently, another fragment of the fibrinogen molecule was found that is 
capable of accelerating the plasminogen activation by t-PA; i.e. FCB-5 (Yonekawa 
et al. 1989, 1990). FCB-5 consists of γ-(311-336) disulfide linked to γ-(337-379). 
Both γ-chain remnants and the disulfide bridge seem to be involved since 
reduced FCB-5 nor γ-(311-336) or γ-(337-379) have rate-enhancing capacity. 
It is interesting to note that γ-(315-322) has a charge distribution analogous to 
that of Ασ-(150-158), i.e. 
Aa-(150-158): Leu-Glu-Val-Asp-Ile-Asp-Ile-Lys-Ile 
0 - 0 - 0 - 0 + 0 
γ-(315-322): Trp-Asp-Asn-Asp-Asn-Asp-Lys-Phe 
0 - 0 - 0 - + 0 
We reasoned that, like we have shown (Schielen et al. 1989) for Αα-(148-160), 
also a part of FCB-5, e.g. γ-(315-322), may be burled in fibrinogen, and become 
exposed upon the fibrin formation. To assess this hypothesis we elicited 
monoclonal antibodies (MoAbs) against synthetic γ-(312-324). 
In this paper we describe the production of MoAbs against this sequence of 
FCB-5. A conjugate of BSA and a synthetic peptide with the sequence γ-(312-
324) was used as immunogen. The resulting antibodies react exclusively with 
fibrin, and not with fibrinogen. This clearly demonstrates that like Ασ-(148-160), 
γ-(312-324) is a fibrin-specific neo-epltope. This finding supports our hypothesis 
that (at least parts of) the rate-enhancing fragment FCB-5 exists in a latent form 
in fibrinogen, but becomes exposed in fibrin. 
MATERIALS AND METHODS 
Synthesis of [Ata-Nle3"1-fibrinogen-Y-(311-324Vtetradecapeptide 
Fibrinogen-Y-(312-324)-tridecapeptide (Phe-Ser-Thr-Trp-Asp-Asn-Asp-Asn-Asp-
Lys-Phe-Glu-Gly) was extended with Ata-Nle at the amino-terminus. Thus, Gin 
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present in fibrinogen at γ 311 is replaced by Nie. This procedure allows the 
coupling to a carrier protein and (via the nor leucine content) the subsequent 
determination of the number of coupled peptides per carrier protein molecule. 
The [Ata-Nle31,]-fibrinogen-v-(311-324)-tetradecapeptide was synthesized on p-
alkoxybenzyl alcohol resin (Wang 1973) using NT-Fmoc amino acid derivatives 
(ten Kortenaar et al. 1966) with the aid of a half-automated peptide synthesizer 
(SP 640, Labortec, Bubendorf, Switzerland). 
During solid phase peptide synthesis the amino acid side chains were protected 
with acid-labile protecting groups: the e-amino group of lysine with Boc, the γ-
carboxyl group of glutamic acid and the 6-carboxyl group of aspartic acid with 
OBu', and the ß-hydroxyl group of serine and threonine with Bu'. The carboxyl 
terminal amino acid derivative, Fmoc-Gly-OH [0.9 equivalents (eq.)] was coupled 
to the resin (1.07 mmol/g) by in situ activation with DCC (0.9 eq.) and DMAP (0.9 
eq.). To suppress racemization, HOBt (1.8 eq.) was added (van Nispen et al. 
1985). All reactants were dissolved in DMF. After 16 hours at 5 "C the resin was 
washed three times with successively each of DMF, dichloromethane, and 
isopropyl alcohol. Finally, the resin was washed with diisopropyl ether and dried 
in vacuo. The amount of Fmoc-amino acid attached to the resin was determined 
by elemental analysis of the amount of nitrogen in a sample of the resin. The 
cleavage of the Fmoc groups was carried out with 20% (vol/vol) piperidine in 
DMF, during three consecutive cycles of 6 minutes. Coupling of the second 
amino acid derivative (3 eq. relative to the amount of first amino acid attached to 
the resin) was performed by in situ activation with TBTU (3 eq.) (Knorr ef al. 
1989), HOBt (3 eq.) and N-methylmorfoline (4.5 eq.). After coupling of each 
amino acid derivative, completion of the acylation reaction was monitored by a 
ninhydrin test on free amino groups (Kaiser ef al. 1970), followed by acylation of 
any remaining free amino groups with 10% (vol/vol) acetic acid anhydride in 
DMF. The fully-protected peptide was cleaved from the resin during a 4 h 
reaction with 2.5% (vol/vol) ethanedithiol and 2.5% (vol/vol) water in 
trifluoroacetic acid followed by precipitation in diethyl ether. The crude peptide 
was washed several times with diethyl ether and dried at the air. 
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Coupling of the tetradecapeptide to BSA 
To 50 mg BSA (Carl Roth, Karlsruhe, FRG; 99% pure) dissolved in 1 ml buffer 
(phosphate, pH = 8.0), 4.5 mg 6-(1-maleimido)hexanoic acid 1-succinimide ester 
was added (MHS, Peelers ef al. 1989). After 5 minutes the reaction mixture was 
subjected to gel filtration on a Sephadex G-25 column (Pharmacia, Uppsala, 
Sweden), run in phosphate buffer pH = 6.0. 
The peptide derivative was activated by cleaving the acetyl group from the Ata-
moiety by dissolution in a mixture of 4 M NaOH/methanol/dioxane (1/5/14) for 
exactly 15 seconds and subsequent neutralization with acetic acid. The solution 
containing the neutralized thioacetyl-tetradecapeptide (Tha-P14) was added to the 
functionalized BSA and allowed to react for two hours at ambient temperature 
(Keller and Rudinger 1975). The reaction mixture was dialyzed against distilled 
water for 24 hours and lyophilized. The amount of incorporated Nie, as 
determined by amino acid analysis, showed that on average 4 to 5 Tha-P14 
molecules were linked per BSA molecule. 
Antigens 
Human fibrinogen was purified as described before (van Ruijven-Vermeer and 
Nieuwenhuizen 1978). 
Fibrin monomers were prepared according to Haverkate and Timan (1976) and 
stored as a 13.4 mg/ml solution in 20 mM acetic acid at -20°C. Prior to use they 
were diluted to 0.45 mg/ml with 20 mM acetic acid (fibrin monomer solution, see 
below). 
Fibrinogen γ-chain was obtained by reduction and carboxymethylation of 
fibrinogen and purified according to Doolittle and coworkers (1977). 
Cyanogen bromide digestion of fibrinogen was performed according to Blombäck 
et al. (1968). CNBr fragment FCB-5 was isolated from the digest as described by 
Yonekawa et al. (1989, 1990). 
Soluble fibrin was generated in plasma by addition of thrombin (Leo, Ballerup, 
Denmark; 10 μ\, 2 NIH/ml) to 0.1 ml portions of normal pooled citrated plasma. 
At timed intervals (between 0-60 seconds) 40 μΙ aliquots were taken in which the 
thrombin reaction was quenched by 20-fold dilution in PBS containing 0.05% 
49 
Tween 20 and hirudin (0.2 U/ml). 
In some experiments Arvin (= Agkistrodon rhodostoma venom protease) (Arwin, 
Knoll AG Ludwigshafen) was used Instead of thrombin, under the same 
conditions. In these experiments, however, the reaction was quenched by the 
addition of diisopropylfluorophosphate (DFP) to a final concentration of 1 mM. 
Immunization scheme 
Female BALB/c mice were injected intraperitoneally with 62.5 μQ immunogen 
(corresponding with approximately 5 μg of BSA-linked peptide) In Freund 
complete adjuvant (Difco, Amsterdam, The Netherlands) and then 6 times at 1 
week intervals with 62.5 μg immunogen in Freund incomplete adjuvant. An 
intraperitoneal injection of 125 μg immunogen in 0.15 M NaCI was given three 
days before fusion. 
Fusion 
The immunized mice were killed in carbondioxide vapor and spleen cells were 
harvested. Spleen cells (9.8*107) were fused for 1 minute with 2.4*107 non-
producing myeloma cells (Sp2/0 AG14) in the presence of 40% 
polyethyleneglycol 1500 (Boehringer Mannheim), essentially as described by 
Köhler and Milstein (1975). The cell suspension was washed, diluted, and 
divided over four 96 wells microtitration plates (Costar, Cambridge, Mass.). 
Media of growing cells were screened for antibody production as described 
below. The cell line producing reactive antibody was subcloned three times by 
limiting dilution (0.5 cells/well) as described by Oi and Herzenberg (1980). 
Hybridoma selection procedure 
Hybridoma's were selected using an enzyme-linked immunosorbent assay 
(ELISA). The ELISA was performed essentially as described before (Koppert et 
al. 1985 and 1986) with thrombin treated purified fibrinogen as immobilized 
antigen. Immunoreactive mouse immunoglobulin was visualized with horse-
radish peroxidase (HRP) labelled rabbit antimouse immunoglobulin (from Nordic, 
Tilburg, The Netherlands) using a.S'.S.S'-tetramethyl benzidine (TMB, from Aldrich 
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Chemical Co, Milwaukee), and H202 as the substrate mixture (Bos ef al. 1981). 
Subclass assessment and purification of the MoAb's 
Subclass assessment was carried out with a isotyping kit for monoclonal 
antibodies (Serotec, Oxford, England). 
Since the MoAb appeared to precipitate at low ionic strength, purification was 
carried out by simply dialysing of the ascites fluids against 0.005 M sodium 
phosphate pH 6.0. 
Sandwich-type EIA 
Wells of polystyrene microtitration plates were coated with anti-Y-(312-324) by 
overnight incubation at 4 0C with a 10 μg/ml solution of the antibody in 0.1 M 
sodium carbonate buffer, pH 9.6. The anti-Y-(312-324) coated wells were 
incubated with serial dilutions of a pooled normal plasma which was spiked with 
fibrin monomer solution. Captured antigen was tagged with G8 conjugated with 
HRP (Hoegee ef a/. 1988), and visualized by incubation with TMB/H202 substrate. 
RESULTS 
Preparation of the monoclonal antibodies 
Two weeks after fusion and selection, cell growth was observed in most of the 
seeded wells. The medium of one well reacted with the thrombin treated 
fibrinogen in the ELISA system. The cells from the positive well were cloned and 
recloned. After cloning and recloning one clone was chosen for further study 
and is described in this paper. This line has been in culture for 2 months and 
has been injected into the peritoneal cavity of BALB/c mice for in vivo production 
of ascites fluid. Also in vivo the clone appeared to be stable i.e. more than 2 
months (3 passages). 
We will refer to the MoAb produced by this clone as anti-Y-(312-324). 
Subclass assessment showed that anti-Y-(312-324) is of the ІдМ/к subclass. 
Therefore it could not be purified by protein A-Sepharose chromatography. It 
precipitates, however, during dialysis against a low ionic strength buffer (0.005 M 
sodium phosphate, pH 6), and can easily be redissolved by addition of a high 
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ionic strength buffer (1.7 M NaCI, 0.05 M sodium phosphate, pH 6) and remains 
in solution upon dilution to physiological ionic strengths. 
Specificity of the monoclonal antibodies 
In purified systems anti-Y-(312-324) showed the following characteristics in the 
ELISA system (see above). It did not react with BSA which was used as a carrier 
protein. It reacted, however, strongly with coated, thrombin treated fibrinogen 
and with purified γ-chain. As illustrated by figures 1 and 2, in a sandwich-type 
EIA, anti-Y-(312-324) shows virtually no reaction with normal plasma with a 
Figure 1 Dose-response curves of 60-fold diluted plasma with a fibrinogen concentration 
of 2.4 mg/ml (0) and of the same 60-fold diluted normal plasma but with fibrin 
monomer added to a final concentration of 5 pg/ml (•) 
fibrinogen concentration of 2.4 mg/ml. ΑηΙί-γ-(312-324) is able to interact with 
fibrin (in the цд/т\ range) in a plasma milieu i.e. in excess fibrinogen, as shown 
in figures 1 and 2. In figure 1, results of an experiment are depicted in which 
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microtitration plates coated with апіі-у-(312-324) were used (sandwich-type EIA). 
Fibrin concentrations in the 0.1-1 /jg/ml range are readily detectable. 
Virtually identical dose-response curves were obtained when the fibrin 
monomer concentration was varied and the plasma dilution kept constant (not 
shown). In figure 2 a similar experiment is shown. Now the soluble fibrin was 
generated in plasma by treating the plasma for different periods of time with 
thrombin. A progressive increase in response with time of thrombin treatment is 
seen. Treatment with Arvin, which releases only fibrinopeptide A, yields 
comparable results. Normal plasma gives virtually no response. 
Figure 2 Dose-response curves of normal plasma with a fibrinogen 
concentration of 2 4 mg/ml (0) and of the same normal plasma 
treated with thrombin for 20 sec (D), 40 sec (•). or 60 sec (•) 
DISCUSSION 
The activation of plasminogen, as catalyzed by t-PA, is accelerated in the 
presence of fibrin. Fibrinogen has virtually no effect on the plasminogen 
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activation (Wallen 1977). Fragments derived of fibrin(ogen) also can have an 
accelerating effect on the plasminogen activation by t-PA (Verheijen ef al. 1982*). 
Such fragments can be generated from fibrin(ogen) by digestion with plasmin or, 
chemically, with cyanogen bromide. It was concluded from these experiments 
that latent stimulatory sites pre-exist in fibrinogen which become exposed upon 
the conversion to fibrin or upon fragmentation of fibrinogen by plasmin or CNBr. 
Voskuilen ef al. (1987) showed that the peptide Ασ-(148-160), which is part of 
FCB-2, plays an important role in the acceleration of the plasminogen activation 
by t-PA. 
A second type of stimulatory site was discovered by Yonekawa ef al. 1989, 
1990) in a region of the γ-chain, known as FCB-5. The FCB-5 fragment 
constitutes two γ-chain fragments (i.e. γ-(311-336) and γ-(337-379)), linked by 
one disulfide bond. Both γ-chain remnants and the disulfide bridge are required 
for rate enhancement. 
In the case of Aa-(148-160), we have shown that this sequence is buried in 
fibrinogen and is exposed upon transformation of fibrinogen to fibrin, or by 
fibrinogen digestion with plasmin or with CNBr. The approach was to elicit 
MoAbs against synthetic Ασ-(148-160). These anti-Aa-(148-160) MoAbs react 
with fibrin and not with fibrinogen (Schielen ef al. 1989). Like Aa-(148-160), at 
least part(s) of FCB-5 may constitute a fibrin-specific epitope, i.e. be buried in 
fibrinogen and exposed in fibrin. 
The sequence Aa-(150-158) in Aa-(148-160) has an interesting charge 
distribution, /.е.: 
L e u - G l u - V a l - A s p - I l e - A s p - I l e - L y s - I l e 
0 - 0 - 0 - 0 + 0 
Negative and neutral amino acid residues alternate and the sequence ends with a 
lysine followed by a neutral residue. The sequence γ-(315-322) ¡η γ-(311-336) 
has a similar charge distribution: 
Trp-Asp-Asn-Asp-Asn-Asp-Lys-Phe 
0 - 0 - 0 - + 0 
The major differences are that the neutral amino acid residues in γ-(315-322) are 
much more polar (Asn instead of He) than in Ασ-(150-158), and that the neutral 
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residue preceeding the lysyl residue is missing in the γ-chain 
Because of these analogous charge patterns of γ-(315-322) and Aa-(150-158) 
we selected a stretch of FCB-5, which includes γ-(315-322) to be part of a 
synthetic peptide, against which monoclonal antibodies were elicited. The 
obtained MoAbs appear to react only with fibrin and not with fibrinogen, thus 
providing evidence for our hypothesis that, like Αα-(148-160), γ-(312-324) which 
is part of the stimulatory fragment FCB-5, is buried in fibrin but becomes 
exposed upon the fibrinogen-to-fibnn conversion. 
In summary, we have shown that γ-(312-324) is a fibrin-specific epitope. 
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ABSTRACT 
The rate of activation of plasminogen by tissue-type plasminogen activator is 
greatly Increased by fibrin, but not by fibrinogen. We have previously shown that 
fibrin(ogen) fragments such as the fibrin(ogen) cyanogen bromide fragment 2 
and a synthetic peptide with the sequence of fibrinogen Aa-(148-160) also have 
rate-enhancing properties. It was suggested that Lys157 in the Aa-chain plays an 
important role. In order to find a possibly smaller, still stimulating site within Ασ-
(148-160) we synthesized successive linear amino-terminally acylated 
hexapeptides [i.e. Aa-(148-153), Ao-(149-154) Aa-(155-160)] and a 
tetrapeptide [/.β. Aa-(155-158)] from the sequence Aa-(148-160). The only 
hexapeptide capable of enhancing the rate of plasminogen-to-plasmin conversion 
by t-PA appears to be the amino-terminally acylated peptide comprising the 
sequence Aa-(154-159). 
INTRODUCTION 
Upon activation of the coagulation system, thrombin is generated from its 
zymogen prothrombin. Thrombin converts circulating fibrinogen molecules to 
fibrin monomers by the cleavage of fibrinopeptides, A and B, from the amino-
terminal ends of the two Ασ and Bß chains of fibrinogen, respectively. The 
resulting new amino-termini of the α and ß chain contain sites that are capable of 
binding to complementary sites in the carboxyl-terminal domains (Doolittle 1981, 
Laudano and Doolittle 1981) of other fibrin(ogen) molecules. At low 
concentrations fibrin monomer is kept in solution by complexing with fibrinogen. 
At a certain critical (local) concentration, fibrin aggregates to form a fibrin gel, 
that will eventually form the water-insoluble protein matrix of a blood clot. After 
a clot has fulfilled its role in the haemostatic process, e.g. in tissue repair, the 
matrix is dissolved by proteolysis by plasmin. Plasmin can be generated from its 
zymogen plasminogen by several plasminogen activators, such as tissue-type 
plasminogen activator (t-PA) (Rijken ef al. 1979, Collen 1980). 
Fibrin, and not fibrinogen, has the capacity to accelerate the plasminogen-to-
plasmin conversion, mediated by t-PA. Fragments of fibrin and fibrinogen that 
enhance the rate of plasmin formation can be generated by digestion with 
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plasmin or, chemically, with cyanogen bromide. In particular the plasmin-
generated fibrinogen fragment DEeTA (Verheijen ef al. 1982*) and CNBr fragment 
FCB-2 (Nieuwenhuizen ef al. 1983") can mimic the effect of fibrin. More detailed 
studies have shown that the sequence Aa-(148-197) (Nieuwenhuizen ef al. 1983*) 
and in particular the sequence Aa-(148-160) and Lys157 in the Aa-chain (Voskuilen 
ef al. 1987) play an essential role in this activation. The sequence Aa-(148-160) 
seems to be buried in fibrinogen and becomes exposed upon the fibrinogen-to-
fibrin conversion by thrombin as evidenced by the reactivity with fibrin (and not 
with fibrinogen) of monoclonal antibodies raised against a synthetic peptide with 
the sequence Ασ-(148-160) (Schielen ef al. 1989). 
In order to localize the stimulating site within Ασ-(148-160) more precisely we 
describe in this paper the synthesis and the accelerating capacity, on the 
plasminogen-to-plasmin conversion by t-PA of successive linear amino-terminally 
acylated hexapeptides {i.e. a window of six residues moving from the amino 
terminus to the carboxyl terminus) covering the sequence Aa-(148-160). The 
results clearly demonstrate that the hexapeptide comprising the sequence Aa-
(154-159) is the only one that is capable of accelerating the plasminogen 
activation by t-PA. 
MATERIALS AND METHODS 
Tissue-type plasminogen activator 
Two-chain t-PA was purified from large scale melanoma cell culture according to 
Rijken ef al. (1979), as modified by Kluft ef al. (1983). 
Plasminogen 
Native plasminogen (glu-plasminogen) was purified from fresh human plasma by 
affinity chromatography (Deutsch and Mertz 1970) on lysine-Sepharose 
(Pharmacia Fine Chemicals, Uppsala, Sweden), precipitated with ammonium 
sulfate and dialysed extensively against 0.1 M Tris.HCI, pH 7.5, containing 0.1% 
(vol/vol) Tween 80 (Baker Chemicals). 
Esplides 
The hexapeptides, Ata-Aa-(148-153); Ata-Aa-(149-154); Ata-Aa-(150-155); Ata-Aa-
(151-156); Ata-Aa-(152-157); Ata-Aa-(153-158); Ata-Aa-(154-15g), and Ata-Aa-(155-
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160) were synthesized simultaneously on p-alkoxybenzyl alcohol resin (Wang 
1973) using Fmoc amino acid derivatives (ten Kortenaar ef al. 1966) and a 
multiple peptide synthesis system (RaMPS, Du Pont de Nemours, Boston, Mass., 
USA). The tetrapeptide Aa-(155-158) was synthesized on a half-automated 
peptide synthesizer (SP 640, Labortec, Bubendorf, Switzerland). 
During solid phase peptide synthesis the amino acid side chains were protected 
with acid-labile protecting groups: the e-amino group of lysine with Boc, the 6-
guanidino group of arginine with Pmc, the γ-carboxyl group of glutamic acid and 
the ß-carboxyl group of aspartic acid with OBu', and the ß-hydroxyl group of 
serine with Bu'. The carboxyl terminal amino acid [2 equivalents (eq.)] was 
coupled to the resin (1.07 mmol/g) by in situ activation with DCC (2 eq.) and 
DMAP (2 eq.). To suppress racemization HOBt (4 eq.) was added (van Nispen ef 
a/. 1985). All reactants were dissolved in DMF. After 16 hours at 5 "c the resin 
was washed three times with successively each of DMF, dichloromethane, and 
isopropyl alcohol. Finally, the resin was washed with diisopropyl ether and dried 
in vacuo. The amount of Fmoc-amino acid attached to the resin was determined 
by elemental analysis of the amount of nitrogen in a sample of the resin. The 
cleavage of the Fmoc groups was carried out with 50% (vol/vol) piperidine in 
DMF. Coupling of the second amino acid derivative (3 eq. relative to the amount 
of first amino acid attached to the resin) was performed by In situ activation with 
TBTU (3 eq.) (Knorr ef al. 1989), HOBt (3 eq.) and NMM (4.5 eq.). After coupling 
of each amino acid derivative, completion of the acylation reaction was 
monitored by a ninhydrin test on free amino groups (Kaiser ef al. 1970), followed 
by acylation of any remaining free amino groups with 10% (vol/vol) acetic acid 
anhydride in DMF. Finally, the Ata group was introduced via an active ester 
coupling with Ata-N-hydroxysuccinimide. The fully protected peptides were 
cleaved from the resin during a 4 h reaction with 2.5% (vol/vol) ethanedithiol and 
2.5% (vol/vol) water in trifluoroacetic acid followed by precipitation in diethyl 
ether. The crude peptides were washed several times with diethyl ether, dried at 
the air, and analyzed by HPLC, specific rotation and amino acid composition. 
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HPLC analyses 
HPLC analyses were performed on a RP-18 column (Techsil 5 C18, 250 χ 4.6 mm, 
HPLC Technology, Cheshire, UK) at a flow-rate of 1.0 ml/min., using a 5 min. 
isocratic elution with 7% (vol/vol) acetonitrile and 0.1% (vol/vol) trifluoroacetic 
acid in water followed by a 30 min. linear gradient from 7% (vol/vol) acetonitrile 
and 0.1% (vol/vol) trifluoroacetic acid in water to 70% (vol/vol) acetonitrile and 
0.08% (vol/vol) trifluoroacetic acid in water. Peptides were detected by UV 
measurement at 215 nm. The UV data were analyzed using JCL 6000 
Chromatography Data System software (Jones Chromatography, Mid Gian, UK). 
Amino acid analyses 
Peptides were hydrolysed in 5.7 M HCl (Merck Suprapur) in evacuated sealed 
glass tubes for 24 hours at 120 °C. The hydrolysates were lyophilized and 
analyzed with a Varían 9095 amino acid analyzer using the Fmoc-protocol. 
Specific rotations 
The specific rotations were measured with a Perkin Elmer Polarimeter 241. All 
peptides were dissolved in DMF and centrifuged for 10 minutes at 4500 rpm prior 
to the measurement. 
Assay system for the assessment of the rate-enhancing properties of the 
In total volumes of 0.250 ml 0.1 M Tris.HCI, containing 0.1% (vol/vol) Tween 80 
were present 0.11 μΜ glu-plasminogen, 0.3 mM H-D-Val-Leu-Lys-p-nitroanilide, 
300 mlU t-PA, and varying concentrations of the synthetic peptide to be tested 
for stimulating activity. In this assay, the concentration of p-nitroaniline formed 
per time-squared is proportional to the rate of plasmin formation (activation rate) 
(Drapier ef al. 1979). The ratio of the activation rate in the presence of the 
peptide over that in the absence of peptide was designated as stimulation factor. 
RESULTS 
Table I shows that the amino acid compositions are as expected. 
Table II summarizes the HPLC data and specific rotations obtained for each of 
the crude peptides. As indicated by the data, the purity of the peptides was 
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TABLE I 
Amino acid compositions of the synthetic peptides prepared in this study. 
Expected values between parentheses. 
mola/mot· of popttd· 
Ρ · ρ β * 
At»-*i-(148-1S3) 
A»Al-(149-1S4) 
Α1^Αα-(150-155) 
ΑΙι·Αο·(151·1ΐβ) 
ΑΙ«-Ασ-(152-157) 
ΑΙ^Αα-(153-15β) 
Ata-Aa-<154-1S9) 
AI»-Aa-(1S5-ieO) 
Л£і-(15Я5в) 
Are 
100(1) 
100(1) 
092(1) 
100(1) 
** 
0 95(1) 
108(1) 
г oo(2) 
2 00(2) 
196(2) 
192(2) 
100(1) 
ios(i) 
ιοο(ΐ) 
Oh/ 
оаз(і) 
098(1) 
oœ<i) 
0412(1) 
— 
— 
— 
— 
— 
»β 
103(1) 
10β<1) 
2 02(2) 
2 02(2) 
3 00(3) 
3 07(3) 
2 07(2) 
2 09(2) 
Lau 
іоэ(і) 
097(1) 
ioo(i) 
— 
— 
— 
— 
— 
— 
Ly» 
100(1) 
097(1) 
108(1) 
102(1) 
103(1) 
0 96(1) 
s*· 
— 
— 
— 
— 
— 
— 
0β«(1) 
— 
vu 
i oíd) 
1 01(1) 
099(1) 
095(1) 
100(1) 
The value for Ser has not been corrected for losses during hydrolysis 
such that no purification of any of the synthetic peptides was required. 
Table III summarizes the stimulation factors found for the individual peptides, and 
the concentration of peptides needed for half-maximal stimulation. From table III 
it is clear that the synthetic amino-terminally acylated peptide with the sequence 
comprising fibrinogen-Aa-(154-159) has rate-enhancing potency. This shows that 
the rate-enhancing potency resides within Aa-(154-159). The tetrapeptide Aa-
(155-158) also shows some rate-enhancing capacity, which is just significant. 
DISCUSSION 
It was concluded from previous work (Nieuwenhuizen et al. 1983*Λ 1985, 
Verheijen ef al. ^ г * · " , ІЭвЗ0, 1985, Voskuilen ef al. 1987) that the sequence 
fibrinogen-Aa-(148-160) plays an important role in the fibrin-induced rate 
enhancement of the plasminogen activation by t-PA. Aa-(148-160) is localized 
near the outer disulfide rings which terminate the coiled-coil regions, connecting 
the two fibrinogen D-domains with the central Ε-domain (Doolittle ef al. 1978, 
Doolittle 1981). Fibrin, FCB-2 (Nieuwenhuizen et al. 1983"), some 
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TABLE II 
Reversed phase HPLC data and [ak-values of the 
synthetic peptides used in this study 
peptide rettime (mins) % main peak [a]D 
Ata-Aa-(148-153) 
Ata-Aa-(149-154) 
Ata-Aa-(150-155) 
Ata-Aa-(151-156) 
Ata-Aa-(152-157) 
Ata-Aa-(153-158) 
Ata-Aa-(154-159) 
Ata-Aa-(155-160) 
Aa-(155-158) 
19.76 
23.15 
24.99 
24.89 
23.70 
24.50 
23.89 
23.82 
18.43 
89.4 
83.2 
85.3 
92.7 
93.8 
87.1 
89.4 
89.8 
96.4 
-21.25 
-6.25 
-19.23 
-29.47 
-14.40 
-9.60 
-15.20 
-8.00 
-2.82 
(C=0.08, DMF) 
(C=0.16, DMF) 
(C=0.13, DMF) 
(C=0.10P DMF) 
(C=0.13, DMF) 
(0=0.13. DMF) 
(c=0.13, DMF) 
(c=0.05, DMF) 
(0=0.43, DMF) 
plasmin degradation products, such as Ο^ΤΑ (Verheijen ef al. 1982*) and 
fibrinogen-Aa-(148-197) (Nieuwenhuizen ef al. 1983'), but not intact fibrinogen, all 
have rate enhancing properties. These facts led to the conclusion that the sites 
involved in the rate-enhancing properties exist in fibrinogen in a buried form. 
The hidden rate enhancing capacity can apparently be brought to expression 
upon the fibrinogen-to-fibrin conversion by thrombin, or by chemical or 
enzymatic digestion of fibrinogen. 
Radcliff (1983) presented evidence that lysine residues in fibrin are essential 
for the accelerating capacity of fibrin on the plasminogen activation by t-PA. 
Plasmin is known to have lysine binding sites which are localized in the kringle I-
IV domain. These lysine binding sites are crucial to the rate enhancing effect of 
FCB-2 (Verheijen ef al. 1983") as evidenced by the fact that the activation of mini-
plasminogen (Val^-plasminogen), lacking the kringle l-IV domain, is not 
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TABLE III 
Stimulation factors of the synthetic peptides (obtained with the assay 
system described in the Materials and Methods section), and the 
peptide concentrations required for half-maximal stimulation. 
peptide stimulation factor half-maximal stimulation at 
Ata-Aa-(148-153) 
Ata-Aa-(149-154) 
Ata-Aa-(150-155) 
Ata-Aa-(151-156) 
Ata-Aa-( 152-157) 
Ata-Aa-(153-158) 
Ata-Aa-( 154-159) 
Ata-Aa-(155-160) 
Aa-(155-158) 
1.3 ± 0.2 
1.1 ± 0.1 
1.8 ± 0.6 
2.2 ± 1.4 
1.1 ± 0.3 
1.3 ± 0.2 
6.0 ± 2.0 
1.9 ± 0.5 
3.2 ± 0.7 
56 ± 50 μΜ 
715 ± 439 μΜ 
'Since the stimulation factors of these peptides are very low and probably not significant, the 
concentrations at half-maximal stimulation are not given. 
accelerated by FCB-2. The rate enhancement of fibrin is diminished by the lysine 
analogue 6-amino hexanoic acid, which is an other indication of the importance 
of the lysine binding sites in the plasminogen molecule. The rate enhancement 
of the plasminogen activation by t-PA has been ascribed mainly to carboxyl-
terminal lysines (Christensen 1984, Suenson ef al. 1984, Norrman ef al. 1985). 
The carboxyl-terminal lysines seem to fulfil the postulated requirements for 
binding to the lysine binding sites of plasminogen, i.e., an e-amino- and an cr-
carboxyl group separated by an aliphatic carbon chain. However, Voskuilen ei 
al. (1987) have shown that Lys157 in the Aa-chain plays an essential role in the 
rate-enhancement, since succinylation of this lysine residue annihilates the 
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stimulating effect of Aa-(148-160) completely. This lysine residue, however, is 
not a carboxyl-terminal residue and, therefore, also non-carboxyl-terminal lysine 
residues may contribute to the observed rate enhancement by fibrin. 
The present study indicates that the orientation of this lysine side chain must 
meet special requirements. Only in the synthetic hexapeptide Aa-(154-159) the 
lysine side chain appears to be properly exposed to the environment, since the 
other Lys157 containing hexapeptides [¡.β. Aa-(152-157), Aa-(153-158) and Ao-
(155-160)] do not stimulate. 
It is likely that the typical charge distribution in the sequence Aa-(148-160), i.e. 
-Lys-Arg-Leu-Glu-Val-Asp-Ile-Asp-Ile-Lys-Ile-Arg-Ser-
+ + 0 - 0 - 0 - 0 + 0 + 0 
where negative and neutral amino acid residues alternate, and are embraced by 
two sets of positively charged residues, induces (or perhaps could be a part of) a 
typical local conformation. Only if the local conformation fulfils special 
requirements, is the Lys157 side chain exposed properly to allow acceleration of 
the plasminogen activation. Voskuilen eí al. (1987) suggest that the interaction 
of Lys157 with the postulated "aminohexyl sites" (Christensen 1984) in 
plasminogen, or with t-PA, might be explained by a spatial conformation of e.g. 
Ασ-(148-160) in which the side-chain carboxyl function of one of the aspartic acid 
residues or the glutamic acid residue, together with the e-amino group of the 
lysine side chain are in a position in which a carboxyl-terminal lysine can be 
mimicked. Implicit in this suggestion is a conformation in which the lysine side 
chain is oriented properly relative to other residues (e.g. Asp) in the same 
conformation. 
As reported before (Nieuwenhuizen ef al. 1983", Voskuilen ef al. 1987) the 
effectivity drops with decreasing molecular weight of the stimulator, while the 
concentration needed for half-maximal stimulation increases. In this assay 
system, fibrin and FCB-2 enhance the activation rate of plasminogen about 35-
fold, with a concentration needed for half maximal stimulation of 0.02 μΜ for 
fibrin monomers and 0.12 μΜ for FCB-2. The maximum stimul^ Jion by the Ασ-
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chain remnant of FCB-2 [i.e. Ασ-(148-207)] is about 20-fold (concentration at half 
maximal stimulation is 0.5 μΜ), by Aa-(148-160) it is about 11-fold (concentration 
at half maximal stimulation is 12 μΜ). For Aa-( 154-159) the stimulation factor is 
6; the half maximal concentration is 50 μΜ. The observed decrease in 
accelerating capacity (and increase in the concentration needed for half maximal 
stimulation) has been ascribed (Voskuilen et al. 1987) to the possibility that 
amino acid residues other than those in Aa-(148-160) are also involved in the rate 
enhancing effect of fibrin monomer, FCB-2 and its Aa-chain remnant. These 
observations would fit in the assumption of the existence of a local conformation 
of which the sequence Ασ-(148-160) is a component. In fibrin monomers this 
local conformation is fully expressed and stabilized, and would thus give an 
optimal rate enhancement (at the lowest concentration) of the plasminogen 
activation. When a part of the fibrin molecule (e.g. FCB-2 or its Aa-chain 
remnant) is taken, the expression of the local conformation decreases (the 
stimulation factor decreases, and the required concentrations increases). The 
conformations of the smaller peptides such as Aa-(148-160) or Aa-(154-159) are 
little or not stabilized (since other supporting parts of the fibrin molecule are 
absent) and this leads to a low accelerating capacity, and the need for relatively 
high concentrations. 
Although the non-stimulating hexapeptides Ata-Aa-(152-157), Ata-Aa-(153-158), 
and Ata-Aa-(155-160) are part of the proposed secondary structure element, they 
seem not to be able to adopt the required conformation. 
The synthetic tetrapeptide Ασ-(155-158) appears to have a weak stimulating 
capacity. If the aforementioned arguments are correct, this could indicate that 
the lysine side chain exposure is far from optimal in Ασ-(155·158). 
In conclusion, we have presented evidence that the peptide with the 
fibrinogen sequence Aa-(154-159) contains the structural information required for 
enhancement of the plasminogen activation by t-PA. 
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ABSTRACT 
The sequence fibrinogen-Aa-(148-160) сап mimic part of the fibrin-induced 
rate enhancement of the activation of plasminogen by t-PA. Previously, we have 
reported that the lysyl residue at Αα-157 is crucial. During our further 
investigations on Αα-157 we found that Lys at position Αα-157 may be replaced 
by Glu. This unexpected finding prompted us to re-investigate the requirements 
of this position. 
We prepared analogues of Aa-(148-160) in which the lysyl residue at Αα-157 
was replaced by lysine-deri vati ves [Lys(Ac), Lys(Z), Lys(Msc)]; acidic residues 
(Asp, Glu); basic residues (Arg, Orn); polar residues [Gin, Orn(Msc)]; apolar 
residues [Ala, Val, Nie, Glu(ONb)], and Gly. These analogues were tested for 
their stimulatory activity. When Asp, Glu(ONb), Val, or Nie is present at position 
Αα-157 in Αα-(14θ-160) virtually all stimulatory capacity is lost. None of the other 
replacements of Αα-157 caused loss of rate-enhancing properties. From these 
results we conclude that for the rate-enhancing effect of Aa-(148-160), the side 
chain of the amino acid residue at position Αα-157 must fulfil some requirements: 
there must be one (as in Ala) or no (as in Gly) carbon atom in the side chain, or 
at least two carbons and a polar group (charged or uncharged) to which a rather 
bulky group (such as the Z-group) or a polar group (like the Msc group) may be 
attached. The highest activity [even higher than native Αα-(14β-1β0)] was 
obtained with Orn, Orn(Msc), or Lys(Msc) at position Αα-157. 
INTRODUCTION 
Activation of the coagulation system leads to the formation of thrombin, which 
converts circulating fibrinogen molecules to fibrin by cleaving off fibrinopeptides 
A and В from the amino-terminal ends of the two Aa- and В -chains of 
fibrinogen, respectively. The new amino-termini of the α and ß chain contain 
sites that bind to complementary sites in the carboxyl-terminal domains (Doolittle 
1981, Laudano and Doolittle 1981) of other fibrin(ogen) molecules. At low 
concentrations fibrin monomers are kept in solution by complexation to 
fibrinogen until a certain critical (local) concentration is reached. Beyond this 
critical concentration, fibrin monomers start to form a fibrin gel which constitutes 
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the protein matrix of a blood clot. After such a blood clot has fulfilled its role in 
the haemostatic process, the fibrin matrix is dissolved by plasmin. The 
proteolytic enzyme plasmin can be generated from its zymogen plasminogen by 
several activators, such as tissue-type plasminogen activator (t-PA) (Rijken eí al. 
1979, Collen 1980). 
The plasminogen-to-plasmin conversion, as mediated by t-PA, is greatly 
enhanced by fibrin, but virtually not by fibrinogen (Wallen 1977, Allan and Pepper 
1981, Hoylaerts ef al. 1982). Detailed studies (Nieuwenhuizen eí al. 1983', 
Voskuilen ef al. 1987, Yonekawa ef al. 1989, 1990) showed that part of this rate-
enhancing effect of fibrin can be ascribed to two sites on the fibrin molecule: 
one in Aa-(148-160) and one in FCB-5. The sequence Aa-(148-160) seems to be 
buried in fibrinogen and becomes exposed upon the fibrinogen-to-fibrin 
conversion by thrombin as evidenced by the reactivity with fibrin (and not 
fibrinogen) of monoclonal antibodies raised against a synthetic peptide with the 
sequence Ασ-(148-160) (Schielen ef al. 1989). Also, at least part of the FCB-5 
fragment [i.e. γ-(312-325)] seems to be buried in fibrinogen and becomes 
exposed by the fibrinogen-to-fibrin conversion, since monoclonal antibodies 
raised against synthetic γ-(312-325) are fibrin-specific (Schielen ef al.. Chapter 3). 
Voskuilen ef al. (1987) presented evidence that Lys,S7 in Ασ-(148-160) is 
essential for the rate-enhancing effect of fibrin since succinylation of synthetic 
Aa-(148-160) annihilated the accelerating capacity of this peptide completely. 
Moreover, replacing Lys157 by Val yielded a synthetic peptide that also showed no 
rate enhancement of the plasminogen activation as mediated by t-PA. However, 
our recent investigations revealed that Aa-(148-160) in which Lys157 was replaced 
by Glu maintained its rate-enhancing capacity. This indicates that lysine at 
position Aa-157 is not an absolute prerequisite for rate enhancement. This 
unexpected finding prompted us to re-investigate the requirements of the side-
chain of the residue in position Aa-157. We prepared analogues of Aa-(148-160) 
in which the lysyl residue at Aa-157 was replaced by lysine-analogues [Lys(Ac), 
Lys(Z), Lys(Msc)]; acidic residues (Asp, Glu); basic residues (Arg, Orn); polar 
residues [Gin, Orn(Msc)]; apolar residues [Ala, Val, Nie, Glu(ONb)], and Gly. 
These analogues were tested for their stimulatory activity. Witff Asp, Glu(ONb), 
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Val, and Nie at position Αα-157 in Αα-(148-160) virtually all stimulatory capacity is 
lost. None of the other replacements caused loss of rate-enhancing properties. 
From these results we conclude that for the rate-enhancing effect of Aa-(148-
160), the side chain of the amino acid residue at Αα-157 must fulfil some 
requirements: there must be one (as in Ala) or no (as in Gly) carbon atom in the 
side chain, or at least two carbons and a polar group (charged or uncharged) to 
which a rather bulky group (such as the Z-group) or a polar group (like the Msc 
group) may be attached. The highest activity [even higher than native Aa-(148-
160)] was obtained with Orn, Orn(Msc), or Lys(Msc) at position Αα-157. 
MATERIALS AND METHODS 
Tissue-type plasminogen activator 
Two-chain t-PA was purified from large scale melanoma cell culture according to 
Rijken et al. (1979), as modified by Kluft ef a/. (1983). 
Plasminogen 
Native plasminogen (glu-plasminogen) was purified from fresh human plasma by 
affinity chromatography (Deutsch and Mertz 1970) on lysine-Sepharose 
(Pharmacia Fine Chemicals, Uppsala, Sweden), precipitated with ammonium 
sulfate and dialysed extensively against 0.1 M Tris.HCI, pH 7.5, containing 0.1% 
(vol/vol) Tween 80 (Baker Chemicals). 
Peptides 
The peptide analogues [Xxx1S7]-Aa-(148-160), where Xxx157 = Lys(Ac), Lys(Msc), 
Lys(Z), Asp, Glu, Arg, Orn, Gin, Orn(Msc), Ala, Val, Nie, Glu(ONb), or Gly, were 
synthesized on p-alkoxybenzyl alcohol resin (Wang 1973) using (tf'-Fmoc amino 
acid derivatives (ten Kortenaar ef al. 1986) with the aid of a half-automated 
peptide synthesizer (SP 640, Labortec, Bubendorf, Switzerland). 
During solid phase peptide synthesis the amino acid side chains were protected 
with acid-labile protecting groups: the e-amino group of lysine with Boc, the 6-
guanidino group of arginine with Pmc, the γ-carboxyl group of glutamic acid and 
the B-carboxyl group of aspartic acid with OBu', and the ß-hydroxyl group of 
serine with Bu'. The carboxyl terminal amino acid [0.9 equivalents (eq.)] was 
coupled to the resin (1.07 mmol/g) by in situ activation with DCC (0.9 eq.) and 
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DMAP (0.9 eq.). To suppress racemization, HOBt (1.8 eq.) was added (van 
Nispen ef al., 1985). All reactants were dissolved in DMF. After 16 hours at 5 "С 
the resin was washed three times with successively each of DMF, 
dichloromethane, and isopropyl alcohol. Finally, the resin was washed with 
diisopropyl ether and dried in vacuo. The amount of Fmoc-amino acid attached 
to the resin was determined by elemental analysis of the amount of nitrogen in a 
sample of the resin. The cleavage of the Fmoc groups was carried out with 20% 
(vol/vol) piperidine in DMF, during three consecutive cycles of 6 minutes. 
Coupling of the second amino acid derivative (3 eq. relative to the amount of first 
amino acid attached to the resin) was performed by in situ activation with TBTU 
(3 eq.) (Knorr ef al. 1989), HOBt (3 eq.) and N-methylmorfoline (4.5 eq.). After 
coupling of each amino acid derivative, completion of the acylation reaction was 
monitored by a ninhydrin test on free amino groups (Kaiser ef al. 1970), followed 
by acylation of any remaining free amino groups with 10% (vol/vol) acetic acid 
anhydride in DMF. The fully protected peptides were cleaved from the resin 
during a 4-hr reaction with 2.5% (vol/vol) ethanedithiol and 2.5% (vol/vol) water 
in trifluoroacetic acid followed by precipitation in diethyl ether. The crude 
peptides were washed several times with diethyl ether, dried at the air, and 
analyzed by HPLC, specific rotation and amino acid composition. 
HPLC analyses 
HPLC analyses were performed on a RP-18 column (Techsil 5 C18, 250 χ 4.6 mm, 
HPLC Technology, Cheshire, UK) at a flow-rate of 1.0 ml/min., using a 5 min. 
isocratic elution with 7% (vol/vol) acetonitrile and 0.1% (vol/vol) trifluoroacetic 
acid in water followed by a 30 min. linear gradient from 7% (vol/vol) acetonitrile 
and 0.1% (vol/vol) trifluoroacetic acid in water to 70% (vol/vol) acetonitrile and 
0.08% (vol/vol) trifluoroacetic acid in water. Peaks were detected by UV 
measurement at 215 nm. The UV data were analyzed using JCL 6000 
Chromatography Data System software (Jones Chromatography, Mid Gian, UK). 
71 
TABLE I 
Amino acid compositions of the synthetic peptides used in this study. 
Expected values between parentheses. 
[ X x ï 1 5 7 ] -
Αα-(148-160) 
ΧϊΧ= 
Uà 
Ar<j 
Asp 
Gin 
Glu 
Glu(OHb) 
Gly 
Lys 
Lys(Ac) 
Lys(Use) 
Lys(I) 
Nie 
Ora 
Oni(Hsc) 
Val 
Ala 
1.06 
(1) 
— 
— 
— 
— 
— 
— 
— 
— 
— 
— 
— 
— 
— 
Arg 
2.07 
(2) 
3.00 
(3) 
2.02 
(2) 
2.09 
(2) 
2.05 
(2) 
2.00 
(2) 
2.07 
(2) 
2.04 
(2) 
1.89 
(2) 
2.11 
(2) 
1.91 
(2) 
2.00 
(2) 
1.97 
(2) 
2.12 
(2) 
2.00 
(2) 
Asp 
1.94 
(2) 
2.08 
(2) 
3.06 
(3) 
2.00 
(2) 
2.00 
(2) 
n.d. 
2.02 
(2) 
1.96 
(2) 
n.d. 
1.96 
(2) 
n.d. 
1.97 
(2) 
2.03 
(2) 
2.05 
(2) 
1.93 
(2) 
Glu 
1.02 
(1) 
1.03 
(1) 
1.00 
(1) 
2.04 
(2) 
2.03 
(2) 
1.9Í 
(2) 
1.01 
(1) 
1.00 
(1) 
0.97 
(1) 
1.00 
(1) 
1.00 
(1) 
1.00 
(1) 
1.02 
(1) 
0.98 
(1) 
1.02 
(1) 
•ole/Mie of peptide 
Gly Ile Leu Lys 
... 
— 
— 
— 
— 
1.02 
(1) 
— 
— 
— 
— 
— 
— 
— 
— 
3.05 
(3) 
3.02 
(3) 
2.97 
(3) 
3.01 
(3) 
3.01 
(3) 
3.06 
(3) 
3.00 
(3) 
2.98 
(3) 
3.04 
(3) 
3.13 
(3) 
2.93 
(3) 
3.24 
(3) 
3.04 
(3) 
3.07 
(3) 
3.0Í 
(3) 
0.94 
(1) 
1.06 
(1) 
1.09 
(1) 
1.00 
(1) 
1.04 
(1) 
1.07 
(1) 
1.01 
(1) 
1.04 
(1) 
1.07 
(1) 
1.04 
(1) 
1.09 
(1) 
1.02 
(1) 
1.12 
(1) 
1.07 
(1) 
1.05 
(1) 
1.09 
ID 
1.00 
(1) 
1.03 
(1) 
1.05 
(1) 
0.98 
(1) 
1.02 
(1) 
0.97 
(1) 
2.07 
(2) 
2.00 
(2) 
2.00 
(2) 
2.12 
(2) 
0.95 
(1) 
1.00 
(1) 
1.87 
(2) 
0.98 
(1) 
He 
.. . 
— 
... 
— 
... 
. . . 
. . . 
— 
— 
— 
— 
1.02 
(1) 
— 
— 
— 
Orn 
— 
— 
— 
— 
— 
— 
— 
— 
— 
— 
— 
— 
1.06 
(1) 
1.05 
(1) 
— 
Ser' 
0.71 
(1) 
0.82 
(1) 
0.82 
(1) 
0.80 
(1) 
0.81 
(1) 
n.d. 
0.85 
(1) 
0.83 
(1) 
n.d. 
0.81 
(1) 
n.d. 
0.83 
(1) 
0.74 
(1) 
0.80 
(1) 
0.73 
(1) 
Val 
0.96 
(1) 
1.04 
(1) 
1.06 
(1) 
0.98 
(1) 
0.94 
(1) 
0.95 
(1) 
1.00 
(1) 
1.08 
(1) 
0.99 
(1) 
0.97 
(1) 
1.08 
(1) 
0.97 
(1) 
1.03 
(1) 
1.00 
(1) 
2.05 
(2) 
The value for Ser has not been corrected for losses during hydrolysis 
n.d.: not determined 
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Amino acid analyses 
Peptides were hydrolysed in 5.7 M HCl (Merck Suprapur) in evacuated sealed 
glass tubes for 24 hours at 120 "c. The hydrolysates were lyophilized and 
analyzed with a Varian 9095 amino acid analyzer using the Fmoc-protocol. 
Specific rotations 
The specific rotations were measured with a Perkin Elmer Polarimeter 241. All 
peptides were dissolved in DMF and centrifuged for 10 minutes at 4500 rpm prior 
to the measurement. 
Assay system for the assessment of the rate-enhancing properties of the 
pepiidfis 
In total volumes of 0.250 ml 0.1 M Tris.HCI, containing 0.1% (vol/vol) Tween 80 
were present 0.11 μΜ glu-plasminogen, 0.3 mM H-D-Val-Leu-Lys-p-nitroanilide, 
300 mlU t-PA, and varying concentrations of the synthetic peptide to be tested 
for stimulating activity. In this assay, the concentration of p-nitroaniline formed 
per time-squared is proportional to the rate of plasmin formation (activation rate) 
(Drapier ef al. 1979). The ratio of the activation rate in the presence of the 
peptide over that in the absence of peptide was designated as stimulation factor. 
RESULTS 
Table I shows that the amino acid compositions are as expected. 
Table II summarizes the H PLC data and specific rotations obtained for each of 
the crude peptides. As indicated by the data, the purity of the peptides was 
such that no purification of any of the synthetic peptides was required. 
Table III summarizes the stimulation factors found for the individual peptides. 
The concentrations needed for half-maximal stimulation were around 50 μΜ. 
DISCUSSION 
It was concluded from previous work (Nieuwenhuizen ef a/. 1983*'b
>
 1985, 
Verheijen ef al. 1982, 1983,b, 1985, Voskuilen et al. 1987) that the sequence 
fibrinogen-Aa-(148-160) plays an important role in the fibrin-induced rate 
enhancement of the plasminogen activation by t-PA. Aa-(148-160) is localized 
near the outer disulfide rings which terminate the coiled-coil regions, 
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TABLE II 
Reversed phase HPLC data and [a]0-values of the 
synthetic peptides used in this study. 
[Xxx,57]-Aa-(148-160) ret.time (mins) % main peak [a] D 
Xxx= 
Ala 
Arg 
Asp 
Gin 
Glu 
Glu(ONb) 
Gly 
Lys 
Lys(Ac) 
Lys(Msc) 
Lys(Z) 
Nie 
Orn 
Orn(Msc) 
Val 
22.70 
20.10 
22.26 
22.20 
23.49 
25.71 
21.12 
21.00 
22.59 
23.28 
23.64 
24.78 
21.75 
22.80 
23.70 
87.6 
81.8 
90.1 
74.0 
93.3 
85.6 
85.7 
90.1 
88.3 
84.6 
93.0 
71.6 
88.4 
89.9 
86.3 
- 8.3 (C= 1.01, DMF) 
- 3.5 (c= 1.08, DMF) 
-23.3 (C= 1.07, DMF) 
-5.0(C=1.07, DMF) 
- 9.6 (C= 1.11, DMF) 
-6.8 (0=0.60, DMF) 
-18.3 (c=0.99, DMF) 
-7.3(c=1.00, DMF) 
- 5.8 (c = 1.06, DMF) 
-3.3(c=1.15, DMF) 
- 5.2 (0 = 1.10, DMF) 
-4.8(0 = 1.02, DMF) 
- 2.9 (C= 1.12, DMF) 
- 6.6 (C = 1.05, DMF) 
-6.1 (C= 1.05, DMF) 
connecting the two distal fibrinogen D-domains with the central E-domain 
(Doolittle et al. 1978, Doolittle 1981). Fibrin, FCB-2 (Nieuwenhuizen et al. 1983ь), 
some plasmin degradation products, such as DEQTA (Verheijen et al. 1982*) and 
fibrinogen-Aa-(148-197) (Nieuwenhuizen ef al. 1983*), but not intact fibrinogen, all 
have rate enhancing properties. These facts led to the conclusion that the sites 
involved in the rate-enhancing properties exist in fibrinogen in a buried form. 
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TABLE III 
Stimulation factors of the synthetic peptides, obtained with the assay 
system described in the Materials and Methods section 
peptide stimulation factor 
[Ala,57]-Aa-(148-160) 17.0 ± 0.3 
[Arg157]-Aa-( 148-160) 14.9 ± 2.1 
[Asp1S7]-Aa-(148-160) 2.4 ± 0.1 
[Gln,S7]-Aa-(148-160) 10.6 ± 1.9 
[Glu1S7]-Aa-(148-160) 8.6 ± 1.6 
[Glu(ONb)157]-Aa-(148-160) 2.0 ± 0.6 
[Gly157]-Aa-(148-160) 5.6 ± 1.6 
[Lys1S7]-Aa-(148-160) 14.9 ± 3.3 
native Aa-(148-160) 
[Lys(Ac)157]-Aa-( 148-160) 14.4 ± 2.4 
[Lys(Msc)1S7]-Aa-(148-160) 17.3 ± 0.4 
[Lys(Z)157]-Aa-(148-160) 9.1 ± 1.3 
[Nle157]-Aa-(148-160) 1.8 ± 1.0 
[Orn,57]-Aa-(148-160) 20.3 ± 2.7 
[Orn(Msc)157]-Aa-(148-160) 23.7 ± 4.4 
[Val157]-Aa-(148-160) 3.7 ± 0.2 
The hidden rate enhancing capacity can apparently be brought to expression 
upon the fibrinogen-to-fibrin conversion, e.g. by thrombin, or by chemical or 
enzymatic digestion of fibrinogen. 
Radcliff (1983) presented evidence that lysine residues in fibrin are essential 
for the accelerating capacity of fibrin on the plasminogen activation by t-PA. 
Plasmin is known to have lysine binding sites which are localized in the kringle I-
IV domain. These lysine binding sites are crucial to the rate enhancing effect of 
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FCB-2 (Verheijen et al. 1983b) as evidenced by the fact that the activation of mim-
plasmmogen (Val^-plasmmogen), lacking the kringle l-IV domain, is not 
accelerated by FCB-2 The rate enhancement of fibrin is diminished by the 
lysme-analogue 6-amino hexanoic acid, which is another indication for the 
importance of the lysine binding sites in the plasminogen molecule. The rate 
enhancement of the plasminogen activation by t-PA have been ascribed mainly 
to carboxyl-termmal lysines (Christensen 1984, Suenson et al. 1984, Norrman et 
al. 1985) The carboxyl-termmal lysines seem to fulfil the requirements for 
binding to the lysine binding sites of plasminogen, i.e., an e-ammo- and an or-
carboxyl group separated by an aliphatic carbon chain. However, Voskuilen ef 
al. (1987) showed that Lys157 in the Αα-chain plays an essential role in the rate-
enhancement, since succmylation of this lysine residue annihilates the 
stimulating effect of Aa-(148-160) completely This lysine residue at Aa-157 is 
not a carboxyl-termmal residue and, therefore, also some non-carboxyl-termmal 
lysine residues may contribute to the observed rate enhancement by fibrin. 
In an other study (Schielen er al.. Chapter 4), in which we prepared the ammo-
terminally acylated hexapeptides Aa-(152-157), Aa-(153-158), Aa-(154-159), and 
Aa-(155-160), we showed that only the hexapeptide Ασ-(154-159) is capable of 
stimulating the plasmmogen-to-plasmm conversion. Since all of these peptides 
comprise Lys at position Aa-157, we concluded that the orientation of Lys1S7 is 
important and we assumed that the stretch Aa-(148-160) is involved in inducing 
(or perhaps is part of) a typical (local) conformation that pre-exists in fibrinogen 
m a latent form and is exposed in fibrin 
The general believe is that lysine residues play a crucial role in the rate-
enhancing properties of fibrin Therefore it was surprising to find that when we 
replaced Lys at position Ασ-157 by Glu in the peptide Aa-(148-160), the resulting 
peptide induced a significant rate enhancement 
The results of the present study clearly show that Lys is not the only residue 
that is allowed at position Ασ-157 in the peptide Aa-(148-160) to maintain 
stimulatory capacity. In fact, from table III it seems that many different residues 
are allowed in this position. These findings support the hypothesis of a certain 
typical (local) conformation, in which not the lysyl residue at Aa-157 per se is 
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important, but rather the degree in which the inferred conformation is stabilized 
by the residue at position Aa-157. Introduction of Nie, Glu(ONb), Asp, or Val at 
position Aa-157 in the peptide Aa-(148-160) probably induces a conformation 
which does not fulfil the requirements for rate enhancement. All other peptide 
analogues tested in this study show a significant stimulating capacity, indicating 
that the rate-enhancing conformation is maintained by the introduction of the 
residues at position Aa-157, listed in figure 1. 
In a previous paper (Voskuilen et al. 1987) we showed that [Arg157]-Aa-(148-
160) did not exert any stimulating capacity. We now found (table III) that [Arg157]-
Aa-(148-160) stimulates equally well as native Aa-(148-160). The difference is 
probably due to the fact, that we used high concentrations of [Arg157]-Aa-(148-
160) in the rate enhancement experiments. It now appears, that (too) high 
concentrations of the peptide inhibit the plasminogen activation by t-PA. 
In figure 1 the structures of the residues that were incorporated at position Aa-
157 in the peptide Aa-(148-160) are listed in order of increasing stimulating 
capacity. From figure 1 we conclude that for the rate-enhancing effect of Aa-
(148-160), the side chain of the amino acid residue at Aa-157 must fulfil some 
requirements: there must be one (as in Ala) or no (as in Gly) carbon atom in the 
side chain, or at least two carbons and a polar group (charged or uncharged) to 
which a rather bulky group (such as the Z-group) or a polar group (like the Msc-
group) may be attached. Introduction of the ONb-group on the Glu side chain 
annihilates the rate enhancement completely, possibly due to the apolar nature of 
the resulting side chain, which may be similar to that of Val or Nie. The peptides 
[Glu(ONb)157]-, [Val157]-, and [Nle1S7]-Aa-(148-160) tend to have a high affinity for 
the column material (C18) in reversed phase HPLC, as evidenced by the long 
retention times of these peptides (table II). Introduction of a succinyl group at 
the e-amino group of Lys may also give rise to an apolar side chain, since the 
results of Voskuilen ei al. (1987) show that succinylation of synthetic Aa-(148-
160) annihilates the stimulating effect of Aa-(148-160) completely. On the other 
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hand, introduction of the rather apolar Z-group at the c-amino group of Lys at 
Αα-157 has only little effect on the stimulating capacity of Αα-(14β-160), possibly 
due to compensation by the polar ε-amido group. 
From table III and figure 1 it is clear that increases in stimulating capacity of 
Aa-(148-160) can be obtained, which is largest by introduction of Orn, or the 
Msc-group at the ε-amino group of Lys or the 6-amino group of Orn at position 
Αα-157. 
In conclusion, we have shown that the lysyl residue at position Αα-157 can be 
replaced by a variety of other residues or amino acid derivatives, indicating that 
not the residue at position Αα-157 is important, but the degree to which a 
presumed typical (local) conformation in Aa-(148-160) is induced, maintained, or 
stabilized by the residue at Αα-157. This typical (local) conformation is 
recognized by plasminogen or t-PA and can be regarded as crucial in the rate 
enhancement of the plasminogen-to-plasmin activation by t-PA. 
— Figure 1 Structures of Xxx in the peptide analogues [Xxx1s7]-Aa-(148-160), listed In order 
of increasing stimulating capacity 
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ABSTRACT 
Fibrin, but not fibrinogen, enhances the rate of plasminogen activation by 
t-PA. We have described a site in fibrin(ogen), i.e. Aa-(148-160), which can 
mimic part of the rate enhancement induced by fibrin. During the fibrinogen-to-
fibrin conversion, Aa-(148-160) appears to become accessible to proteins, since 
monoclonal antibodies against synthetic Aa-(148-160) react with fibrin, but not 
with fibrinogen. In previous publications we have reported on the role of position 
Aa-157. In this study we investigated the influence of the typical charge 
distribution in Aa-(148-160), i.e. 
Lys-Arg-Leu-Glu-Val-Asp-Ile-Asp-Ile-Lys-Ile-Arg-Ser 
+ + 0 - 0 - 0 - 0 + 0 + 0 
on the rate-enhancing effect. To disturb the charge distribution in the peptide 
152Val was replaced by charged residues (Arg, Lys, Glu). Also incorporated were 
some uncharged polar residues (Ser, Туг), uncharged nonpolar residues (Ala, 
Nie), and Gly and Pro. The results clearly indicate that, to maintain stimulatory 
activity, Val (which possesses an uncharged nonpolar side chain) at position Aa-
152 may only be exchanged by another uncharged nonpolar residue, e.g. Ala or 
Nie. With tyrosine (with its aromatic, though polar side chain) at position Aa-152 
the peptide also retains some rate-enhancing capacity. With the ¡mino acid Pro 
(of which the side chain is nonpolar in nature) at position Aa-152 the peptide 
becomes inactive, possibly due to the known structure breaking capacity of 
proline. Our results indicate that the typical charge distribution in Aa-(148-160) is 
essential for the stimulatory action. 
INTRODUCTION 
An activated coagulation system leads to the formation of thrombin from its 
precursor prothrombin. Thrombin converts the soluble blood protein fibrinogen 
to insoluble fibrin. Up to a limited concentration fibrin is, however, kept in 
solution by complexing with fibrinogen. At higher concentrations, fibrin starts to 
aggregate and forms the insoluble protein matrix of a blood clot. Fibrin has only 
a temporary function; after it has fulfilled its role, e.g. in tissue repair, it will be 
converted to soluble degradation products, with concomitant lysis of the blood 
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clot. The degradation of fibrin is catalysed by plasmin, the product of an 
activated fibrinolytic system. Plasminogen, the precursor of plasmin, is activated 
by plasminogen activators such as tissue-type plasminogen activator (t-PA) 
(Rijken et al. 1979, Collen 1980). Fibrin is not merely the substrate of fibrinolysis, 
but is also a cofactor in the fibrinolytic system i.e. it enhances the rate of plasmin 
formation. Both t-PA and plasminogen interact with fibrin, and the accelerating 
effect of fibrin on the plasminogen activation by t-PA may be explained by these 
interactions (Nieuwenhuizen 1988). Fibrinogen has been reported to have 
virtually no rate-enhancing capacity (Wallen 1977, Allan and Pepper 1981, 
Hoylaerts et al. 1982). 
Detailed studies (Nieuwenhuizen el al. 1983*, Voskuilen ef al. 1987, Yonekawa 
ef al. 1989, 1990) showed that (part of) this rate-enhancing effect of fibrin is 
brought about by two sites in the fibrin molecule: one in Aa-(148-160) and one in 
the cyanogen bromide fragment FCB-5 [i.e. γ-(311-336), disulfide linked to γ-
(337-379)]. The sequence Aa-(148-160) seems to be buried in fibrinogen, and to 
become exposed upon the fibrinogen-to-fibrin conversion as evidenced by the 
reactivity with fibrin (and not fibrinogen) of monoclonal antibodies raised against 
a synthetic peptide with the sequence Aa-(148-160) (Schielen eí al. 1989). 
The rate enhancement of the plasminogen activation by t-PA has been ascribed 
mainly to carboxyl-terminal lysines (Christensen 1984, Suenson ef al. 1984, 
Norrman ef al. 1985). Voskuilen ef al. (1987) have shown that Lys,S7 in the Ασ-
chain plays an essential role in rate-enhancement. This lysine residue, however, 
is not a carboxyl-terminal residue and, therefore, non-carboxyl-terminal lysine 
residues may contribute also to the observed rate enhancement by fibrin. 
In another study (Schielen ef al., Chapter 4), in which we prepared the 
hexapeptides Aa-(152-157), Aa-(153-158), Aa-(154-159), and Aa-(155-160), we 
have shown that Aa-(154-159) is capable of stimulating the plasminogen-to-
plasmin conversion. Only in the synthetic hexapeptide Aa-(154-159) does the 
lysine side chain appear to be properly exposed to the environment, since the 
other Lys,S7 containing hexapeptides [I.e. Aa-(152-157), Aa-(153-158) and Aa-
(155-160)] do not stimulate. 
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It is likely that the typical charge distribution in the sequence Ασ-(148-160)1 I.e. 
-Lys-Arg-Leu-Glu-Val-Asp-Ile-Asp-Ile-Lys-Ile-Arg-Ser-
+ + 0 - 0 - 0 - 0 + 0 + 0 
where negative and neutral amino acid residues alternate, and are embraced by 
two sets of positively charged residues, induces (or perhaps could be a part of) a 
typical local conformation. Only if the local conformation fulfils special 
requirements, is the Lys1S7 side chain properly exposed to allow acceleration of 
the plasminogen activation. 
In the present study we have investigated the influence of the typical charge 
distribution and, hence, the assumed (local) conformation in Ao-(148-160) on the 
rate-enhancing effect. To disturb the charge distribution in the peptide, 152Val 
was replaced by charged residues (Arg, Lys, Glu), uncharged polar residues (Ser, 
Туг), uncharged nonpolar residues (Ala, Nie), and Gly and Pro were incorporated. 
Because we intended to compare some of the synthetic peptides prepared in 
this study with the same peptides (synthesized in a different manner and 
extended at their carboxyl-terminus with a glycine residue) from another study 
(Schielen ef al., Chapter 7), the synthesized analogues were carboxyl-terminally 
elongated with a glycyl residue. 
The results of the present investigations clearly indicate that, in order to 
maintain stimulatory activity, Val (which has an uncharged nonpolar side chain) 
may only be replaced at position Aa-152 by another uncharged nonpolar residue, 
e.g. Ala or Nie. With tyrosine (with its aromatic, though polar side chain) at 
position Aa-152 the peptide also retains some rate-enhancing capacity. 
Our results indicate that the typical charge distribution in Aa-(148-160) is 
essential for the stimulatory action. 
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MATERIALS AND METHODS 
Tissue-type plasminogen activator 
Two-chain t-PA was purified from large scale melanoma cell culture according to 
Rijken et al. (1979), as modified by Kluft et al. (1983). 
Plasminogen 
Native plasminogen (glu-plasminogen) was purified from fresh human plasma by 
affinity chromatography (Deutsch and Mertz 1970) on lysine-Sepharose 
(Pharmacia Fine Chemicals, Uppsala, Sweden), precipitated with ammonium 
sulfate and dialysed extensively against 0.1 M Tris.HCI, pH 7.5, containing 0.1% 
(vol/vol) Tween 80 (Baker Chemicals). 
Peptides 
The peptide analogues [Xxx152],[Glyie,]-Aa-(148-161), where Xxx1K = Ala, Arg, Glu, 
Gly, Lys, Nie, Pro, Ser, Туг, and Val, were synthesized on p-alkoxybenzyl alcohol 
resin (Wang 1973) using №-Ртос amino acid derivatives (ten Kortenaar eí al. 
1986) with the aid of a half-automated peptide synthesizer (SP 640, Labortec, 
Bubendorf, Switzerland). 
During solid phase peptide synthesis the amino acid side chains were protected 
with acid-labile protecting groups: the e-amino group of lysine with Boc, the 6-
guanidino group of arginine with Pmc, the γ-carboxyl group of glutamic acid and 
the ß-carboxyl group of aspartic acid with OBu', and the ß-hydroxyl group of 
serine with Bu'. The carboxyl terminal amino acid [0.9 equivalents (eq.)] was 
coupled to the resin (1.07 mmol/g) by In situ activation with DCC (0.9 eq.) and 
DMAP (0.9 eq.). To suppress racemization, HOBt (1.8 eq.) was added (van 
Nispen ef a/. 1985). All reactants were dissolved in DMF. After 16 hours at 5 °C 
the resin was washed three times with successively each of DMF, 
dichloromethane, and isopropyl alcohol. Finally, the resin was washed with 
diisopropyl ether and dried in vacuo. The amount of Fmoc-amino acid attached 
to the resin was determined by elemental analysis of the amount of nitrogen in a 
sample of the resin. The cleavage of the Fmoc groups was carried out with 20% 
(vol/vol) piperidine in DMF, during three consecutive cycles of 6 minutes. 
Coupling of the second amino acid derivative (3 eq. relative to the amount of first 
amino acid attached to the resin) was performed by in situ activation with TBTU 
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(3 eq.) (Knorr et al. 1989), HOBt (3 eq.) and N-methylmortoline (4.5 eq.). After 
coupling of each amino acid derivative, completion of the acylation reaction was 
monitored by a ninhydrin test on free amino groups (Kaiser ( al. 1970), followed 
by acylation of any remaining free amino groups with 10% (vol/vol) acetic acid 
anhydride in DMF. The fully protected peptides were cleaved from the resin 
during a 4 h reaction with 2.5% (vol/vol) ethanedithiol and 2.5% (vol/vol) water in 
trifluoroacetic acid followed by precipitation in diethyl ether. The crude peptides 
were washed several times with diethyl ether, dried at the air, and analyzed by 
HPLC, specific rotation and amino acid composition. 
HPLC analyses 
HPLC analyses were performed on a RP-18 column (Techsii 5 C18, 250 χ 4.6 mm, 
HPLC Technology, Cheshire, UK) at a flow-rate of 1.0 ml/min., using a 5 min. 
isocratic elution with 7% (vol/vol) acetonitrile and 0.1% (vol/vol) trifluoroacetic 
acid in water, followed by a 30 min. linear gradient from 7% (vol/vol) acetonitrile 
and 0.1% (vol/vol) trifluoroacetic acid in water to 70% (vol/vol) acetonitrile and 
0.08% (vol/vol) trifluoroacetic acid in water. Peaks were detected by UV 
measurement at 215 nm. The UV data were analyzed using JCL 6000 
Chromatography Data System software (Jones Chromatography, Mid Gian, UK). 
Amino acid analyses 
Peptides were hydrolysed in 5.7 M HCl (Merck Suprapur) in evacuated sealed 
glass tubes for 24 hours at 120 °C. The hydrolysates were lyophilized and 
analyzed with a Varian 9095 amino acid analyzer using the Fmoc-protocol. 
Specific rotations 
The specific rotations were measured with a Perkin Elmer Polarimeter 241. All 
peptides were dissolved in DMF and centrifuged for 10 minutes at 4500 rpm prior 
to the measurement. 
Assay system for the assessment of the rate-enhancing properties of the 
peptides 
In total volumes of 0.250 ml 0.1 M Tris.HCI, containing 0.1% (vol/vol) Tween 80 
were present 0.11 μΜ glu-plasminogen, 0.3 mM H-D-Val-Leu-Lys-p-nitroanilide, 
86 
TABLE I 
Amino acid compositions of the synthetic peptides prepared in 
this study. Expected values between parentheses. 
•оі/юі peptide 
[Хп 1 5 2 ]ЛС1у ш ]-
Аа-(Ш-Ш) 
Хп= 
Ala 
Arq 
Glu 
Gly 
Lys 
Ile 
Pro 
Ser 
Туг 
Val 
Ala 
0.99 
(1) 
— 
— 
— 
— 
— 
— 
_ . 
— 
— 
Arq 
2.11 
(2) 
3.11 
(3) 
2.03 
(2) 
2.00 
(2) 
2.13 
(2) 
1.92 
(2) 
1.99 
(1) 
2.07 
(2) 
2.04 
(2) 
2.01 
(2) 
Asp 
2.07 
(2) 
2.11 
(2) 
1.9β 
(2) 
2.0« 
(2) 
2.08 
(2) 
1.94 
(2) 
2.02 
(2) 
2.00 
(2) 
2.00 
(2) 
1.96 
(2) 
Glu 
1.00 
(1) 
1.00 
(1) 
2.01 
(2) 
1.02 
(1) 
0.9« 
(1) 
1.00 
(1) 
0.94 
(1) 
1.03 
(1) 
1.01 
(1) 
1.00 
(1) 
Gly 
0.99 
(1) 
1.07 
(1) 
1.00 
(1) 
1.97 
(2) 
0.9« 
(1) 
1.01 
(1) 
1.00 
(1) 
1.00 
(1) 
1.00 
(1) 
1.07 
(1) 
Ile 
3.14 
(3) 
3.15 
(3) 
3.01 
(3) 
3.00 
(3) 
3.00 
(3) 
3.20 
(3) 
3.02 
(3) 
3.13 
(3) 
2.99 
(3) 
3.06 
(3) 
Leu 
0.95 
(1) 
0.92 
(1) 
1.05 
(1) 
1.02 
(1) 
1.00 
(1) 
1.02 
(1) 
1.03 
(1) 
1.02 
(1) 
1.04 
(1) 
1.03 
(1) 
Lys 
2.0» 
(2) 
2.05 
(2) 
1.97 
(2) 
1.97 
(2) 
2.89 
(3) 
1.93 
(2) 
2.00 
(2) 
2.03 
(2) 
2.03 
(2) 
2.03 
(2) 
Hie 
— 
— 
— 
— 
— 
1.03 
(1) 
— 
— 
— 
— 
Pro 
— 
... 
— 
— 
— 
— 
0.96 
(1) 
— 
— 
— 
Ser" 
0.71 
(1) 
0.77 
(1) 
О.»« 
(1) 
0.«7 
(1) 
0.93 
(1) 
0.69 
(1) 
0.73 
(1) 
1.69 
(2) 
0.14 
(1) 
0.79 
(1) 
Tyr 
— 
— 
— 
— 
— 
— 
— 
— 
1.01 
(1) 
— 
Val 
— 
— 
— 
— 
— 
— 
— 
— 
— 
1.01 
(1) 
T h e value for Ser has not been corrected for losses during hydrolysis 
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300 mlU t-PA, and varying concentrations of the synthetic peptide to be tested 
for stimulating activity. In this assay, the concentration of p-nitroaniline formed 
per time-squared is proportional to the rate of plasmin formation (activation rate) 
(Drapier ef al. 1979). The ratio of the activation rate in the presence of the 
peptide to that in the absence of peptide was designated as stimulation factor. 
RESULTS 
Table I shows that the amino acid compositions were as expected. 
Table II summarizes the HPLC data and specific rotations obtained for each of 
the crude peptides. As indicated by the data, the purity of the peptides was 
such that no purification of any of the synthetic peptides was required. 
Table III summarizes the stimulation factors found for the individual peptides. 
The concentrations needed for half-maximal stimulation were around 50 μΜ. 
DISCUSSION 
Fibrin is known to accelerate the plasminogen-to-plasmin conversion by t-PA. 
This acceleration can not be induced by fibrinogen (Wallen 1977), or only to a 
limited extent. Verheijen et al. (1982') have demonstrated that fragments derived 
from fibrin or fibrinogen by digestion with plasmin, or, chemically, with cyanogen 
bromide, also enhance plasminogen activation. It was concluded, that 
stimulatory sites pre-exist in fibrinogen and become exposed upon the 
fibrinogen-to-fibrin conversion, or fragmentation by plasmin and cyanogen 
bromide. 
Two of these stimulatory sites have been so far identified. One site lies within 
the sequence Aa-(148-160) (Nieuwenhuizen ef al. 1983", Voskuilen ef al. 1987) 
and the other within a fibrin(ogen) fragment known as cyanogen bromide 
fragment FCB-5 [i.e. γ-(311-336), disulfide linked to γ-(337-379)] (Yonekawa ef al. 
1989, 1990). 
The sequence Aa-(148-160) seems to be buried in fibrinogen, and to become 
exposed upon the fibrinogen-to-fibrin conversion as evidenced by the reactivity 
with fibrin (and not fibrinogen) of monoclonal antibodies raised against a 
synthetic peptide with the sequence Aa-(148-160) (Schielen ef al. 1989). Also, at 
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TABLE II 
Reversed phase HPLC data and [a]D-values of the 
peptides used in this study 
[Xxx1K],[Gly,ei]-Aa-
(148-160) ret.time (mins) % main peak (a]D 
Xxx= 
Ala 
Arg 
Glu 
Gly 
Lys 
Nie 
Pro 
Ser 
Туг 
Val 
20.81 
19.56 
20.28 
19.42 
19.41 
20.57 
20.37 
20.07 
20.98 
22.06 
85.9 
94.4 
84.5 
88.4 
86.2 
89.8 
77.1 
85.6 
81.3 
78.1 
- 8.4 (с=0.56, DMF) 
-10.8 (с=0.38, DMF) 
-10.7 (0=0.28, DMF) 
- 9.2 (С=0.26, DMF) 
-10.7 (c=0.59, DMF) 
-9.8 (e=0.54, DMF) 
-30.3 (0=0.31, DMF) 
- 11.9(C=0.57, DMF) 
- 11.4 (C=0.58, DMF) 
- 10.4 (C=0.52, DMF) 
least part of the FCB-5 fragment [I.e. γ-(312-324)] seems to be buried in 
fibrinogen, and becomes exposed by the fibrinogen-to-fibrin conversion, since 
monoclonal antibodies raised against synthetic γ-(312-324) are fibrin-specific 
(Schielen et al., Chapter 3). 
In another study (Schielen et al., Chapter 4), in which the amino-terminally 
acylated hexapeptides Ασ-(152-157), Ασ-(153-158), Αα-(154-159), and Αα-(155-
160) were prepared, it was shown that only the hexapeptide Aa-(154-159) is 
capable of stimulating the plasminogen-to-plasmin conversion. As indicated in 
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TABLE III 
Stimulation factors of the synthetic peptides, obtained with the assay 
system described in the Materials and Methods section 
peptide stimulation factor 
[Ala,52],[Gly,e,]-Aa-(148-161) 
[Arg^MGly'^-Aa-CI^- ie i) 
[Glu,S2],[Gly,ei]-Aa-(148-161) 
[Glyi:a],[Gly,e,]-Aa-(148-161) 
[Lys152],[Glyiei]-Aa-(148-161) 
[Nle152],[Glyiei]-Aa-(148-161) 
[Pro'52],[Glyiei]-Aa-(148-161) 
[Ser152],[Gly,ei]-Aa-(148-161) 
[Tyr,M] l[Gly,ei]-Aa-(148-161) 
[Val152],[Glyiei]-Ao-(148-161) 
4.9 ± 0.1 
1.9 ± 0.5 
2.2 ± 0.7 
2.4 ± 0.9 
2.3 ± 0.8 
9.0 ± 1.0 
2.8 ± 0.7 
3.7 ± 1.2 
4.3 ± 0.8 
8.3 ± 2.3 
the introduction, the general belief is that lysine residues are important in the 
plasminogen-to-plasmiη conversion by t-PA. All of the aforementioned 
hexapeptides contain a lysine residue. The fact that only Aa-(154-159) enhances 
the plasminogen-to-plasmin conversion led to the assumption that the lysine 
residue at position Aa-157 has to be exposed in a proper manner to the milieu. 
We hypothesized that the stretch Ασ-(148-160) is involved in inducing (or 
perhaps is part of) a typical (local) conformation that exists in fibrinogen in a 
latent form, and is exposed in fibrin. The sequence Aa-(154-159) probably 
contains the minimum information for this (local) conformation to be induced. 
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In yet an other study (Schielen ef a/., Chapter 5) we have shown that the 
lysine residue at position Aa-157 perse is not important, since this lysine 
residue can be replaced by several other amino acid residues, such as Gly or 
Ala, virtually without loss of stimulating capacity. These findings support the 
hypothesis of a certain typical (local) conformation, in which not the lysyl residue 
at Aa-157 per se is important, but rather the degree in which the assumed rate-
enhancing conformation is maintained (stabilized) by the residue at position Aa-
157. The proposed typical (local) conformation can probably be stabilized by the 
typical charge distribution in the sequence Aa-(146-160), i.e. 
Lys-Arg-Leu-Glu-Val-Asp-Ile-Asp-Ile-Lys-Ile-Arg-Ser 
+ + 0 - 0 - 0 - 0 + 0 + 0 
where negative and neutral amino acid residues alternate, and are embraced by 
two sets of positively charged residues. 
The aim of the present study was to disrupt this typical charge pattern, by 
replacing valine at position Aa-152 by various charged and uncharged amino 
acid residues with different polarities. 
From the results (table III) it is clear that introduction of charged residues such 
as Arg, Glu and Lys at position Aa-152, or a known structure-breaking residue 
such as the imino acid Pro at position Aa-152, probably disturbs the 
hypothesized conformation such that the resulting peptides show virtually no 
rate-enhancing properties. Introduction of uncharged polar residues such as Ser 
and Tyr at position Aa-152 yields peptides with some stimulatory capacity, 
although the stimulation by the peptide with Ser at position Aa-152 is hardly 
significant. The only residues that can replace Val at position Aa-152, without 
loss of the rate enhancement of the peptides, are Nie and Ala. We conclude that 
the apolar Val192 can only be replaced by another apolar residue (Nie or Ala). 
From table III it is also clear that the peptide with Nie (which is known to be as 
apolar as Val) at position Aa-152, is as equally active as the native peptide. 
In conclusion, we have shown that the typical charge distribution in Aa-(148-
160) can not be disturbed by the introduction of charged (such as Arg, Glu, or 
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Lys), uncharged polar (such as Ser), or known structure-breaking (as Pro) 
residues at position Ασ-152 without loss of rate enhancement. 
This typical charge distribution probably underlies a certain (local) 
conformation that is essential for the rate-enhancing properties of fibrin in the 
plasminogen activation by t-PA. 
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Chapter 7 
THE EFFICIENT ACYLATION OF AN N-TERMINALLY LOCATED ASPARTYL 
RESIDUE; CONTRIBUTION TO THE DEVELOPMENT OF A NEW STRATEGY 
FOR FRAGMENT CONDENSATIONS 
Wim J.G. Schielen, Hans P.H.M. Adams, Willem Nieuwenhuizen*, 
and Godefridus I. Tesser 
Lab. Organic Chemistry, University of Nijmegen 
*Gaubius Institute TNO, Leiden 
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ABSTRACT 
The full solid phase synthesis of peptides longer than ten amino acid residues 
usually yields a preparation contaminated with peptides with an aberrant 
sequence. A way to avoid the full solid phase synthesis of such longe sequences 
is to first synthesize short protected peptide fragments on a solid support. 
Isolation of protected peptides requires a resin which binds the peptide chain 
through a very acid labile linker. The obtained peptide derivatives can then be 
converted in solution to activated compounds, which can directly be condensed 
to give the protected form of the target peptide. Our results show that 
condensations of peptide azides to a ß-unprotected amino-terminal aspartyl 
peptide derivative is quite generally applicable and proceeds in high yields. The 
peptides, analogues of [Gly,61]-fibrinogen-Aa-(148-161), prepared following this 
condensation strategy, appeared to be significantly purer on HPLC than those 
prepared entirely via solid phase peptide synthesis. 
INTRODUCTION 
The concept of solid phase peptide synthesis (SPPS), developed by Merrifield 
(1963), underwent many methodical improvements and can be considered now to 
be the method of choice for synthesizing peptides and small proteins in a fast 
and convenient manner. The most successful and extensively explored method 
employs the base labile Fmoc-group (Carpino and Han 1970, 1972) for temporary 
№-amino protection (Atherton ef al. 1978"", Chang and Meienhofer 1978). A 
comprehensive review about SPPS utilizing Fmoc-amino acids has been given by 
Fields and Noble (1990). 
The synthesis of peptides on a solid support is subject to several peculiarities 
arising from the rigid (polystyrene) matrix. The degree of permeation of 
protected amino acids into the matrix affects the coupling rate and, hence, the 
coupling efficiency. The density of loading of the first amino acid residue (the 
carboxyl-terminal) on the solid support may cause spatial problems during the 
progression of the synthesis and yield truncated sequences. 
Especially the last step in a solid phase synthesis is critical: during the 
simultaneous cleavage/deprotection procedure in acidic media, high local 
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concentrations of carbonium ions in the restricted space within the solid matrix 
can be considered as the cause of considerable damage to the peptide. 
During the synthesis of fibrinogen-Aa-(148-160) [i.e. H-Lys-Arg-Leu-Glu-Val-
Asp-lle-Asp-lle-Lys-lle-Arg-Ser-OH) and many analogues thereof we encountered 
some of the aforementioned problems. Loadings of Fmoc-SertBu1) on a p-
alkoxybenzyl alcohol resin (Wang 1973) amounting to 0.5 mmol and higher per 
gram resin caused very low coupling efficiencies around both arginyl residues. 
Loadings of 0.2-0.3 mmol Fmoc-Se^Bu') per gram resin caused low coupling 
efficiencies around the H1" amino acid derivative, Arg'48, during the syntheses of 
analogues of fibrinogen-Aa-(148-160), i.e., [Nie157]- and [Val'^J-fibrinogen-Aa-
(148-160) and [Xxx1SB],[Glyiei]-fibrinogen-Aa-(148-161) where Xxx=Lys, Arg, Glu, 
Pro, and Ser. Most of the difficulties with regard to low coupling efficiencies in 
the area of Arg148 could be solved by repetition of the cycle, adding 
dichloromethane (up to 50%) to the reaction mixture, and/or by gentle heating 
(40 "С) of the reaction mixture. The introduction of Mpc-Arg(Pmc)-OH at position 
Aa-149 in the synthesis of [Nle1S7]-fibrinogen-Aa-(148-160) instead of Fmoc-
Arg(Pmc)-OH gave a coupling efficiency of almost 100% within 30 min. at 
ambient temperature (Schielen et al., Chapter 8). Generally, the coupling 
efficiencies improve by utilising the relatively slim Mpc-group for the W-amino 
protection of amino acids and amino acid derivatives. 
A relatively new approach to the construction of longer peptides is to 
synthesize first small protected peptides ^up to 9 residues) starting from a solid 
support bearing a very acid labile linker (such as the SASRIN resin, i.e. 
polystyrene functionalyzed with 2-methoxy-4-alkoxybenzyl alcohol, Mergler 
1988,'b). This approach offers rapid access to fully protected peptide fragments 
that can subsequently be coupled in solution to larger fragments. The final 
deprotection of the target peptide can then be performed in a homogeneous 
solution, thus shortening the contact time between the carbonium ions and the 
peptide and increasing the chance of an effective encounter between the 
liberated carbonium ions and the scavengers present in the deprotection 
medium. 
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Ten Kortenaar ef al. described in 1985 a highly efficient procedure in which 
the condensation of a peptide azide and a fragment bearing H-Asp(OH)- as the 
amino terminal proceeded without any detectable by-products. They assumed 
that the coupling proceeds via an intramolecular reaction of the free amino 
terminus and the mixed anhydride formed at the ß-carboxyl group of the aspartyl 
residue. Such a mixed anhydride seems to be easily formed (Bodanszky and 
Natarjan 1975, Natarjan and Bodanszky 1976), since the reaction of a peptide 
azide (carboxyl component) with a peptide derivative of which the ß-unprotected 
aspartyl residue is not located amino-terminally (amino component), yields a 
reaction product in which the ratio amino-component/carboxyl-component is 
roughly 1/2 (ten Kortenaar ef a/. 1985). 
At present we studied the applicability of this reaction to some fragment 
condensations in the syntheses of peptide analogues of the type [Xxx^l.tGly181]-
fibrinogen-Aa-(148-161) (i.e. Lys-Arg-Leu150-Glu-Xxx,5î-Asp-lle-Asp-lle-Lys-lle-Arg-
Serieo-Gly). For Xxx, the carboxyl-terminal residue of the peptide azide, we have 
chosen Arg, Glu, Gly, Lys, Pro, Ser, Phe, and Val. 
Most of these peptides have also been synthesized completely by SPPS 
(Schielen ef a/., Chapter 6). Thus, the peptides obtained via the present 
procedure for fragment condensation can be compared with peptides that were 
prepared fully stepwise on a solid support. 
The results indicate that the reaction of most peptide azides (i.e. [Xxx152]-
fibrinogen-Aa-(148-152)-azide) with the fragment whose amino-terminal residue is 
H-Asp(OH)- (i.e. [Glyie,]-fibrinogen-Aa-(153-161)) proceeds in high yields. The 
peptide azides in which the carboxyl-terminus was Se^Bu1) or Phe did not couple 
at all. During the solid phase syntheses of the constituent peptide fragments to 
be condensed no incomplete couplings occurred and the purity of the target 
peptides was significantly higher compared to the same peptides synthesized 
fully stepwise. 
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MATERIALS AND METHODS 
Amino acid analyses 
Peptides were hydrolysed in 5.7 M HCl (Merck Suprapur) in evacuated sealed 
glass tubes for 24 hours at 120 °C. The hydrolysates were lyophilized and 
analyzed with a Varían 9095 amino acid analyzer using the Fmoc-protocol. 
HPLC analyses 
HPLC analyses of fully deprotected peptides were performed on a RP-18 column 
(Techsil 5 C18, 250 χ 4.6 mm, HPLC Technology, Cheshire, UK) at a flow-rate of 
1.0 ml/min., using a 5 min. isocratic elution with 7% (vol/vol) acetonitrile and 
0.1% (vol/vol) trifluoroacetic acid in water followed by a 30 min. linear gradient 
from 7% (vol/vol) acetonitrile and 0.1% (vol/vol) trifluoroacetic acid in water to 
70% (vol/vol) acetonitrile and 0.08% (vol/vol) trifluoroacetic acid in water. Peaks 
were detected by UV measurement at 215 nm. The UV data were analyzed using 
JCL 6000 Chromatography Data System software (Jones Chromatography, Mid 
Gian, UK). 
Melting points were determined with a Buchi melting point apparatus and are 
uncorrected. 
Specific rotations 
The specific rotations were measured with a Perkin Elmer Polarimeter 241. 
Thin-layer chromatography (t.l.c.) was performed on precoated t.l.c. plates 
(Merck, silica gel 60, F-254, 0.2 mm). Solvent systems used were: 
СНСІз/МеОН/АсОН (95/20/3) (system А), СИС\3/МеОИ (4/1) (system B), and n-
butanol/acetic acid/water (4/1/1) (system C). Spots were visualized using one 
or more of the following methods: UV-fluorescence quenching 254 nm, Barton's 
reagent spray (a mixture of equal volumes of FeClj (30 g) in water (170 ml) and 
KaFefCN), (2 g) in water 200 ml), ninhydrin spray (240 mg in 400 ml n-butanol 
and 16 ml acetic acid). 
Assay system for the assessment of the rate-enhancing properties of the 
peptides 
In total volumes of 0.250 ml 0.1 M Tris.HCI, containing 0.1% (vol/vol) Tween 80 
were present 0.11 μΜ glu-plasminogen, 0.3 mM H-D-Val-Leu-Lys-p-nitroanilide, 
300 mlU t-PA, and varying concentrations of the synthetic peptide to be tested 
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for stimulating activity. In this assay, the concentration of p-nitroaniline formed 
per time-squared is proportional to the rate of plasmin formation (activation rate) 
(Drapier ef al. 1979). The ratio of the activation rate in the presence of the 
peptide over that in the absence of peptide was designated as stimulation factor. 
Peptides 
All peptide fragments to be condensed were synthesized using №-Fmoc amino 
acid derivatives (ten Kortenaar et al. 1986) and with the aid of a half-automated 
peptide synthesizer (SP 640, Labortec, Bubendorf, Switzerland). 
During solid phase peptide synthesis the amino acid side chains were protected 
with acid-labile protecting groups: the €-amino group of lysine with Boc, the 6-
guanidino group of arginine with Pmc, the γ-carboxyl group of glutamic acid with 
OBu', the ß-carboxyl group of aspartic acid with OBu' or OBzl, and the ß-hydroxyl 
group of serine with Bu'. The cleavage of the Fmoc groups was carried out with 
20% (vol/vol) piperidine in DMF, during three consecutive cycles of 6 minutes. 
Coupling of an amino acid derivative (3 eq. relative to the amount of first amino 
acid attached to the resin) was performed by in situ activation with TBTU (3 eq.) 
(Knorr ef al. 1989), HOBt (3 eq.) and NMM (4.5 eq.). Following the performance 
of a coupling cycle, completion of the acylation reaction was monitored with 
ninhydrin to detect free amino groups (Kaiser ef al. 1970). If the reaction 
indicated approximate completeness of the acylation the cyclus was terminated 
by acetylation with 10% (vol/vol) acetic acid anhydride in DMF. 
Some physicochemical characteristics of the peptide fragments to be condensed 
are given in tables 1 and 2. 
Peptide derivative 1 (scheme 1) was synthesized on SASRIN resin, starting 
from Fmoc-Gly-SASRIN (0.65 mmol Fmoc-Gly/g resin, BACHEM, Bubendorf, 
Switzerland). The fully protected nonapeptide 1 was cleaved from the resin 
according to Mergler ef al. (1988b), concentrated in vacuo, and precipitated from 
water. 
Peptide derivative 2 (650 mg, 0.375 mmole) was prepared by hydrogenolysis 
of compound 1 in 20 ml acetic acid in the presence of 10% palladium on 
charcoal. The catalyst was removed by filtration and the filtrate was evaporated 
to dryness in vacuo to give TLC-homogeneous 2 in quantitative yield. 
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Boe P K OBU' 
I I I 
Mys-irq-Uu-Clu-Xïï-OB ( 3 - 1 0 ) 
i 
Boe P K OBU1 
Z-Lys-irq-Leu-Glu-Xïx-Ole ( 1 1 - 1 β ) 
l 
Boe P K „t OBzl (Su1 Boe P K BU 1 
Z-Lys-Arq-Leu-Glu-Xxi-MjHj ( 1 9 - 2 6 ) Z-Asp-Ile-isp-Ile-Lys-Ile-Arq-Ser-Gly-OB ( 1 ) 
ι l 
Boe P K OBU 1 OBu1 Boe P K Bu1 
Z-Lys-Arg-Leu-Glu-Xxï-H. H-Asp-Ile-Asp-Ile-Lys-Ile-Arq-Ser-Gly4e ( 2 ) 
Boe P K (Su1 OB OBu1 Boe P K Bu1 
I I I I I I I I 
Z-Lys-Arg-leu-Clu-Xxx-Asp-Ile-Asp-Ile-Lys-Ile-Arq-Ser-Gly-OB (27 - 32) 
l 
Boe P K OBu' u' Boe P K Bu1 
H-Lys-Arq-Leu-Glu-Xxx-Asp-Ue-Àsp-Ile-Lys-Ile-Àrq-Ser-Cly-OB f 3 3 - 3 8 ) 
l 
+ + 
H I 
I К 
+ + 
H H 
I |2 H-Lys-Àrq-Uu-Glu-Xxï-*sp-Ilê-Asp-Ilê-Lys-Ile-Arq-Ser-Gly-(ffl f 3 9 - 44) 
з, 
4, 
5, 
6, 
7, 
В, 
9, 
io, 
11, 
12, 
13, 
14, 
15, 
16, 
17, 
18, 
19, 
20, 
21, 
22, 
23: 
24, 
25: 
26, 
27, 
28, 
29, 
30, 
31, 
32, 
33 : Xxx 
34: 
35, 41: 
36: 
37, 43: 
38, 44: 
= Arq(PKl 
GlufOBu1) 
Gly 
Lys(Boc) 
Pbe 
Pro 
SerIBuM 
Val 
39: 
40: 
42: 
Xxx = Arq(H,+) 
Glu 
L y s ^ ) 
Scheme 1 Schematic representation of the compounds synthesized In this study 
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Peptide derivatives 3, 4, 5, 6, and 9 (scheme 1 ) were synthesized on SASRIN 
resins, starting from Fmoc-Arg(Pmc)-SASRIN (0 55 mmol/g), Fmoc-Glu(OBu')-
SASRIN (0 49), Fmoc-Gly-SASRIN (0 65 mmol/g), Fmoc-Lys(Boc)-SASRIN (0 65 
mmol/g), and Fmoc-Ser(Bu')-SASRIN (0 69 mmol/g), respectively The fully 
protected pentapeptides were cleaved from the resin and worked up as 
described for compound 1 
Peptide derivatives 7, 8, and 10 (scheme 1) were synthesized on PepSyn KH 
resins, starting from Fmoc-Phe-, Fmoc-Pro-, or Fmoc-Val-PepSyn KH (0 1 mmol/g 
resin, MILLIGEN, Etten-Leur, the Netherlands) The fully protected pentapeptides 
were cleaved from the resin and worked up as described for compound 1. 
Peptide derivatives 11-18 
Each peptide derivative 3-10 (0.1 mmol, 100-150 mg) was dissolved in acetone 
(10 ml) After cooling on melting ice, a solution of diazomethane m diethylether 
(0 3 mmol/ml) was added slowly until the colour of the reaction mixture turned 
yellow The excess diazomethane was dispelled by purging a gentle stream of 
nitrogen through the solution. When the conversion was complete, the solution 
was concentrated in vacuo and the residue immediately used in the next reaction 
step 
Peptide derivatives 19 - 26 
Each peptide ester 11-18 was dissolved in 2 ml DMF and N2H4 H20 (0 6 mmole, 
30 μ\) was added to the solution After 24 hours the hydrazide was precipitated 
by the addition of 5 ml water Filtration and washing with water yielded the pure 
compounds, reacting without exception with the reagent of Barton for 
hydrazides 
Peptide derivatives 27 - 32 
Each peptide hydrazide 19 - 26 (0 05 mmol, 50-75 mg) was dissolved in 2 ml 
DMF and cooled to -15 °C The cold solution was treated with 1 6 N HCl m ethyl 
acetate (0 15 mmol, 94 μΙ) and ferf-butyl nitrite (0 06 mmol, 7 2 μ\) After stirring 
for 20 minutes at -15 "c the reaction mixture (Barton negative on TLC) was 
neutralized (pH 7 5) by the addition of dnsopropylethylamme (0 15 mmol, 26 μΙ) 
and added to a solution of 2 (0 05 mmol, 75 mg) m DMF (2 ml) After 3 days at 4 
0C the product was precipitated with water (10 ml), filtered, washed with water 
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TABLE 1 
Yields, melting points, R,-, and [a]0-values of the 
compounds synthesized in this study. 
Compound Yield (%) m ρ ('С) П, A R, В R, С [ a ] D (°) с In DMF 
I 
2 
Э 
4 
S 
в 
7 
в 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
74 
100 
76 
75 
72 
74 
58 
50 
80 
38 
-
-
-
-
-
-
-
-
82 
90 
80 
76 
70 
75 
80 
80 
88 
90 
90 
92 
87 
87 
100 
100 
100 
100 
100 
100 
93 
90 
94 
94 
92 
90 
dec 
dec 
90-92 
114-117 
100-102 
102-104 
114-117 
114-116 
98-100 
128-130 
-
-
-
-
-
-
-
-
87-89 
96-99 
90-92 
94-96 
88-90 
100-102 
94-96 
100-102 
dec 
dec 
dec 
dec 
dec 
dec 
dec 
dec 
dec 
dec 
dec 
dec 
dec 
dec 
dec 
dec 
dec 
dec 
0 49 
0 
0 56 
0 57 
0 40 
0 56 
0 57 
0 58 
0 58 
0 54 
0 75 
0 72 
0 65 
0 74 
0 80 
0 73 
0 78 
0 69 
0 61 
0 62 
0 52 
0 62 
0 65 
0 57 
0 63 
0 61 
0 42 
0 43 
0 37 
0 42 
0 41 
0 43 
0 07 
0 08 
0 04 
0 07 
0 07 
0 07 
-
-
-
-
-
-
0 1 8 
0 
0 25 
0 1 2 
0 1 2 
0 25 
0 28 
0 29 
0 29 
0 22 
0 77 
0 77 
0 71 
0 76 
0 81 
0 79 
0 78 
0 77 
0 71 
0 71 
0 63 
0 69 
0 72 
0 69 
0 70 
0 70 
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
0 79 
0 1 7 
0 83 
0 86 
0 77 
0 93 
0 85 
0 86 
0 8 6 
0 93 
0 88 
0 88 
0 84 
0 88 
0 8 8 
0 88 
0 88 
0 88 
0 93 
0 91 
0 88 
0 90 
0 9 0 
0 92 
0 93 
0 91 
0 69 
0 67 
0 61 
0 69 
0 68 
0 68 
0 48 
0 47 
0 44 
0 49 
0 48 
0 47 
-
-
-
-
-
-
- 1 1 0 
-
- 8 3 
- 1 3 9 
-11 7 
- 1 1 9 
-11 2 
-11 8 
- 6 7 
- 8 3 
-
-
-
-
-
-
-
-
- 1 1 0 
- 1 2 3 
- 1 2 8 
-24 4 
- 1 0 0 
-145 
- 9 0 
- 1 3 3 
-
-
-
-
-
-
-
-
-
-
-
-
- 1 0 0 
-123 
- 1 0 7 
- 1 4 4 
-33 4 
- 1 1 0 
0 30 
-
0 48 
0 38 
1 12 
0 32 
0 34 
0 1 4 
0 30 
0 06 
-
-
-
-
-
-
-
-
0 20 
0 30 
0 60 
0 09 
0 0 6 
0 06 
0 48 
0 06 
-
-
-
-
-
-
-
-
-
-
-
~ 
0 38 
0 30 
0 27 
0 55 
0 29 
0 50 
dec decomposition, solvent systems A, B, and С In Materials and Methods section 
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and dried. The reaction products of peptide hydrazides 23 and 25 did not 
precipitate in water but formed an oil that turned out to be a (Barton negative on 
TLC) mixture of the reactants: no reaction product (expected around R, 0.40 in 
system A or R, 0.70 in system C) could be detected. 
Peptide derivatives 33 - 38 
The Z-group of each of the derivatives 27 - 32 was quantitatively removed by 
hydrogenolysis in acetic acid In the presence of 10% palladium on charcoal. The 
catalyst was removed by filtration and the filtrate was lyophilized. 
Peptides 39 - 44 
Each of the derivatives 33-38 was dissolved in 2 ml of a mixture of TFA, 
ethanedithlol and water (95/2.5/2.5). After 4 hours at ambient temperature the 
peptide was precipitated in diethyl ether, washed several times with diethyl ether, 
dried at the air, and analyzed by HPLC, measurement of the specific rotation and 
amino acid composition (tables 1, 2, and 3). 
RESULTS AND DISCUSSION 
Table 2 shows that the amino acid compositions are as expected. 
Table 3 summarizes the HPLC data and specific rotations for each of the 
peptides obtained via fragment condensations. 
The overall yields of the tetradecapeptides obtained via fragment 
condensations are comparable to those obtained by sequential SPPS. More 
important is that the purity of the tetradecapeptides prepared in this study is 
significantly higher compared to the peptides that were synthesized sequentially 
on Wang's resin (shown in italics in table 3), notwithstanding the fact that none 
of the Intermediate peptide derivatives had been recrystalllzed. Generally, most 
of the difficulties, with respect to the coupling efficiency, arising in a sequential 
SPPS from acylation cycle 10 until 15, can be avoided by the present procedure 
of fragment condensation. In this approach none of the peptide derivatives is 
larger than 9 residues. 
Another advantage is that the deprotection of the target peptides is carried out in 
solution, allowing optimal mixing of the reactants. 
102 
TABLE 2 
Ammo acid compositions of the peptide derivatives prepared in 
this study. Expected values between parentheses. 
Compound 
27 
28 
29 
30 
31 
32 
33 
34 
35 
3 6 
37 
38 
39 
40 
41 
42 
43 
44 
Arg 
3 06 
О) 
2 02 
(2) 
1 9β 
(2) 
2 07 
(2) 
2 1 3 
(2) 
1 8 9 
(2) 
3 01 
(3) 
1 9 6 
(2) 
2 00 
(2) 
2 1 4 
(2) 
2 00 
(2) 
1 8 9 
(2) 
2 98 
(3) 
2 00 
(2) 
2 02 
(2) 
2 01 
(2) 
2 00 
(2) 
2 02 
(2) 
Asp 
1 9 8 
(2) 
1 96 
(2) 
2 06 
(2) 
1 9 8 
(2) 
2 06 
(2) 
2 00 
(2) 
1 8 9 
(2) 
2 08 
(2) 
1 9 6 
(2) 
1 9 8 
(2) 
2 01 
(2) 
2 06 
(2) 
2 01 
(2) 
2 02 
(2) 
1 98 
(2) 
1 96 
(2) 
2 02 
(2) 
2 00 
(2) 
Glu 
1 02 
(1) 
2 00 
(2) 
0 96 
(1) 
1 0 0 
(1) 
0 98 
(1) 
1 02 
(1) 
1 01 
( i ) 
2 09 
(2) 
1 01 
(1) 
1 00 
(1) 
1 08 
(1) 
1 0 0 
(1) 
0 99 
(1) 
2 00 
(2) 
1 00 
( i ) 
1 00 
(1) 
1 02 
(1) 
1 00 
( i ) 
Gly 
ιοί 
(1) 
1 03 
(1) 
2 00 
(2) 
1 0 8 
(1) 
1 0 0 
(1) 
0 98 
(1) 
0 98 
(1) 
0 96 
(1) 
2 1 1 
(2) 
1 04 
(1) 
0 99 
(1) 
1 0 2 
(1) 
101 
(1) 
1 02 
О) 
2 00 
(2) 
1 0 3 
(1) 
1 00 
(1) 
0 99 
(1) 
Ile 
3 03 
(3) 
3 17 
(3) 
2 87 
(3) 
3 09 
(3) 
3 03 
(3) 
2 97 
(3) 
3 1 1 
(3) 
3 00 
(3) 
3 18 
(3) 
3 1 5 
(3) 
2 88 
(2) 
3 08 
(3) 
2 9 9 
(3) 
3 05 
(3) 
3 06 
(3) 
3 0 6 
(3) 
2 97 
(3) 
3 05 
(3) 
mol/mol peptide 
Leu 
0 98 
( i ) 
0 99 
(1) 
1 03 
( i ) 
0 9 9 
(1) 
0 97 
(1) 
1 00 
( i ) 
0 97 
(1) 
0 97 
(1) 
1 05 
(1) 
1 01 
(1) 
0 97 
(1) 
0 93 
( i ) 
1 00 
(1) 
1 03 
(1) 
0 98 
(1) 
1 00 
( i ) 
1 01 
(1) 
1 02 
( i ) 
Lys 
1 0 0 
(1) 
2 02 
(2) 
2 06 
(2) 
2 90 
(3) 
1 9 9 
(2) 
2 09 
(2) 
2 00 
(2) 
2 13 
(2) 
2 03 
(2) 
2 86 
(3) 
2 01 
(2) 
1 9 6 
(2) 
2 00 
(2) 
2 00 
(2) 
2 01 
(2) 
3 03 
(3) 
2 02 
(2) 
2 04 
(2) 
Pro 
-
— 
... 
— 
0 98 
(1) 
— 
— 
— 
— 
— 
1 04 
(1) 
— 
— 
— 
— 
— 
1 00 
(1) 
—, 
Ser* 
0 76 
(1) 
0 68 
(1) 
0 77 
(1) 
0 73 
(1) 
0 79 
(1) 
0 81 
(1) 
0 76 
(1) 
0 70 
(1) 
0 76 
(1) 
0 81 
(1) 
0 75 
(1) 
0 76 
(1) 
0 82 
(1) 
0 74 
(1) 
0 84 
(1) 
0 82 
(1) 
0 80 
(1) 
0 81 
(1) 
Val 
-
— 
— 
— 
— 
1 03 
( i ) 
— 
— 
— 
— 
— 
1 0 3 
(1) 
-
— 
— 
— 
— 
0 99 
(1) 
*The value for Ser has not been corrected for losses during hydrolysis 
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TABLE 3 
Reversed phase H PLC data and [a]D-values of the peptides prepared in 
this study. Values obtained by sequential syntheses are in italics. 
39 
40 
41 
42 
43 
44 
[Xxx^l.tGly181] 
-Ασ-(148-160) 
Xxx= 
Arg 
Glu 
Gly 
Lys 
Pro 
Val 
ret.time 
(mins) 
19.55 
Ï9.56 
20.26 
20.28 
19.40 
19.42 
19.46 
19.41 
20.37 
20.37 
21.96 
22.06 
% main peak 
97.8 
94.4 
94.6 
84.5 
96.0 
88.4 
89.8 
86.2 
96.7 
77.1 
95.4 
78.1 
[a]0 
-10.0 (c=0.38, DMF) 
-10.8 (c = 0.38, DMF) 
-12.3 (c=0.30, DMF) 
-10.7 (C=0.28, DMF) 
-10.7 (c=0.27, DMF) 
- 9.2 fc=0.26, DMF) 
-14.4 (c=0.55, DMF) 
-10.7(0 = 0.59, DMF) 
-33.4 (c=0.29, DMF) 
-30.3(0 = 0.31, DMF) 
-11.0(c=0.50, DMF) 
-10.4 (c = 0.52, DMF) 
Racemization of the co-carbon of Val occurring during peptide azide formation 
of 26 would probably lead to a lowered biological activity of [Val1îa],[Glyiei]-
fibrlnogen-Aa-(148-161). This was not observed. Table 3 also shows that the 
[o]D-values of the peptides prepared via both procedures are comparable, which 
is another indication for a low degree of racemization. 
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The method of acylation of a ß-unprotected amino-terminal aspartyl derivative 
includes the possibility of a secondary activation of free ß-carboxyl functions; this 
reaction is obviously slower, since no other products were obtained (cf. Ten 
Kortenaar et al. 1985). 
We have no explanation for the fact that the peptide azides derived from 23 
(Xxx=Phe) and 25 [Xxx=S r(Bu,)] do not react with compound 2. 
In conclusion, we have shown that the coupling of a peptide azide to an 
amino-terminally positioned unprotected aspartyl peptide derivative, as proposed 
by ten Kortenaar et al. (1985), is quite generally applicable and proceeds in high 
yields and without any detectable by-products. The strategy of synthesizing 
small protected peptide fragments via SPPS, their subsequent coupling in 
solution to form target peptides which are deprotected in solution {i.e., in high 
dilution), yields significantly more homogeneous peptides. 
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Chapter 8 
THE USE OF Mpc-AMINO ACIDS IN SOLID PHASE PEPTIDE SYNTHESIS 
LEADS TO IMPROVED COUPLING EFFICIENCIES 
Wim J.G. Schielen, Hans P.H.M. Adams, 
Willem Nieuwenhuizen*, and Godefridus I. Tesser 
Lab. Organic Chemistry, University of Nijmegen 
*Gaubius Institute TNO, Leiden 
Int. J. Peptide Protein Res., in the press 
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ABSTRACT 
The Mpc-group has a somewhat better stability than the Fmoc-group, resists 
catalytic hydrogenolysis, is highly stable in acidic media and its elimination 
product does not polymerize spontaneously In a direct comparison of coupling 
efficiencies obtained in solid phase peptide syntheses using Mpc- or Fmoc-amino 
acids it is shown that the use of Mpc-ammo acids leads to better coupling 
efficiencies and, consequently, a more homogeneous peptide 
An improved synthesis of Mpc-ONSu and of Mpc-ammo acid derivatives is 
presented 
INTRODUCTION 
The ammo protective Mpc group (Verhart and Tesser 1988), derived from the 
Msc group (Tesser and Balvert-Geers), was designed to be of use both m 
solution and in solid phase peptide synthesis, to be comparable, m base-lability 
terms, with the Fmoc group (Carpino and Han 1970, 1972), and to expel an 
alkene with a lower tendency to polymerize than dibenzofulvene 
The frequently used Fmoc-group is suitable for solid phase syntheses, since 
the protection of ammo groups is only required for a short period of time 
Furthermore, it is relatively simple to wash away the small impurities which result 
from dibenzofulvene and which, during classical synthesis, cause the formation 
of insoluble, hard to remove polymers 
On several occasions we have observed incomplete coupling when using 
Fmoc-amino acids in SPPS, even when repeated coupling had been performed 
using the same Fmoc-amino acid In contrast, the use of Mpc-ammo acids has 
led, m some cases, to a complete acylation reaction 
Compared with the Fmoc-group, the Mpc-group is rather slim, and therefore it 
might be expected that there is improved coupling when using Mpc-ammo acids 
in SPPS 
In order to investigate the suggested improvement of the coupling efficiency, a 
comparative study was set up 
Fibrinogen-Ao-(148-160) (H-Lys-Arg-Leu-Glu-Val-Asp-Ile-Asp-Ile-Lys-Ile-Arg-Ser-
OH) is known to enhance the plasminogen activation mediated by t-PA with a 
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factor of about 12 (Voskuilen ef al. 1987) whereas [Nle157]-fibrinogen-Aa-(148-160) 
does not enhance this activation. The presence of Nie at position 157 causes an 
incomplete coupling of Fmoc-Arg(Pmc)-OH at position 149 (even after double 
coupling, coupling at higher temperatures and coupling in different solvents). 
The tridecapeptides fibrmogen-Aa-(148-160) and [Nle157]-fibrinogen-Aa-(148-
160) were synthesized by SPPS twice; each with Mpc-amino acids and with 
Fmoc-amino acids. The results clearly indicate that the use of Mpc-amino acids 
leads to more constant coupling efficiencies and, obviously, to more 
homogeneous peptides. 
In this article we also present an improved synthesis of Mpc-ONSu and of 
Mpc-amino acids. 
MATERIALS AND METHODS 
Methods 
Amino acid analyses were performed on a Varían 9095 amino acid analyzer using 
the Fmoc protocol. Peptides were hydrolyzed in 5.7 N HCl (Merck Suprapur) in 
evacuated sealed glass tubes for 24 hours at 120 "C and concentrated in vacuo. 
Elemental analyses were performed on a Carlo Erba Strumentazione EA MOD 
1106. 
H PLC analyses were performed on an Advanced Chromatography Systems 
apparatus. Chromatography was run in reversed phase mode on a Techsil 5C18 
column at a flowrate of 1 ml/min using a 5 min isocratic elution with 7% (v/v) 
acetonitrile and 0.1% (v/v) trifluoroacetic acid in water, followed by a 30 min 
linear gradient of 7% (v/v) acetonitrile and 0.1% (v/v) trifluoroacetic acid in water 
to 70% (v/v) acetonitrile and 0.08% (v/v) trifluoroacetic acid in water. Peaks 
were detected by UV absorption at 215 nm. The UV data were analyzed using 
JCL 6000 Chromatography Data System software. 
Infrared spectra were obtained from a Perkin-Elmer 298 IR Spectrophotometer. 
Melting points were determined with a Buchi melting point apparatus and are 
uncorrected. 
1H-NMR spectra were obtained in appropriate solvents from a Bruker 90 Mhz 
Spectrophotometer. 
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s - ^ ^ , (Çï^sov Н з С з Н О Ь - TSSfcT H . c - c s - ^ ^ , 
HS-CHj-CH,-OH H.CO-
H 3 C — o z s — < ^ ^ — s o 2 — с н , - с н , - о н • Ν Η α ^ θ 4 H j c — o , s — ( С Ъ — S-CH,-CH,-0 
o=c 
HjC—OjS ( O y ^ S 0 2 — C H , — C H j — o — c ' 
HjC—OjS ( C / - S 0 2 — C H , — C H ; 
0—N 
1 , - 0 - c 
Scheme 1 Synthesis of Mpc-ONSu (fi) 
Optical rotations were obtained on a Perkin Elmer 241 Polarimeter with a 1.0 dm 
cell in appropriate solvents and at ambient temperature. 
Peptides were synthesized on a Labortec SP 640 semi-automated peptide 
synthesizer. 
Thin-layer chromatography (t.l.c.) was performed on precoated t.l.c. plates 
(Merck, silica gel 60, F-254, 0.2 mm). Solvent systems used were: 
СНСІз/М ОН/АсОН (95/20/3) and n-butanol/acetic acid/water (4/1/1). Spots 
were visualized using one or more of the following methods: UV-fluorescence 
quenching 254 nm, Barton's reagent spray (a mixture of equal volumes of FeCI3 
(30 g) in water (170 ml) and KaFeiCN),, (2 g) in water 200 ml), ninhydrine spray 
(240 mg in 400 ml n-butanol and 16 ml acetic acid). 
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Syntheses 
4-Chlorophenyl methyl sulphide (1) Scheme 1. 
The reaction was performed according to Schutz and Ciponn (1958), starting 
from 170 g 4-chlorothiophenol (1.175 mole). The distillation following the 
extraction by which Schutz and Ciponn obtained the sulfide was omitted, since 
the compound appeared to be chromatographically pure· one spot (R, 0 83) was 
found using the system CHCVMeOH/AcOH (95/20/3, v/v/v); detection· UV-
fluorescence quenching and Barton's reagent; pale yellow needles, yield 182.7 g 
(98%), m.p. 17 "C. Ή NMR (CDCI3): CH3, s, (ЗН), δ 2.44 ppm; phenyl, m, (4H), δ 
7.20 ppm. 
4-Chlorophenyl methyl sulphone (2) 
Compound 1 (182 g, 1.147 mole) was dissolved m 1 I ethanol and 200 ml water. 
An aqueous solution (150 ml) of Na2W04«2H20 (2%, g/v) was added as a 
catalyst. Hydrogen peroxide (105 ml of an aqueous 35% g/g solution) was then 
slowly added to the previously warmed (40 "C) solution The temperature was 
kept at this value until the addition was complete and the sulfoxide had formed. 
The temperature was then increased to 80 °C and a further equivalent of 
hydrogen peroxide was added (105 ml) in the same way After completion of the 
addition, the reaction mixture was refluxed for 1 h to complete the oxidation 
reaction and to decompose small amounts of residual hydrogen peroxide. The 
reaction mixture was allowed to cool down slowly to 4 °C. The sulphone 2 
crystallized spontaneously to form colourless needles, 192.4 g (88%), m.p. 96-97 
0C. TLC: R, 0.79 in СНСІз/МеОН/АсОН (95/20/3, v/v/v); detection: UV-
fluorescence quenching, the reaction with Barton's reagent (for reducing 
compounds) was negative. 'H NMR (CDCLj); CH3, s, (3H), δ 3.07 ppm, phenyl, 
AA'BB', (4H), δ 7.71 ppm. Elemental analysis caled.: С 44 10, Η 3.70, found: С 
44 02, Η 3 71 %. 
2-[4-(Methylsulphonyl)phenylthio]ethanol (3) 
Sodium methoxide (prepared from 23 g clean sodium and water-free methanol) 
was dissolved in a solution of 77 ml (1.1 mole) 2-mercaptoethanol in 500 ml 
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dimethylformamide. The solution turned slightly green when 195.6 g (1 mole) of 
compound 2 was added, under a gentle stream of nitrogen. The mixture was 
heated for 1 hr at 60 °C (under nitrogen). A fine white precipitate (NaCI, 58 g) 
formed, which could be removed by filtration. The reaction mixture was allowed 
to stand at ambient temperature for 12 hours. After filtration the yellow filtrate 
was concentrated and the residue diluted with water (2.5 I). The resulting two-
phase system was then heated until it was homogeneous, and was then slowly 
cooled to room temperature. The product 3 crystallizes spontaneously and 
195.15 g (84%), m.p. 81-82 t , was obtained. TLC: R, 0.68, in 
СНСІз/М ОН/АсОН (95/20/3, v/v/v); detection UV-fluorescence quenching, 
positive reaction with Barton's reagent. Ή NMR (CDCI3): OH, t, (1H), δ 2.00 ppm; 
CHj, s, (3H), δ 3.04 ppm; fl-CH2, t, (2H), δ 3.22 ppm (J 6 Hz); a-CH2, double t, 
(2H), δ 3.86 ppm {J 6 Hz); phenyl, AA'BB', (4H), δ 7.62 ppm {JAB 8 Hz). Elemental 
analysis caled.: С 46.53, Η 5.21; found: С 46.40, Η 5.20 %. 
2-[4-(Methylsulphonyl)phenylsulphonyl]ethanol (Мре-ОН, 4) 
Compound â (195 g, 0.84 mole) was dissolved in 400 ml ethanol containing 150 
ml water and 150 ml of a 2% (g/v) Na2W04 solution in water. The oxidation was 
performed under a gentle stream of nitrogen, essentially as described for 2, 
using two 75 ml portions of 35% HsOz. On slowly cooling the reaction mixture to 
room temperature, white needles were yielded, 197.6 g (89%), m.p. 165-167 "c. 
TLC: Rf 0.63 in CHCI3/MeOH/AcOH (95/20/3, v/v/v); detection: UV-fluorescence 
quenching; the reaction with Barton's reagent was negative. Ή NMR 
(CDCI3/CDOD 10/1): CH3, s, (3H), δ 3.11 ppm; ІЗ-СН
г
, t, (2H), δ 3.40 ppm (J 6 
Hz); a-CH2, broadened t, (2H), δ 4.04 ppm (J 6 Hz); phenyl, s, (4H), δ 8.16 ppm. 
Elemental analysis caled.: С 40.90, H 4.58; found: С 40.77, H 4.58 %. 
2-[4-{Methylsulphonyl)phenylsulphonyl]ethyl chloroformate (Mpc-CI, 5) 
Phosgene (30 ml) was condensed in a 2 I three-necked flask and, with stirring, a 
solution of é (36.5 g, 138 mmoles) in 500 ml acetonitrile was slowly added to the 
cold (-78 0C) acid chloride. The reaction mixture was allowed to warm up slowly 
to room temperature overnight, contained in a reaction flask sealed with a 
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calcium chloride guard tube. Residual phosgene and hydrogen chloride were 
removed in a water trap by purging with N2 for three hours. The solvent was 
evaporated in vacuo and the residue recrystallized from acetomtnle. M.p. of the 
clear colourless crystals (40.7 g, 90%) 159 "C. IR: С=О, 1700 cm1; S02 
complicated peaks of two non-equivalent sulfone groups at 1140-1160 (symm) 
cm·1 and 1290-1330 (ass) cm1. 'H NMR (CDCy CHg, s, (3H), δ 3.08 ppm; 8-СН
г
, 
t, (2H), δ 3 58 ppm (J 6 Hz); а-СН
г
, t, (2H), δ 4.67 ppm (J 6 Hz); phenyl, s, (4H), 
δ 8 16 ppm. Elemental analysis caled : С 36.76, Η 3.39; found· С 36 95, Η 3.53 
%. 
2-[4-(Methylsulphonyl)phenylsulphonyl]ethyl succinimidyl carbonate (Mpc-ONSu, 
6) Compound 5 (27 g, 82 6 mmol) was slowly added to a solution of 9 55 g (83 
mmol) of N-hydroxysuccimmide and 6 7 ml (83 mmol) of dry pyridine in 165 ml 
dry (К
г
СОз) acetomtnle. In 1 hr, a white compound precipitated, which, on 
filtration, and after washing with water and drying, proved to be pure g (31.2 g, 
93%, m.p. 174-176 "С). Recrystallization from acetic acid/water (4/1, v/v) gave a 
product which was dried over solid sodium hydroxide and which melted at 174-
175 °C. 'H NMR (acetone-d«): CHj, s, (3H), δ 3.11 ppm; succmimide CH2, s, (4H), 
δ 2.72 ppm; fl-CH2, t, (2H), δ 3.78 ppm; а-СНз, t, (2H), δ 4 62 ppm, phenyl, s, 
(4H), δ 8 07 ppm. 
Mpc derivatives of Phe, Va!, Ile, Leu, Nie, Glu(OBu'), AspíOBu'), Ser(Bu'), 
Arg(Pmc), Lys(Boc) via the Mpc-ONSu procedure 
Introduction of the Mpc function is performed using the route depicted by Ten 
Kortenaar ef al. (1986). 
To a suspension of 10 mmol ammo acid in 40 ml acetomtnle/water (1/1) an 
amount of triethylamme was added to give an apparent pH of 9.0. The apparent 
pH was kept 8.5-9.0 after the addition of 9 9 mmole Mpc-ONSu (4.0 g) by adding 
triethylamme. The suspension turned clear. After 5-15 mm, the uptake of base 
ceased. The mixture was stirred for 30 mm. at room temperature The solution 
was then acidified to an apparent pH of 5. After filtration of traces of unreacted 
ammo acid the solution was concentrated in vacuo to about 20 ml and acidified 
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with О 1 N HCl until a reading of pH 2 was recorded on a pH-meter At this point 
a white solid precipitated The precipitate was distributed between 100 ml 
ethylacetate and 100 ml water/HCI pH=2 The ethylacetate layer was washed 
with water until neutral, dried over NajSO«, filtered, and concentrated 
Recrystalhzation from ethylacetate/n-hexane gave homogeneous products and 
analytical results as shown in tables 1 and 2 
Mpc derivative of Cys(Acm) via the Mpc-ONSu procedure 
The synthesis of Mpc-Cys(Acm)-OH is essentially the same as that described 
above The precipitated crude Mpc-Cys(Acm)-OH, however, could not be 
distributed between ethylacetate and water/HCI pH=2 The precipitate was 
filtered, washed with water and dried to give a chromatographically pure product. 
Mpc-Cys(Acm)-OH can be recrystallized from acetic acid/water (4/1). Analytical 
results are shown in tables 1 and 2 
Mpc derivatives of lie and Lys(Boc) via the Tms-CI procedure 
Introduction of the Mpc group is performed as described by Bolm et al. (1989) 
The finely ground amino acid (15 mmol) was suspended in 60 ml dry CHjClj. 
Under vigorous stirring 5 22 ml (ЭО mmol) diisopropylethylamine was added 
followed by careful addition of 3 78 ml (30 mmol) trimethylsilyl chloride. The 
mixture was allowed to reflux for 1 5 hr. After cooling in an ice bath, 3.68 g 
(11 25 mmol) Mpc-CI was added in one portion The solution was stirred in ice 
for 20 mm , allowed to warm up to room temperature, left for 1 hour, supplied 
with 10 ml of methanol, and concentrated in vacuo. The residue was distributed 
between 100 ml diethyl ether and 125 ml 2 5% (g/l) NaHCO, solution in water 
The aqueous layer was extracted with 2 χ 50 ml diethyl ether. The ether layers 
were backwashed twice with 25 ml water. The combined aqueous layers were 
acidified to pH 2 with 1N HCl and extracted with 3 χ 50 ml ethyl acetate. The 
combined ethyl acetate layers were dried over NajSO ,^ filtered and concentrated 
in vacuo Recrystallization from ethyl acetate/n-hexane gave homogeneous 
products and analytical data as shown in tables 1 and 2. 
114 
Solid Phase Peptide Syntheses 
The peptides to synthesize were fibrinogen-Aa-(148-160)-tridecapept¡de (H-
Lys-Arg-Leu-Glu-Val-Asp-Ile-Asp-Ile-Lys-Ile-Arg-Ser-OH, A) and [Nle1ï7]-fibrinogen-
Aa-(148-160)-tridecapeptide (H-Lys-Arg-Leu-Glu-Val-Asp-Ile-Asp-Ile-Nle-Ile-Arg-Ser-
OH, В). Each peptide was synthesized twice; once with Mpc-amino acid 
derivatives (peptides Mpc-A and Mpc-B), and once with Fmoc-amino acid 
derivatives (peptides Fmoc-A and Fmoc-B). 
During solid phase peptide synthesis the amino acid side chains were 
protected with acid-labile protecting groups: the ε-amino group of lysine with 
ferf-butyloxycarbonyl (Boc), the δ-guanidino group of arginine with 2,2,5,7,8-
pentamethylchroman-6-sulphonyl (Pmc), the γ-carboxyl group of glutamic acid 
and the ß-carboxyl group of aspartic acid with ferf-butyl ester (OBu1), and the ß-
hydroxyl group of serine with ferf-butyl (Bu'). The carboxyl terminal amino acid 
[0.9 equivalents (eq.) Mpc-SeriBu'^ OH or Fmoc-SeriBu'VOH] was coupled to 
Wang's resin (Wang 1973) (p-alkoxybenzyl alcohol resin, 1.07 mmol of alcohol 
groups/g) by in situ activation with DCC (0.9 equivalent [eq.]) and DMAP (0.9 
eq.). To suppress racemization, HOBt (1.8 eq.) was added (Van Nispen et al. 
1985). All reactants were dissolved in DMF. After 16 hours at 5 °C the resin was 
washed three times with successively each of DMF, dichloromethane, and 
isopropyl alcohol. Finally, the resin was washed with diisopropyl ether and dried 
/л vacuo. The amount of Mpc- or Fmoc-amino acid attached to the resin was 
calculated from the amount of nitrogen in a sample of the resin. The cleavage of 
the Mpc or Fmoc groups was carried out with 20% (v/v) piperidine in DMF during 
three consecutive cycles of 6 minutes. Three samples of the pooled 
piperidine/DMF fractions were diluted each with DMF to an appropriate 
concentration (giving an optical density of about 0.5). The relative amount of 2-
[4-(methylsulphonyl)phenylsulphonyl]ethyl-piperidine (Mpc-pipendine adduct) or 
9-fluorenylmethyl-piperidine (Fmoc-piperidine adduct) was calculated using molar 
absorption coefficients of 4500 l/mol-cm at 279 nm and 17600 l/mol-cm at 267 
nm, respectively. The relative amounts of measured Mpc-piperidine adduct or 
Fmoc-piperidine adduct served as a measure of the amount of Mpc-amino acid 
or Fmoc-amino acid that had been coupled. 
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TABLE 1 
Yields, melt ing points and R,-values of Mpc-amino acid derivatives 
C o m p o u n d Yield(%)' Yield(%)b m.p. fC) R,0 R,d 
Mpc-Arg(Pmc)-OH 
Mpc-AspiOBu'J-OH 
Mpc-Cys(Acm)-OH 
Mpc-GluiOBu'J-OH 
Mpc-lle-OH 
Mpc-Leu-OH 
Mpc-Lys(Boc)-OH 
Mpc-Nle-OH 
Mpc-Phe-OH 
Mpc-Ser(Bu') 
Mpc-Val-OH 
76 
75 
80 
84 
79 (95) 
85 
74 (92) 
87 
85 
87 
85 
60 
58 
59 
69 
71 (87) 
76 
62(83) 
79 
78 
77 
77 
100-3 
104-5 
117-8 
76-8 
96-7 
120-1 
110-2 
140-1 
72-4 
97-9 
105-6 
0.27 
0.46 
0.13 
0.49 
0.51 
0.49 
0.48 
0.49 
0.46 
0.49 
0.47 
0.60 
0.65 
0.35 
0.68 
0.70 
0.71 
0.69 
0.70 
0.66 
0.66 
0.67 
* Crude yield, values In parentheses are obtained by the Tms-CI procedure 
" Yield after recrystallizatlon, values in parentheses are obtained by the Tms-CI procedure 
c
 In СНСІэ/МеОН/АсОН (95/20/3) 
• In n-BuOH/AcOH/water (4/1/1) 
The second Mpc-amino acid derivative, Mpc-Arg(Pmc)-OH (2 eq.), or Fmoc-
amino acid derivative, Fmoc-Arg(Pmc)-OH (3 eq.), was coupled via in situ 
activation with TBTU (2 and 3 eq. respectively) (Knorr et al. 1989), HOBt (2 and 3 
eq. respectively) and NMM (3 and 4.5 eq. respectively). The Mpc- or Fmoc-amino 
acid derivatives were allowed to couple for exactly 30 min, fol lowed by acylation 
of any remaining free amino groups with 10% (v/v) acetic acid anhydride and 5% 
(v/v) di isopropylethylamine in DMF. Thus, no attempt was made to obtain 
optimal coupl ing of the Mpc- or Fmoc-amino acid derivatives. After each 
coupl ing the relative amount of coupled Mpc- or Fmoc-amino acid derivative was 
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calculated as described above. Finally, the fully protected peptides were 
deprotected and cleaved from the resin during a 4 h reaction with 2.5% (v/v) 
ethanedithiol and 2.5% (v/v) water in trifluoroacetic acid. The crude peptides 
were precipitated with diethyl ether, washed several times with diethyl ether, 
dried at the air, and analysed by HPLC and amino acid composition. 
RESULTS 
Table 1 lists the obtained yields, melting points, and FVvalues for Mpc-amino 
acid derivatives. Table 2 shows the measured optical rotations of Mpc-amino 
acid derivatives dissolved in DMF and dioxane. 
Elemental analyses on the nitrogen content in samples of polystyrene bound 
Mpc-SeriBu') and Fmoc-SeriBu') showed that the amount of amino acid derivative 
attached to the resin is 0.21 mmol/g and 0.27 mmol/g respectively. 
The change in the relative amount of coupled Mpc- or Fmoc-amino acid 
derivatives during the progress of the synthesis is shown in figure 1 [for the 
synthesis of fibrinogen-Aa-(148-160), peptides Mpc-A and Fmoc-A] and in figure 
2 [for the synthesis of [Nle1S7]-fibrinogen-Aa-(148-160)l peptides Mpc-B and 
Fmoc-B]. 
Table 3 lists the data obtained from the amino acid analyses. 
Chromatograms prepared from the crude peptides are shown in figure 3. The 
chromatogram of the crude peptide Mpc-A (figure 3a) shows a major peak at 
21.1 min of 96% of the total area and a small, tailing peak at 21.8 min of 4% of 
the total area, whereas the chromatogram of peptide Fmoc-A shows a major 
peak at 21.1 min of 87%, a small, tailing peak at 21.5 min of 4% and a minor 
peak at 21.8 min of 9% of the total area. 
In figure 3b, the chromatogram of the crude peptide Mpc-B shows a major 
peak at 22.1 min of 91% of the total area and a minor tailing peak at 23.0 min of 
9% of the total area, whereas the chromatogram of peptide Fmoc-B shows a 
major peak at 22.1 min of 79% and a peak at 22.8 min of 21% of the total area. 
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TABLE 2 
Optical rotations obtained for some Mpc-ammo acid derivatives 
Compound [a]D ( ) m DMF [a]D ( ) in dioxane 
Mpc-Arg(Pmc)-OH 
Mpc-AspiOBu'j-OH 
Mpc-Cys(Acm)-OH 
Mpc-GluiOBu'î-OH 
Mpc-lle-OH 
Mpc-Leu-OH 
Mpc-Lys(Boc)-OH 
Mpc-Nle-OH 
Mpc-Phe-OH 
Mpc-SeriBu') 
Mpc-Val-OH 
+ 2 5, c=0 67 
- 17, c=0 42 
-25 1,0=165 
- 6 1 , 0=104 
+ 06, C=104 
-12 5, C=0 72 
- 4 1, C=0 78 
-5 5, C = 0 66 
•12 9,0=100 
+ 8 5, C=0 65 
+ 04, C=0 48 
+ 1 5, C = 1 10 
+ 10 1, C = 109 
-10 1,0=1 10 
+ 29, C=1 16 
+ 18,0=1,21 
-10 2,0 = 122 
+ 1 7, C=1 06 
- 2 0, C = 1 05 
+ 13 2,0 = 105 
+ 13 8, C=1 10 
- 0 6 , 0 = 1 14 
DISCUSSION 
The synthesized Mpc-ammo acid derivatives were obtained as easy to isolate 
solids m good yields From table 1 it is clear that Mpc-ammo acid derivatives 
synthesized via the Tms-CI procedure give, in general, higher yields Although 
the Tms-CI procedure is more laborious than the Mpc-ONSu procedure, the 
crude derivatives are of higher purity, so in most cases recrystallization may not 
be necessary Via the Mpc-ONSu procedure, however, most crude Mpc-ammo 
acid derivatives can be obtained directly as solids (and not as oils, as is the case 
with most crude Fmoc-ammo acid derivatives obtained via the Fmoc-ONSu 
procedure) that are easily recrystallized from ethylacetate/hexane Since there is 
no trace of oligomenzation (9), Mpc-ONSu is the method of choice for the 
introduction of the Mpc-group 
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TABLE 3 
Amino acid analyses of the synthesized peptides, expected values in parentheses 
peptide Arg Asp 
mole/mole of peptide 
Qlu II· Leu Lys Ser 
Mpc-A 
Fmoc-A 
Mpc-B 
Fmoc-B 
193(2) 
180(2) 
2 06(2) 
1 76 (2) 
1 95 (2) 
1 97 (2) 
2 01 (2) 
2 11 (2) 
100(1) 
100(1) 
100(1) 
100(1) 
2 90(3) 
2 95(3) 
3 02(3) 
313(3) 
094(1) 
0 97(1) 
0 99(1) 
1 02 (1) 
1 93 (2) 
1 75 (2) 
103(1) 
065(1) 
« 
-
1 02 (1) 
1 07 (1) 
0 72(1) 
0 66(1) 
0 72(1) 
0 71 (1) 
0 99(1) 
0 96(1) 
1 02 (1) 
104(1) 
t h e value for Ser has not been corrected for losses during hydrolysis 
F m o c - a m m o acids 
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Figure 1 Amount of obtained plperidlne adduct following each coupling step in the 
synthesis of Mpc-A and Fmoc-A, 1 coupling of Mpc- or Fmoc 8ег(Ви') OH to the 
resin, 2 coupling of Mpc- or Fmoc-Arg(Pmc) OH to H-SertBu'^resIn, 3 coupling 
of Mpc- or Fmoc-lle-OH to H-ArgfPmcJ-SerfBu'J-resin, efc Triangels reflect an 
estimated SD of the spectrophotometrlcal measurements (n=3) 
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Fmoc-amino acids 
Mpc—amino acids 
-л— — — "S 
Δ 
ι ' 1 r 1 1 1 1 г 
3 4 5 6 7 8 9 10 11 12 
Number of coupled Fmoc- or Цэс-amino acid 
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Figure 2 Amount of obtained plperldine adduct per coupling step In the synthesis of Mpc-
B and Fmoc-B, 1 coupling of Mpc or Fmoc-Ser(Bu')-OH to the resin, 2 coupling 
of Mpc- or Fmoc-Arg(Pmc)-OH to H-SerfBuVesin, э coupling of Mpc- or Fmoc-
lle-OH to H-Arg(Pmc)-Ser(Bu') resin etc Triangels reflect an estimated SD of the 
spectrophotometrical measurements (n=3) 
Figures 1 and 2 show that the coupling of (3 equivalents) Fmoc-Arg(Pmc)-OH 
(cycle 12) is not complete within 30 minutes, whereas the coupling of (2 
equivalents) Mpc-Arg(Pmc)-OH does reach completion within 30 minutes As a 
result of this, the ammo acid analyses (see table 3) of Fmoc-A and Fmoc-B 
show that the content of Arg is lower than expected. In these crude peptides the 
content of Lys is also lower than expected, since Fmoc-Lys(Boc)-OH is the last 
ammo acid derivative to be coupled (cycle 13). The ammo acid analysis data 
obtained for Lys confirm the low coupling efficiency of Fmoc-Arg(Pmc)-OH (cycle 
12) to the growing chain 
Figures 1 and 2 (and table 3) also show much more consistent coupling 
efficiencies for the peptides synthesized with Mpc-ammo acid derivatives; the 
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Figure 3 Partial HPLC patterns of crude products of Mpc-A and Fmoc-A (a), and Mpc-B 
and Fmoc-B (b) 
overall slope of the line connecting the obtained relative amounts of coupled 
Mpc-amino acid derivatives reaches almost zero. From the partial 
chromatograms in figure 3 it is clear that solid phase syntheses of peptides via 
Mpc-amino acid derivatives lead to more homogeneous products. 
In conclusion, we have shown that when solid phase peptide syntheses are 
performed with Mpc-amino acids higher coupling efficiencies are obtained than 
with Fmoc-amino acids. 
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Samenvatting 
In een normale, gezonde bloedsomloop bestaat er evenwicht tussen 
bloedstolling (coagulatie) en het oplossen van een bloedstolsel (fibrinoiyse). Dit 
evenwicht wordt de haemostatische balans genoemd. 
Zoals in figuur S1 is weergegeven 
zal bij een relatief (tov. fibrinoiyse) 
verhoogde coagulatie thrombose 
optreden, terwijl bij een relatief (tov. 
coagulatie) verhoogde fibrinoiyse 
bloedingen zullen optreden. 
Het bloedeiwit fibrinogeen, dat in 
bloedplasma een concentratie van 
circa 2.5 mg/ml heeft, speelt in 
<y-
Flguur Si De haemostatische balans 
beide processen een belangrijke rol. Wanneer het coagulatie-mechanisme wordt 
geactiveerd, bijvoorbeeld door een verwonding, zal thrombine worden gevormd, 
dat op zijn beurt fibrinogeen zal omzetten in fibrine. Het onoplosbare fibrine 
vormt het eiwitnetwerk dat aan een bloedstolsel stevigheid geeft. Wanneer een 
stolsel zijn rol heeft vervuld, bijvoorbeeld tijdens weefselherstel of wondheling, 
zal het fibrinolyse-mechanisme, relatief tov. het coagulatie-mechanisme, 
toenemen. 
De hoofdroute in de fibrinoiyse (de zogenaamde t-PA route) is weergegeven in 
figuur S2: Door het zeer specifieke 
enzym weefsel-type plasminogeen 
activator (t-PA) wordt plasminogeen 
omgezet in piasmine, hetwelk op zijn 
beurt fibrine afbreekt tot oplosbare 
degradatie producten van fibrine. 
De activering van plasminogeen Figuur S2 De t-PA route ¡n de fibrinoiyse 
t -PA 
P l a s m i n o g e e n — ^ — -
I 
F ibr ine 
Fibr ne 
(mei oplosboo') 
Plasmine — ^ 
1
 ibnne degradai 
produclen 
(oplosbaar) 
ie 
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door t-PA blijkt nagenoeg alleen plaats te vinden in aanwezigheid van fibrine. De 
werking van t-PA (en dus van piasmine) blijft daardoor beperkt tot fibrine-
oppervlakken (bv. bloedstolsels) en fibrine draagt dus de informatie voor z'n 
eigen afbraak met zich mee. 
Tot nog toe zijn er twee plaatsen op het fibrine-molecuul bekend die in staat 
zijn de door t-PA gekatalyseerde omzetting van plasminogeen naar plasmine te 
versnellen: de een in Aa-(148-160) en de ander in een fragment dat FCB-5 
genoemd wordt (en bestaat uit γ-(311-336) verbonden met γ-(337-379) via een 
disulfide brug). Het feit dat fibrinogeen (nagenoeg) geen versnellende werking 
heeft op de plasminogeen activering leidde tot de hypothese dat Aa-(148-160) is 
geëxposeerd in fibrine en "begraven" in fibrinogeen. Deze hypothese hebben we 
kunnen staven door monoclonale antilichamen (MoAbs) op te wekken tegen 
synthetisch Aa-(148-160); de verkregen MoAbs blijken specifiek te zijn voor 
fibrine. Door deze MoAbs wordt fibrinogeen niet herkend (Hoofdstuk 2). 
Eenzelfde hypothese kan opgesteld worden voor het fragment FCB-5, waarvan 
waarschijnlijk (minstens) een gedeelte geëxposeerd is in fibrine. In dit fragment 
FCB-5 blijkt zich een sequentie te bevinden, nl. γ-(315-322), die, wat betreft de 
ladingsverdeling, sterk lijkt op Aa-(150-158): 
Aa-(150-158): Leu-Glu-Val-Asp-Ile-Asp-Ile-Lys-Ile 
0 - 0 - 0 - 0 + 0 
γ-(315-322): Trp-Asp-Asn-Asp-Asn-Asp-Lys-Phe 
0 - 0 - 0 - + 0 
MoAbs, opgewekt tegen synthetisch γ-(312-324) blijken fibrine-specifiek te zijn 
(Hoofdstuk 3), zodat de hypothese ook voor FCB-5 is bevestigd. 
Aa-(148-160) dat, zoals reeds eerder vermeld, in staat is om de plasminogeen 
activering door t-PA te stimuleren, heeft de volgende aminozuurvolgorde en 
ladingverdeling: 
Lys-Arg-Leu-Glu-Val1"-Asp-Ile-Asp-Ile-Lys1S7-Ile-Arg-Ser 
+ + 0 - 0 - 0 - 0 + 0 + 0 
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Een sequentie van alternerend neutrale en negatieve aminozuurresten wordt 
ingesloten door twee paar positief geladen aminozuurresten. Het onderzoek 
heeft zich, wat betreft Aa-(148-160), geconcentreerd op een drietal vragen: 
1. Is er een kleinere sequentie binnen Αα-(14β-160) die in staat is de 
plasminogeen activering door t-PA te stimuleren? 
2. Wat is de rol van de zijketen van het aminozuur in positie Aa 157? 
3. Is de typische ladingsverdeling in Aa-(148-160) van belang voor de 
versnellende werking? 
ad '\. In hoofdstuk 4 staat de synthese beschreven van opeenvolgende lineaire 
hexapeptiden uit Aa-(148-160). Deze aminoterminaal geacetyleerde peptiden zijn 
getest op hun stimulerende capaciteit. Daarbij bleek dat Aa-(154-159) het enige 
hexapeptide is dat in staat is de plasminogeen activering door t-PA te versnellen. 
Hoewel Аа-Обг-Іб?), Аа-(153-158), Аа-(154-159) en Аа-(155-159) alle (de volgens 
de literatuur belangrijke) Lys"7 bevatten, vertoont slechts Аа-(154-159) een 
significante stimulerende werking, hetgeen er sterk op duidt dat deze lysine op 
een speciale manier georiënteerd moet zijn. 
ad 2. Het is algemeen geaccepteerd dat lysyl resten van belang zijn voor de 
stimulerende werking op de plasminogeen activering. In het verleden werd 
gevonden dat het lysine residu op positie Aa 157 van cruciaal belang is. Nader 
onderzoek toonde echter aan dat dit lysine residu zonder problemen vervangen 
kan worden door glutaminezuur. Dit verrassende resultaat was voor ons 
aanleiding om vast te stellen wat de minimum eisen zijn, die gesteld moeten 
worden aan het aminozuur op positie Ao 157, voor het vervullen van zijn functie 
in fibrine. Daartoe zijn een aantal analoga van het type [Xxxl57]-Acr-(148-160) 
gesynthetiseerd en getest op hun stimulerende werking op de plasminogeen 
activering. In hoofdstuk 5 wordt geconcludeerd dat het lysine residu op positie 
Aa 157 mag worden vervangen door de lysinederivaten Lys(Ac), Lys(Z) en 
Lys(Msc), en door een groot aantal aminozuurresten, waarbij aan de volgende 
criteria moet worden voldaan. Het residu op positie Aa 157 mag géén (zoals in 
Gly) of één C-atoom (zoals in Ala) in de zijketen hebben. Wanneer de zijketen 
twee of meer C-atomen atomen bezit, moet er ook een polaire groep aanwezig 
zijn, waaraan eventueel een nogal volumineuze groep mag zitten (bijv. Lys(Z)). 
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ad 3 Om de invloed van de typische ladingsverdeling in Αα-(148-160) op de 
stimulerende werking te onderzoeken, zijn er analoga van Aa-(148-160) 
gesynthetiseerd waarbij valine op positie Aa 152 vervangen is door geladen, 
neutraal polaire, neutraal apolaire aminozuurresten, of door glycine of proline In 
hoofdstuk 6 wordt beschreven dat valine op positie Aa 152 slechts door een 
ander apolair neutraal aminozuur mag worden vervangen (zoals bijvoorbeeld 
norleucme of alanine) 
De resultaten van deze experimenten (beschreven in de hoofdstukken 4, 5 en 
6) duiden erop dat de ladingsverdeling in Aa-(148-160) belangrijk is, onder 
andere voor de juiste oriëntatie van het lysine residu op positie Aa 157 Het lijkt 
erop dat met zozeer Lys157 belangrijk is, of Val152, maar veeleer de structuur die 
door hun zijketens gestabiliseerd wordt Dit zou dan betekenen dat 
plasmmogeen en/of t-PA een bepaalde, typische structuur op het fibrine-
molecuul herkennen en binden, en dit leidt dan tot de versnellende werking 
Hoofdstuk 7 beschrijft de ontwikkeling van een nieuwe strategie voor 
fragmentcondensaties in de peptide chemie De vaste drager synthese van 
peptiden groter dan 10 aminozuren leidt vaak tot een mengsel van het 
doelpeptide en, als verontreiniging, sequenties met inserties of deleties van 
aminozuurresten 
Een manier om dit probleem te ondervangen is het aan een vaste drager 
synthetiseren van korte fragmenten De korte, volledig beschermde, fragmenten 
kunnen in oplossing gekoppeld worden tot het doelpeptide De resultaten van 
experimenten, beschreven in hoofdstuk 7, tonen aan dat condensatie reacties 
van peptide aziden met onbeschermde aspartyl peptide derivaten als ammo 
component vrij algemeen toepasbaar zijn en aflopen met hoge opbrengsten De 
aldus vervaardigde peptiden, een selectie van de analoga uit hoofdstuk 6, blijken 
significant zuiverder (volgens HPLC analyse) dan de volledig sequentieel 
gesynthetiseerde peptiden 
Hoofdstuk 8 tenslotte beschrijft een verbeterde synthese van Mpc-ONSu en 
van Mpc-ammozuren Wanneer de koppelmgsefficienties in vaste drager 
syntheses van Aa-(148-160) en [Nle157]-Aa-(148-160), van Mpc- en Fmoc-
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aminozuren worden vergeleken, blijken de Mpc-aminozuren beter te koppelen 
dan Fmoc-aminozuren. Het gevolg hiervan is dat peptiden die gesynthetiseerd 
zijn aan een vaste drager met behulp van Mpc-aminozuren, zuiverder zijn 
(volgens HPLC analyses van de ruwe producten). De verklaring hiervoor is 
waarschijnlijk dat de Mpc-groep slanker (minder volumineus) en minder rigide is 
(en daardoor beter in de matrix van de vaste drager kan doordringen) dan de 
Fmoc-groep. 
135 

Kód en jód 
^ 
In inne jeweune, jezonge blódumloof jieët 't eevewieet tusje blódjerinning 
(coagulatie) en 't luëze van e jerinsel (fibrinolyse). Dit eevewieet weed d'r 
haemostatische balans jeneumd. 
Zoeewie i fiejoer K1 sjteet zal bij 
ing hoeëjere (tov. fibrinolyse) 
coagulatie thrombose optreëne, 
ongerwiels bij ing hoeëjere (tov. 
coagulatie) fibrinolyse blouwinge 
zalle optreëne. 
't Blódaiwies fibrinogeen, dat i 
blódplasma ing konsentrasie van 
\ % 
-(>-
/ \ 
\ 
^_oa qu I a ti e \_ 
ónjeveer 2.5 mg/ml hat, sjpilt i beide р | е | о е г K 1 D ' r h a e m o s t a t l s c h e ™*™ 
protsesse ing wiechtije rol. Wen 't coagulatie-mechanisme weed aajesjwungeld, 
bijvuurbeeld bij ing wond, zal thrombine weêde aajemaad, dat óp zienne toer 
fibrinogeen umsetst i fibrine. Oes 't nit-lüeslieje fibrine, weed 't aiwiesnetswirk 
jemaad dat an e blódjerinsel sjterkde jieeft. Wen 't jerinsel zie wirk jedoa hat, 
bijvuurbeeld bij wond- of weefselreparatoer, da zal 't fibrinolyse-mechanisme 
aajesjwungeld weëde (dat weed da hoeëjer tov. 't coagulatie-mechanisme). 
D'r hoofdwég in de fibrinolyse (d'r zoeëjeheesje t-PA wég) sjteet i fiejoer K2: 
Durch 't hoeëgjenauwe enzym 
weefsel-type plasminogeen activator 
weed plasminogeen umjezatsd i 
plasmine, dat óp zienne toer fibrine 
aafbrikt bis lüeslieje degradatie 
producten va fibrine. De 
aktievieroeng va plasminogeen 
durch t-PA bliecht benoa ailing tse 
t -PA r^nre 
Plasm, noqeen - ->-— Γ ' ο s m ne ^ . 
ί \ 
S t i m u l a t o r 
F ibr ine d e g r a d n t 
ρ г ο d и с t e π 
(lueel eg) 
ie 
Fiejoer K2 O'r t-PA wég in de fibrinolyse 
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jebeure wen d'r óch fibrine prezent is. De wirkoeng va t-PA (en dus va plasmine) 
bliet doadurch besjrenkt bis fibrine-oppervlakken (bijvuurbild jerinsels) en fibrine 
dreët dus de oeskónf vuur zienne eje aafbrooch mit zich mit. 
Bis noe zunt d'r tswai plaatsje óp 't fibrine-molecuul bekank die in sjtaat zunt 
um de durch t-PA gekatalyseerde umzetsoeng tse versjnelle: de ing i Αα-(148-
160) en de anger in e fragment dat FCB-5 jeneumd weed (en besjteet oes γ-(311-
336) verbónge mit γ-(337-379) via ing disulfide bruk). 
't Feit dat fibrinogeen (benoa) jing versjnellende wirkoeng hat óp de 
plasminogeen aktievieroeng leiet noa de hypothese dat Aa-(148-160) is 
jeëksposeerd i fibrine en "bejrave" i fibrinogeen. Dis hypothese hant vuur kenne 
bewieze durch monoclonale antilichamen (MoAbs) óp tse wekke teëje 
synthetisch Ao-(148-160); de verkrèje MoAbs blieche sjpetsiefiek tse zieë vuur 
fibrine. Durch dizze MoAbs weed fibrinogeen nit herkankd (Kapiettel 2). 
Ing jelieche hypothese kan opjestald weëde vuur 't fragment FCB-5, woava 
waarsjainlieg (minnestens) e jedeelte jeëksposeerd is i fibrine. I dit fragment 
FCB-5 bliecht ziech ing tsekwèns tse bevinge, nl. γ-(315-322), die, wat betruft de 
ladingsverdeling, sjterk liecht op Aa-(150-158): 
Aa-(150-158): Leu-Glu-Val-Asp-Ile-Asp-Ile-Lys-Ile 
0 - 0 - 0 - 0 + 0 
γ-(315-322): Тгр-Asp-Asn-Asp-Asn-Asp-Lys-Phe 
0 - 0 - 0 - + 0 
MoAbs, ópjewekt teëje synthetisch γ-(312-324) blieche fibrine-sjpetsiefiek tse ziee 
(Kapiettel 3), zoeëdat de hypothese óch vuur FCB-5 is vas-jelaad. 
Ασ-(148-160) dat, zoeëwie al ieëder vermeld, i sjtaat is urn de plasminogeen 
aktievieroeng durch t-PA tse versjnelle, hat de volgende aminozuurvolgorde en 
ladingsverdeling: 
Lys-Arg-Leu-Glu-Val^-Asp-Ile-Asp-Ile-Lys^'-Ile-Arg-Ser 
+ + 0 - 0 - 0 - 0 + 0 + 0 
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Ing tsekwèns va alternerende neutrale en negatieve aminozuurresten weed i-
jesjloase durch tswai paar positief jelane aminozuurresten, 't Óngerzuk hat ziech, 
wat Аа-(14в-160) aajeet, tsouwjesjpitst óp drei vroage: 
1. Is d'r ing klinger tsekwèns binne Aa-( 148-160) die i sjtaat is de plasminogeen 
aktievieroeng durch t-PA tse sjtiemulère? 
2. Wat is de rol van d'r zijketen van 't aminozuur i positie Aa 157? 
3. Is de tiepiesje ladingsverdeling i Αα-(148-160) va belang vuur de versjnellende 
wirkoeng? 
ad 1. I kapiettel 4 sjteet de synthese besjreëve va ópeevolgende lineaire 
hexapeptiden oes Αα-(148-160). Dizze aminoterminaal geacetyleerde peptiden 
zunt jetést op hun sjtiemulèrende capaciteit. Doabij bliechet dat Aa-(154-159) 't 
intsiegste hexapeptide is dat i sjtaat is de plasminogeen aktievieroeng durch t-PA 
tse versjnelle. Hoewel Ασ-(152-157), Αα-(153-158), Αα-(154-159) en Αα-(155-160) 
allenâu (de volgens de lieteratoer wiechtije) Lys157 hant, tseegt ailing Αα-(154-159) 
ing significante sjtiemulèrende wirkoeng, hetgeen d'r sjtirk op wiest dat dis lysine 
óp ing sjpetsiejaal maneer georiënteerd mós zieë. 
ad 2. 't Weed aljemeen aajenoame dat lysyl reste wiechtieg zunt vuur de 
sjtimulèrende wirkoeng óp de plasminogeen aktievieroeng. In 't verleie woeët 
jevonge dat 't lysine residu óp positie Aa 157 va cruciaal belang is. Noader 
óngerzuk hat oes-jewieëze dat ewel dis lysine residu oane problème vervange 
kan weëde durch glutaminezuur. Dit uberrasjend resultaat woar vuur ós anlas 
um vas tse sjtelle wat de minimum eisen zunt, die jesjteld mòsse weëde aan 't 
aminozuur óp positie Aa 157, vuur 't oesveure va zieng functie i fibrine. Doarum 
zunt e aantal analoga van 't type [Xxx157]-Aa-(148-160) gesynthetiseerd en jetést 
óp hun sjtimulèrende wirkoeng óp de plasminogeen aktievieroeng. I kapiettel 5 
weed geconcludeerd dat 't lysine residu óp positie Aa 157 maag weëde vervange 
durch de lysinederivaten Lys(Ac), Lys(Z) en Lys(Msc), en durch e jroeës aantal 
aminozuurresten, woabij aan de noekómende criteria mós weëde voldoa. 't 
Residu óp positie Aa 157 maag jee (zoeëwie i Gly) of ее C-atoom (zoeëwie in Ala) 
in d'r zijketen han. Wen d'r zijketen tswai of mieë C-atomen hat, mós d'r óch 
inne polaire jroep doa zieë, woa-aa eventueel inge nogal volumineuze jroep maag 
zitte (bijv. Lys(Z)). 
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ad 3. Um d'r invloed van de tiepiesje ladingsverdeling in Aa-(148-160) óp de 
sjtiemulèrende wirkoeng tse óngerzukke, zunt d'r analoga va η Αα-(148-160) 
gesynthetiseerd, woabij valine óp positie Aa 152 vervange is durch jelane, 
neutraal polaire, neutraal apolaire aminozuurresten, of durch glycine of proline. I 
kapiettel 6 weed besjreëve dat valine óp positie Ασ 152 ailing durch a anger 
apolair neutraal aminozuur maag weëde vervange (zoeëwie bijvuurbild norleucine 
of alanine). 
De resultaten va dis experimenten (besjreëve in de kapiettele 4, 5 en 6) wieze 
drop dat de ladingsverdeling i Αα-(148-160) wiechtieg is, onger angere vuur de 
riechtije oriëntatie van 't lysine residu op Aa 157. 't Liecht drop dat nit zoeëzier 
Lys157 wiechtieg is, of Val is, mer vöalmieë de structuur die durch hun zijketens 
gestabiliseerd weed. Dit zouw da betseechene dat plasminogeen en/of t-PA ing 
bepaalde tiepiesje structuur óp 't fibrine-molecuul herkenne en binge, en dit leit 
da bis de versjnellende wirkoeng. 
Kapiettel 7 besjrieft de ontwikkeling van e nui kontsep vuur fragment 
condensaties in de peptide chemie. De vaste drager synthese va peptiden 
jroeëser wie 10 aminozuren leit duk bis ing misjoeng van 't doelpeptide en, als 
verontreiniging, tsekwénse mit inserties of deleties va aminozuurresten. Ing 
maneer urn dit probleem tse ongervange is 't aan inge vaste drager synthetiseren 
va kótte fragmenten. De kótte, jans besjermde, fragmenten könne i luësoeng 
jekoppeld weëde bis 't doelpeptide. De resultaten va experimenten, besjreëve i 
kapiettel 7, jeëve aa dat condensatie reacties va peptide aziden mit ónbesjermde 
aspartyl peptide derivaten als amino component, tsemmelieg aljemeen tsouw tse 
passe zunt en aaflofe mit hoeëg ópbringste. De óp dis maneer jemaade 
peptiden, ing selectie van de analoga oes kapiettel 6, blieche significant 
zuuverder (volgens H PLC analyses) dan de jans sequentieel gesynthetiseerde 
peptiden. 
Kapiettel 8 sjlieslieg besjrieft ing verbesserde synthese va Mpc-ONSu en va 
Mpc-aminozuren. Wen de kóppelingefficiënties i vaste drager syntheses va Aa-
(148-160) en [Nle,57]-Aa-(148-160), va Mpc- en Fmoc-aminozuren weëde 
verjelèche, blieche de Mpc-aminozuren besser tse koppele dan de Fmoc-
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aminozuren, 't Jevolg heiva is dat peptiden die gesynthetiseerd zunt aan inge 
vaste drager mit behulp va Mpc-aminozuren, zuuverder zunt (volgens HPLC 
analyses van de rauw producten). De verkloartng heivuur is waarsjainlieg dat d'r 
Mpc-jroep sjlanker (winniejer volumineus) en winniejer sjtief is (en doadurg 
besser in d'r matrix van d'r vaste drager kan durchdringe) wie d'r Fmoc-jroep. 
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Abbreviations 
Abbreviations and nomenclature recommended by the IUPAC-IUB commission 
(1984) are used in most cases 
Special abbreviations 
BSA bovine serum albumin 
CNBr cyanogen bromide 
DCC dicyclohexylcarbodnmide 
dec decomposes 
DEQTA plasmin-generated fragment of fibrinogen, formed in the presence of 
EGTA, consisting of fibrinogen chain fragments Aa 111-197, Bß 134-
461, and γ 86-303, disulfide-bond linked 
DMAP 4-(dimethylamino)pyridine 
DMF dimethylformamide 
EGTA ethyleneglycol-bis-(2-ammoethyl)-fefraacet!C acid 
FCB-2 CNBr fragment of fibrin(ogen) consisting of fibrin(ogen) chain 
fragments Aa 148-207, Bß 191-224, 225-242, 243-305 and γ 95-265, 
disulfide bond linked [also fibrin(ogen) cyanogen bromide 
fragment 2) 
FCB-5 CNBr fragment of fibnn(ogen) consisting of fibrin(ogen) chain 
fragments γ 311-336 and 337-379, disulfide bond linked [also 
fibrin{ogen) cyanogen bromide fragment 5) 
FDM fibrin(ogen) derived material 
Fmoc 9-fluorenylmethyloxycarbonyl 
HOBt 1 -hydroxy-1 H-benzotnazole 
Msc methylsulphonylethyloxycarbonyl 
Mpc 2-[4-(methylsulphonyl)phenylsulphonyl ]ethyloxycarbonyl 
NMM 4-methylmorfoline 
PBS phosphate-buffered saline 
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Pmc 2,2,5,7,8-pentamethylchroman-6-sulphonyl 
Pms pentamethylphenylsulphonyl 
R, relative mobility 
TBTU 2-(1H-benzotriazol-1-yl)-1l1,3,3-tetramethyluronium tetrafluoroborate 
Tha thioacetyl 
TLC thin layer chromatography 
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